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High throughput sequencing technologies in blood group
genotyping and applications in transfusion medicine: es-
tablishment of Rh genes reference allele sequences
Wajnat A. Tounsi
The Rh blood group system (ISBT004) is the second most important blood
group after ABO and the most polymorphic one, with 55 antigens encoded
by two genes, RHD and RHCE. The two genes are homologous and located
on chromosome 1 with 10 coding exons.
This research uses next generation sequencing (NGS) on Ion Torrent Per-
sonal Genome Machine™ (Ion PGM™) to sequence the Rh genes (RHD,
RHCE, RHAG) using overlapping Long Range-PCR (LR-PCR) amplicons.
The aim was to study different RHD and RHCE alleles present in the pop-
ulation to establish reference RHD and RHCE allele sequences by utilis-
ing the analysis of intronic single nucleotide polymorphisms (SNPs) and
their correlation to a specific Rh haplotype. We also aimed to use single
molecule sequencing (SMS), MinION™, to test the feasibility of applying
SMS in blood group genotyping (BGG).
Genomic DNA (gDNA) samples (n=218) were sequenced for the RHD
gene and 100 samples were sequenced for the RHCE gene using Ion PGM™.
The RHAG gene was also sequenced from samples where no mutation was
detected in the RHD gene that would explain weak D reactivity in sero-
logical testing. The RHD gene was sequenced from samples (n=13) using
MinION™. Data generated was mapped to the human genome reference
sequence hg38 and variants were called. Variants detected by the Min-
VIII
Abstract
ION™ were compared to the ones detected from the Ion PGM™.
The RHD gene data analysis lead to the detection of different exonic SNPs
that correlate to known variants and the identification of 10 novel RHD
variant alleles. Multiple RHD intronic SNPs were found in all samples:
21 intronic SNPs were present in all samples indicating their specificity
to the RHD*DAU0 (RHD*10.00) allele which the hg38 reference sequence
encodes. Twenty-three intronic SNPs were found to be R2 haplotype spe-
cific, and 15 were linked to R1, R0, RZ haplotypes which lead to the es-
tablishment of two RHD reference sequences one for R2 and the other for
R1, R0, Rz. Intronic SNPs were also detected in the RHCE gene in which
89 SNPs were specific to samples with C+/c- and 22 SNPs were found in
C-/c+ samples which lead to the conclusion that these SNPs are Rhc spe-
cific. This work resulted in the establishment of three RHCE allele specific
reference sequences in which one is C+ specific, one is c+ specific and the
other is for e+ allele. MinION™ was successful for determining the RHD
allele in all 13 samples sequenced.
NGS is a high throughput technique that enables the sequencing of poly-
morphic blood group genes and identification of novel variants present in
the population which cannot be detected using the available BGG molec-
ular platforms. Intronic SNPs may represent a novel diagnostic approach
to investigate known and novel variants of the RHD and RHCE genes,
whilst being a useful approach to establish reference RHD and RHCE al-
lele sequences. MinION™ is a powerful tool and was successful here
in BGG. However, challenges remain with developing a straightforward
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1. Introduction
1.1 Introduction to Blood Groups
Blood group antigens are genetically inherited mostly protein or carbohy-
drate structures present on the outer membrane of red blood cells (RBCs)
that can be detected by their corresponding antibody (Reid and Mohan-
das, 2004; Daniels, 2005; Reid et al., 2012; Daniels, 2013c). The most clini-
cally significant blood group, ABO, was discovered in 1901 by Karl Land-
steiner, after he observed that some patients’ plasma agglutinated others’
RBCs. His discovery explained the issue of inconsistent outcome from
blood transfusion at that time (Landsteiner, 1961; Yamamoto, 2000; Poole
and Daniels, 2007). After the introduction of the indirect antiglobulin test
(IDAT) in 1945, scientists were able to identify more blood group anti-
gens (Coombs et al., 1945). As serological tests became more sensitive and
specific, and further techniques like molecular and genetic tests became
available, more blood group antigen polymorphisms were revealed creat-
ing further diversity (Daniels, 2005). Nowadays, there are 43 blood groups
registered with the ISBT which are listed in Table 1.1 ISBT.
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The expression of most blood group antigens is controlled by one gene,
whilst a few are encoded by closely related multiple genes, such as Rh and
MNS (Daniels, 2005). Polymorphism of blood group antigens are most of-
ten caused by one or more single nucleotide polymorphisms (SNPs), re-
sulting in different forms of an antigen in a population. The Rh blood
group system is the most polymorphic blood group with 55 different anti-
gens, and over 300 alleles (Storry et al., 2019). Blood group antigens have
been linked to variant functions. These functions include membrane phys-
ical support, molecules transportation through the cell membrane, recep-
tors for extracellular ligands, adhesion molecules, complement compo-
nents and regulator (Reid and Mohandas, 2004).
1.1.1 Blood Antigen Identification and Classification
Blood groups verified by serology are categorized into either systems, col-
lections, low or high incidence antigens. Systems contain one or more
antigens encoded by a single gene, such as Kel blood group system, or
two genes that are closely linked, such as Rh blood group system (Daniels
et al., 2004), see Table 1.1 for a list of blood group systems. Collections
are antigens that might be linked serologically, biochemically or geneti-
cally, yet lack some of the criteria to fit into a blood group system. Anti-
gens that cannot be assigned to a system due to the lack of carrier protein
or carbohydrate on the RBCs are grouped together into collections which
consist of serologically, biochemically, or genetically related antigens. Col-
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lections are classified into potentially, sometimes, and not clinically signif-
icant. Low and high incidence antigens include low and high incidence
blood antigens that do not meet the other two classification criteria.
Since blood groups were discovered over 100 years ago, they were de-
noted in different styles. In the 1980s, the ISBT initiated the Working Party
on Terminology for Red Cell Surface Antigens to establish a universal pro-
cess for describing blood antigens to eliminate confusion from using dif-
ferent terminologies and create a genetically based database for all blood
group antigens.
The ISBT blood antigen numerical terminology consist of 6 digits; the first
3 represent the blood group system (e.g 006 for the Kell) and the second
3 digits represent the antigen (e.g. 006003 for Kpa) (Table 1.1). Also, the
system symbol can be used followed by the antigen number, and zeros on
the left may be deleted (e.g. KEL003 or KEL3) (Daniels et al., 2004). Phe-
notype is denoted by using the system symbol followed by a semicolon
followed by the antigen number (e.g. KEL;3); following antigen numbers
are separated by commas (e.g. KEL:3,4). In case of a missing antigen, an
antigen number is preceded by a minus sign (e.g. KEL:1,-2,3).
To represent the blood group gene, allele, or a haplotype, the ISBT sys-
tem symbol is used instead of the gene name (italicized) followed with an
asterisk and then the antigen number is used, subsequent antigens are sep-
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arated by commas (e.g. DCe would be represented by RH*1,2,5) (Daniels
et al., 2004; Harmening, 2005).
Although ISBT terminology is useful for tracking and keeping up-to-date
with newly identified antigens , it is hard to use in a clinical setting as num-
bers can be hard to remember and distinguish between different blood
groups. Therefore, alternative terminology is used, for example, Fisher-
Race and Wiener terminologies are still in use to report Rh haplotypes,
sections 1.3.2.1 and 1.3.2.2.
1.2 Rh Blood Group System
The Rh blood group system (ISBT004) is the second most important blood
group system after ABO (Avent and Reid, 2000; Avent et al., 2006) and one
of the most polymorphic blood group systems. The RHD and the RHCE
genes located on chromosome 1 (1p33.1-1p36), encode the RhD protein
and RhCcEe protein, respectively (Colin et al., 1991; Wagner and Flegel,
2000). The two closely related genes encode 55 different antigens in the
Rh system; five of them are considered the leading antigens (RhD, RhC,
Rhc, RhE, and Rhe). Rh antigens are expressed on the surface of the RBCs
on the Rh protein complex that is integrated within the cell membrane
(Iwamoto, 2005). The RhD antigen is the most clinically significant antigen
in the Rh system due to its high immunogenicity and being the main cause
of haemolytic disease of the fetus and newborn (HDFN), section 1.8.2.
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Table 1.1: Blood Group Systems, genes encoding the blood groups, number of antigens,
and chromosomal location. Table adapted from ISBT (2021).
No. System name System symbol Gene name(s) No. of antigens Chromosomal location
001 ABO ABO ABO 4 9q34.2
002 MNS MNS GYPA, GYPB, GYPE 50 4q31.21
003 P1PK P1Pk A4GALT 3 22q13.2
004 Rh RH RHD, RHCE 55 1p36.11
005 Lutheran LU BCAM 27 19q13.2
006 Kell KEL KEL 36 7q33
007 Lewis LE FUT3 6 19q13.3
008 Duffy FY ACKR1 5 1q21-q22
009 Kidd JK SLC14A1 3 18q11-q12
010 Diego DI SLC4A1 22 17q21.31
011 Yt YT ACHE 5 7q22
012 Xg XG XG, MIC2 2 Xp22.32
013 Scianna SC ERMAP 9 1p34.2
014 Dombrock DO ART4 10 12p13-p12
015 Colton CO AQP1 4 7p14
016 Landsteiner- LW ICAM4 3 19p13.2
Wiener
017 Chido/Rodgers CD/RG C4A, C4B 9 6p21.3
018 H H FUT1 1 19q13.33
019 Kx XK XK 1 Xp21.1
020 Gerbich GE GYPC 13 2q14-q21
021 Cromer CROM CD55 20 1q32
022 Knops KN CD1 12 1q32.2
023 Indian IN CD44 6 11q13
024 Ok OK BSG 3 19p13.3
025 Raph RAPH CD151 1 11p15.5
026 John Milton JMH SEMA7A 8 15q22.3-q23
Hagen
027 I I GCNT2 1 6p24.2
028 Globoside GLOB B3GALNT1 2 3q25
029 Gill GIL AQP3 1 9p13
030 Rh-associated RHAG RHAG 4 6p12.3
glycoprotein
031 FORS FORS GBGT1 1 9q34.13-q34.3
032 JR JR ABCG2 1 4q22.1
033 LAN LAN ABCB6 1 2q36
034 Vel VEL SMIM1 1 1p36.32
035 CD59 CD59 CD59 1 11p13
036 Augustine AUG SLC29A1 4 6p21.1
037 KANNO KANNO PRNP 1 20p13
038 Sid SID B4GLANT2 1 17q21.32
039 CTL2 CTL2 SLC44A2 2 19p13.2
continued . . .
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No. System name System symbol Gene name(s) No. of antigens Chromosomal location
040 PEL PEL ABCC4 1 13q32.1
041 MAM MAM EMP3 1 19q13.33
042 EMM EMM PIGG 1 4p16.3
043 ABCC1 ABCC1 ABCC1 1 16p13.11
1.3 Rh Blood Group System
The Rh blood group system (ISBT004) is the second most important blood
group system after ABO (Avent and Reid, 2000; Avent et al., 2006) and one
of the most polymorphic blood group systems. The RHD and the RHCE
genes located on chromosome 1 (1p33.1-1p36), encode the RhD protein
and RhCcEe protein, respectively (Colin et al., 1991; Wagner and Flegel,
2000). The two closely related genes encode 55 different antigens in the
Rh system; five of them are considered the leading antigens (RhD, RhC,
Rhc, RhE, and Rhe). Rh antigens are expressed on the surface of the RBCs
on the Rh protein complex that is integrated within the cell membrane
(Iwamoto, 2005). The RhD antigen is the most clinically significant antigen
in the Rh system due to its high immunogenicity and being the main cause
of HDFN, which is discussed in section 1.8.2.
1.3.1 Discovery
The Rh blood group system was first reported in the literature in 1939
by Levine and Stetson (1939). They reported a case of a female, with
blood group O, who gave birth to a stillborn infant and suffered severe
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haemolytic transfusion reactions (HTRs) after being transfused with her
husband’s blood, blood group O. After more investigations, serological
tests revealed that her blood agglutinated about 80% of the blood units of
the same blood group. They assumed that an agglutinating factor, caused
by the dead infant, was the main reason for the alloimmunisation (Levine
and Stetson, 1939). In 1941, Landsteiner and Wiener used rhesus blood
to immunise rabbits and isolated an agglutinating factor that agglutinated
human blood, which they called Rhesus factor. They came to a conclusion
that the agglutinating factor responsible for the unexplained transfusion
reactions were the Rh antibodies (Levine et al., 1941). It was later found
that the antibody they identified was not the Rh antibody but rather an
antibody now known as anti-LW (Avent and Reid, 2000).
1.3.2 Rh Terminology
There are multiple nomenclature systems in use to denote Rh blood group
haplotype and phenotype. Three Rh terminologies including Fisher-Race
(Fisher and Race, 1946), Wiener (Wiener, 1969), and Rosenfield (Rosenfield
et al., 1962) are used to donate Rh antigens. Fisher-Race and Wiener ter-
minologies were based on the researchers postulation of the Rh genetic
mechanism. Fisher-Race and Wiener terminologies are used in this work
therefore it is important to discuss them in detail in the following section.
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Table 1.2: The Rh most common haplotypes in Wiener, Fisher-Race, and ISBT numerical
terminology, and haplotype frequency in Caucasians.
Wiener Fisher-Race ISBT terminology Occurrence (%)*
R0 Dce RH*1,4,5 4
R1 DCe RH*1,2,5 42
R2 DcE RH*1,3,4 14
Rz DCE RH*1,2,3 0
r dce RH*4,5 37
r’ dCe RH*2,5 2
r" dcE RH*3,4 1
ry dCE RH*2,3 <1
*Frequency in Caucasians according to Singleton et al. (2000); Daniels (2013b).
1.3.2.1 Fisher-Race (DCE) Terminology
Fisher and Race, when studying the Rh antigens in the 1940s, hypoth-
esised that the Rh antigens are encoded by three closely linked alleles,
in which each allele produces a specific antigen (Fisher and Race, 1946;
Watkins et al., 1988; Garratty et al., 2000). They assigned each antigen a
letter with a gene name that corresponded to the same letter but italicized.
They named the Rh antigens (D, d, C, c, E, and e) and the three genes
encoding them D gene, C/c gene, and E/e gene. It is now established that
there is no d antigen but it is used to indicate the absence of antigen D. The
Rh phenotype in the Fisher-Race terminology is based on the presence of
D, C, c, E, and e antigens (Garratty et al., 2000; Harmening, 2005).
Fisher and Race proposed that an individual inherits two set of Rh genes
(haplotype), one from each parent, and because the Rh genes are co-dominant,
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each gene expresses the related antigen on the RBCs. Inherited haplotypes
determine the Rh genotype which controls the Rh phenotype. The most
common Rh haplotypes expressed in Fisher-Race terminology are listed in
Table 1.2. Rh haplotype in the Fisher-Race terminology is written as CDE
as they speculated that the Rh genes are located in C/c, D/d, E/e order; how-
ever, the order now has been changed to DCE after the identification of the
Rh genetic basis.
Individuals with no Rh antigens expressed on the RBCs have Rhnull phe-
notype and individuals with weak expression have Rhmod phenotype, al-
though there is no special way to describe them in the Fisher-Race ter-
minology. Fisher-Race terminology is widely used today to denote Rh
haplotype.
1.3.2.2 Wiener (Rh-Hr) Terminology
Wiener hypothesized that one Rh gene produces three antigens able to
cause agglutination with the corresponding antibodies (Wiener, 1969; Dun-
stan, 1986; Harmening, 2005). The Rh gene in Wiener terminology pro-
duced 3 antigens, which present the Rh haplotype, for example, R1 hap-
lotype in Wiener terminology produces D, C, e antigens. See Table 1.2 for
the most common Rh haplotypes presented in Wiener terminology. Rh
haplotype frequencies and distribution depend on the population ethnic-
ity (Garratty et al., 2000; Harmening, 2005; Daniels, 2013b).
Wiener terminology describes the Rh haplotype by indicating the presence
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or the absence of antigen D with (R) or (r), respectively. The presence of
antigen C is denoted by (1) or (’). Antigen c is implied in the absence of (1)
or (’). The presence of antigen E is denoted by (2) or (”), and the absence
of E antigen symbols implies the presence of antigen e. If both C and E
antigens are present they are indicated by (z) or (y), (Table 1.2).
To describe Rh antigen phenotypes in Wiener (Rh-Hr) terminology, (’) in-
dicates C or c antigens and (”) indicates E or e antigens. The r preceding
h indicates the presence of C (rh’) or E (rh”) antigen; while the h preced-
ing the r indicates the presence of c (hr’) or e antigen (hr”). Interestingly,
Wiener terminology for Rh phenotype does not have designation to ex-
press the absence of antigen D. Wiener terminology for Rh haplotype is
still used today but not phenotype designation as it is difficult to use and
did not accommodate other Rh antigens identified later (Wiener, 1969;
Garratty et al., 2000; Harmening, 2005).
To summarize, Rh phenotyping by serology assesses Rh antigens present
on the outer surface of the RBCs. The results are then expressed as Rh
haplotype using either the Fisher-Race or Wiener terminology. The Rh
haplotype is determined based on the most common haplotype in a cer-
tain population, for example, the most common haplotype in Caucasian
is R1 (DCe) (Daniels, 2013b). If phenotyping results came as D+, C+, c-,
E-, e+, then the most common haplotype will be R1R1 (DCe/DCe) or R1r′
(DCe/dCe), depending on the RHD gene zygosity which cannot be deter-
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mined by serology. Other possible haplotypes (R0r′) are excluded due to
their low frequency in the population.
1.3.2.3 ISBT Terminology
The ISBT Working Party assigned the Rh blood group system number 004,
and the most common Rh antigens are numbered as follow: 001 for RhD,
002 for RhC, 003 for RhE, 004 for Rhc, and 005 for Rhe, (Section 1.1.1). Each
antigen is represented in a unique number, for example, the RhD antigen
is represented by 004001. To shorten, the blood system symbol is used (all
capitals) in conjunction with the antigen number and zeros are removed
(e.g. RH001 or 004001 would be RH1).
Rh Phenotype is represented by the system symbol followed by the anti-
gen number. A minus sign precedes the antigen number when an antigen
is missing (RH:-1). The Rh alleles/ haplotypes are presented by the sys-
tem symbol (capitalised) followed by the antigen numbers (all italicized)
(e.g. DCe would be represented by RH*1,2,5) (Garratty et al., 2000; Daniels
et al., 2004; Harmening, 2005), (Table 1.2).
Although ISBT terminology is useful for tracking and keeping up to date
with new antigens and blood groups, it is hard to use in clinical settings as
numbers can be hard to remember and distinguish. The Fisher-Race and
Wiener terminologies are referred to in this work.
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1.3.3 Genetic Structure of Rh Genes
The Rh blood group system is the most polymorphic blood group system.
Two genes, RHD and RHCE, give rise to 55 Rh antigens. The Rh protein is
expressed in a complex transmembrane structure, where the RhCcEe pro-
tein is encoded by the RHCE gene and the RhD protein is encoded by the
RHD gene (Colin et al., 1991; Carritt et al., 1997).
The RHD and RHCE genes are located on chromosome 1, short arm, at po-
sition 1p36.11, where they lie next to each other in a mirror image format
separated by the small membrane protein 1 (SMP1) gene (Wagner and Flegel,
2000), which is now called transmembrane 50A (TMEM50A) . The two genes
are composed of 10 coding exons, where RHD is located between two ho-
mologous Rhesus boxes that are 9 kilobases (kb) each (Figure 1.1 -1) (Avent
et al., 2006). The RHD and RHCE genes are homologous. The evolution
of the Rh genes and their different alleles are discussed in more detail in
section 1.4.
Recombination, deletion, and point mutations in these two genes generate
the eight most common Rh haplotypes (Table 1.2) (Noizat-Pirenne et al.,
1998). Different studies were conducted to clarify the molecular structure
of the Rh proteins (Section 1.6). This research has improved as the molecu-
lar technology became more advanced, accurate and affordable in the last
two decades. In 2000, the RHD and RHCE genes were fully sequenced us-
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ing Sanger sequencing; nucleotide substitutions, gaps and recombination
events were studied (Okuda et al., 2000).
Figure 1.1: The RHD and RHCE genetic structure. (1) The RHD and RHCE genes are
located on chromosome one and separated by gene segment called TMEM50A. The RHD
gene is located between two homologous structures called Rhesus boxes. (2) RhD negative
phenotype in Caucasians occurs as a result of a complete deletion of the RHD gene by
incomplete cross over resulting in a hybrid Rhesus box. (3) RHD pseudogene (RHD ψ) is
a common variant in RhD negative Africans caused by an insertion of 37bp at the start
of exon 4 resulting in a shift in the reading frame, leading to a stop codon that prevents
successful translation of the RhD protein. (4) A common variant allele in RhD negative
individuals of Afro/ Caribbean descent known as r′s haplotype which have mutated Rh
genes including a hybrid RHD-RHCE-RHD allele on the RHD gene, and ces on the RHCE
gene. The combination of the two mutated genes encode for negative D, partial c, weak
partial e known as es, VS, V antigens. Image courtesy of Avent (2018).
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1.4 The Evolution of the Rh Genes
According to Okuda et al. (2000) the RHD and RHCE genes are 93.8% ho-
mologous in all introns and coding exons. The similarities between these
two genes gives an indication to their evolutionary origin from the same
ancestral gene through duplication event that occurred 240-300 million
years ago (Carritt et al., 1997; Okuda and Kajii, 2002). The findings of Car-
ritt et al. (1997) following analysis of the Rh genes suggest that the RHD
gene is a duplicate of the RHCE*ce allele, which means that the original
Rh lineage is Dce (R0), similar to findings by Kemp et al. (1999) from the
RHCE gene microsatellite variation analysis.
The RHCE*C allele is suggested to originate from one non-reciprocal ge-
netic recombination event of the RHD gene sequence into the RHCE*ce
allele. This was inferred by the identical sequence of the RHD gene and
the RHCE*C allele in exon 2 and its flanking non-coding regions (Carritt
et al., 1997). The RHCE*Ce allele was found to include a 109 base pair
(bp) insertion in intron 2 that does not exist in either the RHD gene or the
RHCE*ce allele (Kemp et al., 1999; Zhou et al., 2008). This 109 bp insertion
is thought to be a remainder of the genetic conversion event from which
the RHCE*C allele originated (Carritt et al., 1997).
The other Rh haplotypes arose from the Dce (R0) allele by various types of
mutation. For example, DcE (R2) haplotype emerged from a single muta-
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tion in exon 5 c.676C>G predicting amino acid change p.Pro226Ala.
1.5 Rh Genetic Polymorphism
1.5.1 RHD Genetic Variation
Although there are many variants of the RhD antigen, they can be placed
into five main categories: RhD positive, RhD negative, RhD weak, RhD
partial, and very weak D (DEL). RhD variations are encoded by the RHD
gene, in which single nucleotide variant (SNV), deletion, and/or recombi-
nation lead to RhD polymorphism. RhD positive individuals carry normal
D antigen on their RBCs. In Caucasians, 82%-85% of individuals are RhD
positive (Singleton et al., 2000).
1.5.1.1 RhD Negative Phenotype
The RhD negative phenotype can be either due to complete deletion of
the RHD gene or associated with RHD gene presence without the protein
production (Figure 1.12). In Rh-D negative Caucasians, complete deletion
of the RHD gene is the most common cause for RhD negative phenotype
(Flegel and Wagner, 2002). While in Asians and Africans, RhD negativity
is associated with an intact or partial RHD gene. Translation to viable RhD
protein fails because of mutations within the RHD gene (Iwamoto, 2005).
For example, the RHD pseudogene (RHD ψ) is a common variant in RhD
negative Africans (66%). RHD ψ is caused by an insertion of 37 bp (Single-
ton et al., 2000) in exon 4 that causes a shift in the reading frame, leading
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to a stop codon that prevents successful translation to a valid RhD pro-
tein (Figure 1.13). Other point mutations found in exons 5 and 6 are also
associated with RHD ψ (Singleton et al., 2000; Flegel and Wagner, 2002).
1.5.1.2 RhD Weak & Partial Phenotypes
Weak expression of antigen D arises when missense mutations lead to a
decreased number of antigen D epitopes expressed on the RBCs. Partial D
phenotype can also be caused by the loss of some antigen D epitopes due
to the presence of hybrid RHD-RHCE genes. Hybrid RHD-RHCE genes
are caused by partial or full exons changes in the RHD gene with ones
from the RHCE. Partial D amino acid changes generally affect the ones at
the extracellular loops of the RhD protein and weak D changes generally
affect amino acids located in the transmembrane loop segments (Figure
1.2).
The difference that distinguishes partial and weak D phenotypes is anti-
body production. Individuals with partial D phenotype are able to pro-
duce antibodies against missing epitopes of normal antigen D when ex-
posed to complete RhD through transfusion or pregnancy. Individuals
with weak D allele are unable to produce antibodies against the D anti-
gen, as mutations in the RHD gene weaken the efficiency of protein an-
choring in the cell membrane leading to decreased number of D epitopes
expressed but the integrity of epitopes is not affected (Avent et al., 2006).
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Figure 1.2: The Rh protein integrated in the red cell membrane in 12 spanning domains.
Mature Rh protein show 416 amino acids presented as circles, in which yellow ones rep-
resent the difference between RhD and RhCE; blue and red ones represent amino acid
changes in partial D and weak D, respectively; green represent amino acids encoding C;
black represent amino acid that encode E. Image courtesy of Flegel (2007b).
1.5.1.3 Very Weak D (DEL) Phenotype
Individuals with DEL phenotype express very low level of antigen D on
the outer membrane of the red cells that cannot be identified using serol-
ogy agglutination (Westhoff, 2007). Adsorption, elution and molecular
genotyping techniques are the only way to detect a DEL allele (Kwon et al.,
2017). DEL phenotype is often mis-phenotyped as D negative by serology.
Transfusing RhD negative patients with seemingly RhD negative blood (in
fact DEL) imposes a risk of sensitisation (Kwon et al., 2017). The risk of im-
munisation in transfusing D negative patients with DEL phenotype RBCs
17
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used to be considered unlikely. However, cases of D sensitisation in D neg-
ative patients have been reported indicating DEL phenotype in donors as
the cause of sensitisation (Wagner et al., 2005; Yasuda et al., 2005). Stud-
ies have linked the transfusion of DEL red cell, such as RHD(K409K) and
RHD(IVS5-38del4), to D negative patients to secondary anti-D immunisa-
tion (Wagner et al., 2005; Yasuda et al., 2005).
There are over 40 DEL alleles listed in the RhesusBase website (Wagner
and Flegel, 2014). DEL phenotype is a common allele among RhD nega-
tive Asians (10-30%) (Shao et al., 2002) but significantly lower among D
negative Caucasians (0.1%) (Kwon et al., 2017). Molecular basis of DEL
allele differs in populations, for example, the most common DEL allele in
Asians is RHD*DEL1 which is caused by c.1227G>A (p.Lys409Lys) in exon
9 predicting splice site disruption (Kwon et al., 2017).
1.5.1.4 Rhnull Phenotype
The Rhnull phenotype is a very rare condition in which an individual lacks
the Rh complex; therefore, RBCs show morphological (stomato-spherocytosis)
and biochemical abnormalities such as defective cation co-transport and
water and phospholipid imbalance. Individuals with Rhnull phenotype
are diagnosed with Rh deficiency syndrome. The phenotype is also linked
to expression deficiency of intercellular cell adhesion molecule 4 (ICAM-
4), previously known as Landsteiner and Wiener glycoprotein (LW), CD47,
and Glycophorin (GYP) B. Rhnull phenotype has also been linked to Rh-
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associated glycoprotein (RHAG) gene mutations which may cause disrup-
tion of the Rh complex leading to Rh complex complete absence from the
cell membrane (Polin et al., 2016; Mu et al., 2019). Rhnull carriers suffer
chronic haemolytic anaemia (Huang, 1998; Avent et al., 2006).
1.5.2 RHCE Genetic Variations
Nucleotide substitutions in the RHCE gene are the reason behind RhC/c
and RhE/e polymorphism. Although there are six point mutations that
lead to four amino acid alterations (p.Cys16Trp; p.Ile60Leu; p.Ser68Asn;
p.Ser103Pro) which have been linked to the RhC/c, the p.Ser103Pro sub-
stitution has been identified as the main mutation that leads to C/c poly-
morphism (Mouro et al., 1993; Simsek et al., 1994). p.Pro226Ala amino
acid substitution is the main cause of Rh E/e polymorphism.
Similarly to RhD, RhE and RhC antigenicity and expression are affected by
different mutations that could lead to a weakened or a partial expression
of the antigens. For example, missense mutations in the RHCE gene cause
the expression of the Cx and Cw antigens, which are a weakened form of
the E and c antigens (Mouro et al., 1993; Noizat-Pirenne et al., 1998; Avent
et al., 2006). Rh Ew is also a form of weakened expression of antigen E,
which results from p.Met167Lys amino acid substitution (Strobel et al.,
2004). Antigen e expression is altered in people who express the VS anti-
gen which occurs as a result of the amino acid substitution p.Leu245Val
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and a hybrid gene (Faas et al., 2001), and it can also be encoded by the
RHCE gene Westhoff et al. (2001). Complete depletion of the C/c and E/e
antigen expression occurs very rarely when the RHD gene replaces the
RHCE. The lack of the RhCcEe protein expression was not linked to any
physical abnormalities (Gardner et al., 1991).
1.6 Rh Protein Complex
In the 1980s, researchers began to investigate the molecular basis of the
Rh antigens, which led to the purification of the RhcE, RhD and RhAG
polypeptides (Avent et al., 1990; Gardner et al., 1991; Mouro et al., 1993;
Simsek et al., 1994). Rh protein is about 30 kilodalton (kDa) integrated in
the RBCs membrane (Avent et al., 1990; Le van Kim et al., 1992). The ma-
ture RhD or RhCE protein is composed of 416 amino acid residues (Figure
1.2), which is found to be limited to the RBCs. Rh polypeptides are inte-
grated in the cell membrane in 12 plasma-membrane-spanning domains
(Okuda and Kajii, 2002; Avent et al., 2006).
The core of the Rh-complex is made up of one Rh non-glycosylated (RhD
or RhCE) protein and two glycosylated RhAG molecules that create a trimeric
structure (Conroy et al., 2005; Avent et al., 2006), where RhAG plays a cru-
cial role in this complex structure (Conroy et al., 2005). Figure 1.3 shows
a 3D module of the Rh protein trimeric complex, which is thought to be
integrated in the cell membrane with band3. This complex binds to the
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RBC membrane by the second repeat of ankyrin and protein 4.2 to the
cytoskeleton (Nicolas et al., 2006; Polin et al., 2016); therefore, this com-
plex has a crucial function in sustaining the structural integrity of the
RBC membrane. Rh-complex is also integrated in the cell membrane with
different associated proteins; which include CD47 glycoprotein, GYP B,
ICAM-4, and Duffy glycoprotein. Rh type B glycoprotein (RhBG) and Rh
type C glycoprotein (RhCG) are two non-erythroid specific Rh glycosy-
lated proteins found in various tissues (Conroy et al., 2005; Avent et al.,
2006), (Figure 1.4).
The specific functions of Rh-proteins are not clearly understood; never-
theless, Rh protein complex is essential for RBC structure and morphol-
ogy. Oxygen and cation transportation were linked to this protein complex
(Bruce et al., 2003; Nicolas et al., 2006; Bruce et al., 2009; Polin et al., 2016).
Different studies have linked Rh-proteins to ammonium transporters (Okuda
and Kajii, 2002; Avent et al., 2006; Planelles, 2007). RhAG protein in red
cells and RhBG and RhCG proteins expressed on different human organs
that are associated with ammonium transportation, are linked to ammo-
nium ion transportation (Liu et al., 2000; Conroy et al., 2005; Avent et al.,
2006; Planelles, 2007). These proteins have shown similarities to the am-
monium channel Ammonia transporter (Amt) proteins, which play an im-
portant role in the transportation of ammonium ion (NH+4 ) (Liu et al., 2001;
Conroy et al., 2005). However, there is no evidence to link RhD and RhCE
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proteins to ammonium transportation (Conroy et al., 2005).
Figure 1.3: 3D module of the trimeric structure of the Rh protein complex (RhD–RhAG2).
The red backbone structure represents the RhAG molecule and the green structure repre-
sents the RhD molecules. RhD– RhAG2 is the most probable structure for the Rh protein
complex. Image courtesy of Conroy et al. (2005).
1.7 Rh Associated Glyoprotein (RhAG)
The RHAG gene is located on chromosome 6 with 10 coding exons. The
RhAG protein is composed of 409 amino acids (Ridgwell et al., 1992; Reid
et al., 2012; Polin et al., 2016). The RhD, RhCE, and RhAG proteins are
expressed in 12 transmembrane spanning domains with both N-terminus
and C-terminus in the cytoplasm (Reid et al., 2012; Polin et al., 2016). The
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RhAG protein is essential for the expression of Rh proteins and different
mutations in the RHAG gene have been linked to Rh deficiency. Over
20 RHAG alleles were linked to severe decline in Rh expression (Rhmod)
or complete absence of Rh (Rhnull) and related antigens like CD47 and
ICAM-4. Different studies have linked RHAG specific SNPs to a weak-
ened RhD expression (Tian et al., 2011; Polin et al., 2016; Mu et al., 2019;
Wen et al., 2019). For example, c.241G>C mutation in the RHAG gene leads
to the replacement of non-polar Glycine to polar Arginine at position 81
which is predicted to be at the third transmembrane -spanning domain of
the protein. This change alters the hydrophobicity of the protein in that
area which weakens the RhAG protein expression (Tian et al., 2011; Polin
et al., 2016).
People with Rhmod or Rhnull may suffer haemolytic anaemia and RBCs
cation leak (Bruce et al., 2009). Mutations in the RHAG gene are also asso-
ciated with RBC morphological changes, for example, stomatocytosis and
spherocytosis Bruce et al. (2009), section 1.5.1.4.
1.8 Blood Group Antigenicity
Among the 55 different antigens in the Rh blood group system, RhD is the
most clinically significant one. Antigen D is considered the highest im-
munogenic antigen in the Rh system (50x more than other Rh antigens)
referring to its ability to elicit an immune response (Urbaniak and Greiss,
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Figure 1.4: The interaction of the Rh protein complex with other proteins in the red cell
membrane. Rh protein complex is integrated in the cell membrane by interacting with
Band3 and CD47 proteins which connect to ankyrin and Band4.2, respectively. Image
courtesy of Iwamoto (2005).
2000). The D antigen immunogenicity might be due to the high number
of epitopes expressed on the cell surface and the position they take on the
cell surface. , referring to its ability to elicit an immune response (Urba-
niak and Greiss, 2000). Antigen D clinical significance comes from the abil-
ity of its antibodies to cause HTRs, HDFN, and autoimmune haemolytic
anaemia (Le van Kim et al., 1992). The first two will be discussed in detail




Since the discovery of the ABO blood group in the early 1900s, blood trans-
fusion has become a common and a safe practice that saves life. However,
adverse immune reactions following a blood transfusion can reduce the
quality of life or in severe cases lead to death (Lubart et al., 2014). Trans-
fusion reactions can range from mild to a severe life threatening events.
Febrile non-haemolytic transfusion reactions (FNHTRs) are the most com-
mon post transfusion reactions, associated with fever, and chill-rigor symp-
toms without haemolysis, which cause by antibodies directed against donor
leucocytes and human leukocyte antigens (HLA) antigens.
HTRs are caused when RBCs are destroyed by an immune response, which
occurs as a result of transfusing an incompatible blood product. Haemol-
ysis can be either intravascular, which is caused by immunoglobulin M
(IgM), or extravascular, which is caused by immunoglobulin G (IgG). In-
travascular HTRs are more common with the ABO incompatibility, where
IgM binds to the membrane of the RBC activating the classical comple-
ment pathway, leading to direct penetration of the RBC’s membrane. Symp-
toms usually include chills, shocks, low blood pressure, anaemia, and
uraemia. Symptoms can be more severe and include disseminated in-
travascular coagulopathy and kidney failure. Intravascular HTRs fatality
rate is about 10% (Klein and Anstee, 2005). Extravascular HTRs are most
commonly involved with other blood groups incompatibility, like Kell and
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Rh. It is caused when IgG (mainly IgG3 and IgG1) bind to the RBC’s mem-
brane targeting them for phagocytosing by splenic macrophages. Symp-
toms are the same involved with intravascular HTRs but are less severe
and associated with a lower mortality rate (Poole and Daniels, 2007).
1.8.2 Haemolytic Disease of the Fetus and Newborn (HDFN)
HDFN occurs when an antigen-negative female has been immunised, whether
through blood transfusion or pregnancy, to develop alloantibodies to an
RBC’s antigen that her baby expresses on the RBCs. Different antibodies
are involved with HDFN; however, anti-D is the most common causative
agent (Bowman, 1998; Urbaniak and Greiss, 2000; Kumpel, 2008). RhD
negative females are susceptible to develop anti-D after delivering the
first RhD positive baby or after Rh incompatible transfusion, (Figure 1.5).
During labour some of the fetus’s blood enters the mother’s circulation
through transplacental haemorrhage (TPH) which causes an immune re-
sponse to develop antibodies against non-self-antigens, in this case anti-D.
The initial immune response stimulates the production of IgM antibod-
ies, which cannot cross the placenta because of their pentamer structure as
they are not bound by the IgG transporter neonatal Fc receptor (FcRn). The
secondary immune response causes production of IgG antibodies which
are able to cross the placenta and cause HDFN. The passing of the IgG
through the placenta is mediated by the FcRn located in the syncytiotro-
phoblast chorionic villi which bind the IgG Fc region in an acidic endo-
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some. The IgG is released in physiological pH of villous stroma, which
then bind FcRn on placental macrophages to be carried to fetal capillaries
(Simister, 2003; Wilcox et al., 2017). The IgG antibodies cross the placenta
and bind to the corresponding antigen on the RBCs of the fetus, which in-
duces destruction of the fetal RBCs by the immune system (Urbaniak and
Greiss, 2000; Poole and Daniels, 2007; de Haas et al., 2015).
The mechanism of cell lysis in HDFN is the same as other antibody me-
diated cell destruction, though Rh antibodies do not bind complement.
The severity of cell destruction in HDFN depends on antibody concentra-
tion, antigen expression, and the placenta’s ability to transfer antibodies.
Haemolysis starts when IgG coated cells are removed mostly by splenic
macrophages. The opsonised RBCs are either completely engulfed by the
macrophages or lose a part of the cell membrane (scission) and go back to
the circulation as microspherocytes, which reduces the cells’ survival rate.
Antibody-dependent cell-mediated cytotoxicity (ADCC) also plays a role
in cell destruction (Urbaniak and Greiss, 2000; Kumpel and Elson, 2001).
Rapid fetal RBC destruction through splenic macrophages results in se-
vere anaemia, and a high level of bilirubin in fetal circulation (“hyper-
bilirubinaemia”). If hyperbilirubinaemia is left untreated, bilirubin accu-
mulation in the brain leads to a disease called “kernicterus” which causes
irreversible damage to the nervous system associated with high morbidity
rate (Kumpel, 2008; de Haas et al., 2015). In 1940, 1% of newborns suffered
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HDFN, with about a 40% mortality rate (Kumpel, 2008).
In the 1960s, anti-D Ig prophylaxis (section 1.8.3) was introduced causing
a significant decrease in the incidence of HDFN from 15% to 1.6% (de Haas
et al., 2015). Mortality rate from HDFN decreased from 50% to 5-9% in the
1970s (Urbaniak and Greiss, 2000).
Figure 1.5: RhD incompatibility between RhD positive fetus and RhD negative mother
leads to HDFN. (a) Fetal RhD positive RBCs enter the mother’s circulation and elicit an
immune response and eventually cause the production of anti-D (IgG) antibody by B
cells in the secondary immune response. (b) In the second pregnancy, RhD IgG cross the
placenta and bind to antigen D inducing haemolysis. (c) Prophylactic anti-D prevent the
initiation of the first immune response by blocking B cell activation. Image courtesy of




Nowadays, the standard neonatal care includes administration of anti-D
Ig (20 μM / 1 mL of packed RBCs) prophylaxis between the 28th and the
34th week of gestation and at birth to prevent sensitisation (NICE, 2007).
Prophylactic anti-D, administered to RhD negative women to prevent anti-
gen D immunisation, is the most successful application of antibody-mediated
immune suppression (AMIS) (Urbaniak and Greiss, 2000; Kumpel and El-
son, 2001; Kumpel, 2008), although the exact mechanism is not fully un-
derstood. There are different suggested mechanisms of how antibody ad-
ministration can prevent an immune activation from the corresponding
antigen. It is important to know that anti-D can only suppresses initial im-
mune response. Therefore it is crucial to prevent primary immunisation
because once initiated it cannot be reversed.
A suggested mechanism of action for anti-D is through inhibition of B
cells activation through antigen-antibody complex. Antibody coated RBCs
bind through antibody Fc region to Fcγ RIIb (which has an immunorecep-
tor tyrosine based inhibitory motif (ITIM) intracellularly) on B cells with
concurrent B-cell receptor (BCR) binding to antigen D on the RBCs, (Fig-
ure 1.5). This complex receptor binding generates a signal of inhibition
and can lead to the lysis of B cells (Kumpel and Elson, 2001; Avent, 2018).
A different mechanism suggests that anti-D completely occupies antigen
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D binding sites not allowing BCR interaction, which causes inactivation
of B cells. Anti-idiotypic antibodies (anti-Id) are also believed to partici-
pate in anti-D mechanism by cross-binding BCR with Fcγ RIIb preventing
B cells activation (Kumpel et al., 1995; Anderson and Sinclair, 1998; Avent
and Reid, 2000; Kumpel and Elson, 2001).
Anti-D prophylaxis has reduced HDFN occurrence about 50% since the
1970s (Visser et al., 2019) nevertheless, HDFN caused by Rh antibodies is
still reported (Bhutani et al., 2013; Hassan et al., 2019). HDFN prevalence
among RhD negative females varies, for example, from 1.5% in Chile to
19% in Brazil, 15% in White European (mainly East Europe), and about
0.5% in China but expected to rise after the amendment to the 1 child pol-
icy (Bhutani et al., 2013; Visser et al., 2019). HDFN occurs mainly as a re-
sult of failure to provide adequate dosage of anti-D prophylaxis to prevent
sensitisation after a sensitisation episode such as abortion, amniocentesis,
antepartum bleeding. Failure to provide an adequate dosage of anti-D
can be as a result of lack of anti-D avilability in some countries like China
(Visser et al., 2019).
Anti-D is a biological product and is collected through apheresis from
donors with high anti-D concentration which could be a limited source
in some countries (Kumpel and Elson, 2001; Visser et al., 2019). The lack of
antenatal care in some developing countries in Africa and Asia is another
cause of HDFN (Bowman, 1988; Urbaniak and Greiss, 2000; Bhutani et al.,
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2013; Visser et al., 2019). According to Bhutani et al. (2013) HDFN results
in 50,000 fetal deaths and 114,000 preventable neonatal morbidities. The
majority of these cases (75%) are reported from Sub-Saharan Africa and
South Asia (Visser et al., 2019).
The limited access to anti-D in some countries and the possibility of un-
necessary administration of anti-D, as in the case of RhD negative fetuses,
created the need for a test to determine whether anti-D administration was
required. Fetal molecular RHD genotyping through testing cell free fetal
DNA (cffDNA) proved to be effective to determine the fetal RhD status
(Finning et al., 2008; Fan et al., 2009; Sillence et al., 2015). Using sequence-
specific primers-polymerase chain reaction (SSP-PCR) is one of the molec-
ular testing advancement to prevent HDFN (Clausen et al., 2012; de Haas
et al., 2016; Hyland et al., 2017; Clausen, 2018).
1.8.4 Fetal RHD Genotyping
Prenatal RHD genotyping has been routinely applied in different coun-
tries such as Belgium (Minon et al., 2015), Finland (Haimila et al., 2017),
the Netherlands (Oepkes et al., 2006; de Haas et al., 2016), and Denmark
(Clausen, 2018) to monitor RhD negative pregnant females who either
have been immunised or are susceptible to RhD immunisation (Hyland
et al., 2017). cffDNA genotyping through targeting one or more of the
RHD exons (5, 7, 10) by SSP-PCR has proven to be an accurate method for
fetal RHD genotyping (Finning et al., 2008; Fan et al., 2009; Clausen et al.,
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2012; Sillence et al., 2015; de Haas et al., 2016; Clausen, 2018). Reliable
genotyping of the fetal RHD gene results in a better use of anti-D Ig, in
which it is only administered to RhD negative females with RhD positive
fetus and eliminates the irrelevant administration of anti-D Ig to RhD neg-
ative females with RhD negative fetus, which was about 40% of the RhD
negative pregnancies (Blanco et al., 2018; Clausen, 2018).
1.9 Serological Testing
1.9.1 Antigen Detection
Blood group antigen detection depends on the agglutination of RBCs by
the corresponding antibody (Landsteiner, 1961). Agglutination occurs in
two steps: first, antigen-antibody reaction, in which antigen epitopes bind
the Fab section of the antibody; second, multiple antigen-antibody bind-
ing occur building a web like structure that can be visualised as an agglu-
tination (Mujahid and Dickert, 2015). There are different methods to carry
out agglutination tests such as classical tube testing or more advanced as-
says such as microplate and gel centrifugation methods (Kim et al., 2006;
Malomgré and Neumeister, 2009). The agglutination is influenced by dif-
ferent factors such as antigen:antibody ratio, temperature, and type of im-
munoglobulin used (Harmening, 2005).
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1.9.2 Direct Antiglobulin Test (DAT)
Direct antiglobulin test (DAT) is used to detect in-vivo sensitised RBCs
(i.e. antibody/ complement coated RBCs) as in case of HDFN and HTRs.
Coombs et al. (1946) first described the use of an antiglobulin test to de-
tect in-vivo sensitised RBCs of newborns diagnosed with HDFN. Anti-
human globulin (AHG) could be mono- or poly-specific. Mono-specific
anti-globulin reagents contain antibody to one specific component either
anti-IgG or anti-complement. Poly-specific anti-globulin reagents contain
antibodies against both immunoglobulin and complement. The test is car-
ried out by using patient washed RBCs mixed with antiglobulin reagent,
which are then incubated to optimise reaction conditions and then the re-
action is examined for agglutination, (Figure 1.6). A positive result might
indicate immunological activity against RBCs (Harmening, 2005; Pamphilon
and Scott, 2007). Such immunological activity might include HDFN, HTRs,
autoimmune haemolytic anaemia, or drug-induced haemolytic anaemia.
1.9.3 Indirect Antiglobulin Test (IDAT)
IDAT is used to detect in-vitro sensitisation of the RBCs, for example, the
presence of unexpected antibodies in the serum (for e.g. antibody screen-
ing, crossmatch), and detect blood group antigen (for e.g. weak D). In-
complete antibodies (IgG), when bound to red cells, are often unable to
produce visible agglutination depending on the number of antigen bind-
ing sites and antigen:antibody ratio in a reaction. Therefore, complete an-
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tibodies (AHG) is added to cross linking the binding IgG to produce a
visible agglutination. Coombs et al. (1945) described this test for detection
of incomplete (weak) D expression in 1945.
To carry out the IDAT for antibody detection in patients’ serum (Figure
1.6), serum is mixed with known cells (e.g. D+ cells) which are then incu-
bated to allow antigen-antibody binding. After incubation, the mixture is
washed to remove unbound antibodies and then AHG is added. If anti-
bodies are present in the serum, the AHG bind to the antigen-antibody
structure forming a visible agglutination (Coombs et al., 1945; Coombs
and Roberts, 1959; Pamphilon and Scott, 2007). IDAT can also be used
for blood antigen phenotyping (e.g. for Du test), where patients’ red cells
are tested with known antisera (IgG) which blocks antigen binding sites.
Complete antibodies are then added to produce visible agglutination (AHG).
Different factors affect the reaction such as the ratio of antibody to cells,
temperature, and reaction medium (Harmening, 2005). Different reaction
media have been reported to enhance antigen-antibody reactivity such as
albumin (Stroup and MacIlroy, 1965), low ionic strength solution (LISS)
(Löw and Messeter, 1974; Walker, 2018), and polyethylene glycol (PEG)
(Shirey et al., 1994; Dinardo et al., 2014).
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Figure 1.6: Direct and indirect antiglobulin testing. Image courtesy of Wikipedia (2015).
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1.10 Blood Group Genotyping (BGG)
1.10.1 BGG Platforms
Although serological tests are fast, cost friendly, and efficient, they are
limited by many factors, for example, the availability of antisera (e.g. no
reagent is commercially available for Yta) (Jungbauer, 2011b), affinity and
concentration of antibodies, and antigen status like weak or partial anti-
gen expression. Genotyping will provide the freedom to genotype a wider
range of blood antigens including low frequency antigens such as Goa,
BARC, and Tar (Daniels, 2013a; Boccoz et al., 2018). Complete blood group
genotyping (BGG) could be widely used in transfusion practice where
serology tests may fail to clarify issues or resolve discrepancies; for in-
stant, in case of positive DAT or IDAT, ABO discrepancies, Rh phenotyp-
ing (Jungbauer, 2011a,b).
Extensive efforts to alternatively use molecular testing to genotype blood
antigens have been made. These methods range from low, medium to high
throughput (Fichou et al., 2014; Avent et al., 2015). Different deoxyribonu-
cleic acid (DNA) microarray-based tests were introduced that enable geno-
typing of variant SNPs that are blood group gene specific (Hashmi et al.,
2005; Avent et al., 2009; Goldman et al., 2015; Chang et al., 2016; Fichou
and Férec, 2017; López et al., 2018; Bub and Castilho, 2019). For exam-
ple, BLOODchip® ID (Progenika Biopharma, a Grifols Company, Derio,
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Spain) (Goldman et al., 2015) and HEA BeadChip® (BioArray Solutions,
Warren, NJ, USA) (Paccapelo et al., 2015), are glass microarrays that enable
genotyping of the most important blood group antigens. IDCore allows
genotyping of 10 of the most important blood group antigens which in-
clude Rh, Kell, Kidd, Duffy, MNS, Diego, Dombrock, Colton, Cartwright,
and Lutheran (Avent et al., 2009; Finning et al., 2016). Although they are
very accurate and efficient, these assays have built-in limitations specif-
ically by the number of blood group gene specific SNPs they can detect
(Boccoz et al., 2018).
They are designed to target certain nucleotides or DNA regions through
polymerase chain reaction (PCR), while novel variants remain unknown
(Avent et al., 2015; Fichou et al., 2014), which may require further testing
using alternative methods like Sanger sequencing or exome sequencing
(Lane et al., 2019). In addition, microarray based tests are limited by their
primer and probe specificities. They detect specific SNPs in blood group
genes on the assumption that the adjacent sequence including primer bind-
ing regions are known. Mutations that might compromise primer/probe
sequences may cause false negative results. Therefore, it is important to
continuously update these tests (Liu et al., 2014; Finning et al., 2016; Orz-
ińska et al., 2018). Full gene sequencing would be the appropriate method
to explore blood group gene variations and resolve issues that might be
faced from using other genotyping platforms (Boccoz et al., 2018).
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1.10.2 BGG Using NGS
Complete DNA sequencing could be the most relevant technique to thor-
oughly study blood group variations. Nevertheless, such an approach
only allows a few samples to be studied at any one time in a given experi-
ment, and is thus an ineffective implementation for screening. Nowadays,
Next-generation sequencing (NGS) is used in HLA testing, which created
a strong drive to introduce NGS for BGG (Möller et al., 2016).
NGS is a sequencing technology that has the capacity to sequence full
genome (Orzińska et al., 2018), and a powerful technique that would over-
come limitations present in current assays used for BGG. NGS of blood
group gene specific SNPs would enable the screening of the clinically sig-
nificant blood antigens for a group of samples in one setup (Orzińska et al.,
2018), where serology or current BGG platform failed to provide clear re-
sults. For example, Wu et al. (2018) utilised NGS to resolve ABO discrep-
ancies in blood donors and successfully determine cis/trans linkage of ABO
genes. Full sequencing of blood group genes enables the maintenance and
update of SNP targeting assays (Tilley and Grimsley, 2014; Lane et al.,
2016; Orzińska et al., 2018) by identifying novel variants and overcomes
the issue of primers/probes specificity.
Genotyping could also be utilized to genotype patients with chronic dis-
eases (e.g. sickle cell disease (SCD), thalassaemia) that require multiple
38
BLOOD GROUP GENOTYPING (BGG)
blood transfusions, which place the patients at risk of developing alloan-
tibodies that could be clinically significant (Bakanay et al., 2013) and may
lead to further complications discussed in sections 1.8.1 and 1.8.2).
To prevent transfusion reactions in patients with alloantibodies, transfused
blood should be lacking the corresponding antigen which patients have
developed antibodies against. Therefore, multiple blood units need to be
tested for the specific antigen. This process could be very frustrating if a
patient has multiple antibodies, antibodies for a high frequency antigen,
or a rare blood group.
BGG is a powerful approach for massive blood group genotyping in blood
donors (Orzińska et al., 2018). Fully genotyping donors and creating a
database would make finding compatible donors and recalling for trans-
fusion easier (Ribeiro et al., 2009; Veldhuisen et al., 2009). Different studies
have developed a system to introduce routine BGG for frequent donors to
create a database to facilitate finding compatible blood units for patients
with allo-antibodies (Perreault et al., 2009; St-Louis et al., 2010). Geno-
typing will reduce the possibility of patient sensitisation by increasing the
compatibility between patients and donors through testing a wider range
of blood group antigens (Jungbauer, 2011b).
NGS could also be used to study the molecular interaction of blood anti-
gens with certain pathogens like Plasmodium vivax that utilises Duffy gly-
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coprotein as a receptor for cell invasion, and study the relationship be-
tween blood groups and specific diseases (Möller et al., 2016). There are
different techniques in sequencing, starting from first generation sequenc-
ing, NGS, and Third generation sequencing (TGS) which will be discussed
in depth in the following section 1.11).
1.11 First Generation DNA Sequencing
In the 1970s, different methods were introduced to sequence DNA which
included chemical breakdown of the DNA (Maxam and Gilbert, 1977)
and the incorporation of the terminating dideoxynucleotide triphosphates
(ddNTPs) during DNA synthesis, introduced by Frederick Sanger in 1975
(Sanger et al., 1977). The products were then separated by size on a poly-
acrylamide gel, smaller products run faster than bigger products on the
gel, creating a pattern. To conclude the DNA sequence, the separation
pattern on the gel is inspected visually. In the following years, this tech-
nique, which was called “Sanger sequencing”, was hugely improved and
was firstly introduced commercially by Applied Biosystems in 1986 (An-
derson and Schrijver, 2010; Pareek et al., 2011).
The sequencing starts first with amplifying the gene of interest either through
PCR or by cloning. After successful amplification, the DNA is purified and
a specific primer is annealed in the presence of DNA polymerase that will
extend the DNA synthesis. During the DNA synthesis, a random addition
40
FIRST GENERATION DNA SEQUENCING
of fluorescently labelled ddNTPs terminates the synthesis. Fluorescently
labelled DNA of varying sizes is subjected to capillary electrophoresis and
the resulting pattern of fluorescent peaks determines the DNA sequence.
The Sanger method can sequence DNA fragments of up to 1200 bp (Zhang
et al., 2011). The Sanger method was used in the Human Genome Project
(HGP) but in order to sequence longer DNA segments, shotgun sequenc-
ing was introduced. Shotgun sequencing is a technology used to sequence
the human genome by targeting DNA for random fragmentation and then
use overlapping reads to reassemble the genome. Sequencing library prepa-
ration included DNA fragmentation into smaller fragments, fragment am-
plification in vectors, and then sequencing of each fragment separately.
Depending on the sequence overlap, the data generated was assembled
creating a complete sequence. The human genome was successfully se-
quenced in 13 years and cost about $ 2.7 billion (Venter et al., 2001; Lander
et al., 2001; Margulies et al., 2005; Zhang et al., 2011).
Although Sanger sequencing has > 99.9% raw base accuracy and can se-
quence for up to 1 kb DNA, its accuracy in sequencing highly polymor-
phic genomic regions like major histocompatibility complex (MHC) genes
is about 10-20%. Very low accuracy in sequencing means it is insufficient
to detect infrequent clinically significant alleles (Anderson and Schrijver,
2010).
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1.12 Next Generation Sequencing (NGS)
Since the submission of the HGP first draft in 2000 (Lander et al., 2001),
there was a need to establish a sequencing technique that is cost efficient,
fast, and has high throughput. This would enable scientists to apply DNA
sequencing in research and clinical use to allow in-depth genome sequenc-
ing to provide thorough understanding of genomic variations in a popu-
lation, susceptibility to diseases, and pharmacogenomics reactions. These
techniques were called NGS or the second generation sequencing (Ander-
son and Schrijver, 2010; Pareek et al., 2011). In this work, the term NGS is
used as it is more commonly used.
In 2000, the Genome Sequencer 20 by 454 Life Sciences was introduced as
the first NGS system. The GS 20 combined the single-molecule emulsion
PCR and pyrosequencing, which indicates the nucleotide additions by the
detection of pyrophosphate release (Pareek et al., 2011). Although the se-
quencing technology in NGS and Sanger sequencing are different (Figure
1.7), they both require the presence of a specific DNA polymerase that
will carry out the reaction to generate a newly synthesized DNA, which
is called DNA sequencing-by-synthesis (Chen, 2014). Another mechanism
for NGS is DNA sequencing-by-ligation which uses DNA ligase mismatch
sensitivity to determine the sequence of a given DNA (Ho et al., 2011;
Huang et al., 2012). In this mechanism, single stranded DNA fragments
are annealed to an anchor sequence to which the probes and primers bind
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and a pool of fluorescent labelled oligonucleotide probes of different length
is used with DNA ligase to carry out the sequencing. The DNA ligase seals
the nick between the 5’ of the growing strand and the 3’ of the oligo (Ho
et al., 2011; Huang et al., 2012). After a nucleotide is incorporated, there is
a release of fluorescence, which indicates the nucleotide has been incorpo-
rated, the primer and anchor primer disassociate resetting the sequencing
and allowing the process to re-initiate (Ho et al., 2011).
Different companies offer different NGS platforms but mostly dominated
by Roche’s 454, Illumina’s Solexa, and Life Technologies’ SOLiD (Huang
et al., 2012). NGS technology, which is described as massively parallel
sequencing, depends on reading randomly through the DNA which is ac-
complished by breaking the DNA into smaller fragments which are then
ligated to adaptors for sequencing-by-synthesis. The read length for NGS
is much shorter than the one offered in Sanger sequencing, 50 to 500 con-
tinuous bp, are referred to as short reads. These short reads are one of the
down sides of NGS as short reads could generate a sequence that cannot
be assembled either because it’s too short or it matches to different regions
in the gene.
Depth of coverage is another critical issue in NGS. Depth of coverage is
known as the frequency of short reads that overlap in a defined genomic
area; for example, if the depth of coverage for a gene is 30, that means
each nucleotide in that gene has been expressed in at least 30 different and
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overlapping short reads. Adequate coverage is crucial for precise assem-
bly of the sequence and variant calling (Zhang et al., 2011; Schatz et al.,
2010). sequencing quality is another important marker in NGS which is
measure by PHRED score. PHRED score is an algorithmic integer value
representing the estimated probability of an error in the identification of a
nucleic base, for instance, PHRED score of 10 represents a 1/10 (10%) er-
ror rate, 20 represents a 1/100 (1%) error rate, and 30 represents a 1/1000
(0.1%) error rate (Ewing et al., 1998; Liao et al., 2017).
In the last few years, NGS has changed the genetic research field by el-
evating both throughput and data generated, at the same time lowering
significantly the cost of sequencing per nucleotide (Fichou et al., 2014) up
to 100-fold reduction in cost/bp (Pareek et al., 2011). NGS allows whole
genome sequencing (WGS) generating a complete sequence data that will
reveal any novel mutations. In BGG, NGS will allow the detection of si-
lencing or weakening expression alleles (Avent et al., 2015). Due to this
technological advancement, scientists were successful in decoding the hu-
man genome, revealing rare variants and utilizing the genomic advances
in cancer researches. Because of the NGS high impact on the research, it
was chosen as the method of the year in 2007 (Anderson and Schrijver,
2010). Modern genomic technology has contributed vastly to our under-
standing of various biological phenomena and altered our understanding
of genes linked to specific diseases (Zhang et al., 2011).
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Figure 1.7: Comparison between first, second and third generation sequencing technolo-
gies. Image courtesy of Patterson et al. (2020).
1.12.1 Ion Torrent Personal Genome Machine™ (Ion PGM™)
NGS, in this study, was carried out on the Ion Torrent Personal Genome
Machine™ (Ion PGM™) (Life Technologies, UK) to genotype for Rh blood
group genes. Ion PGM™ is a metal-oxide semiconductor sequencer that
uses pH sensitivity as an indicator for nucleotide addition. An ion-sensitive
field-effect transistor (ISFET) sensor is used to detect the H+ ion release
by the DNA polymerase during sequencing by synthesis (Lu et al., 2016;
Schatz et al., 2010). Wells, 3.5 mm-diameter, with a sensor plate is used to
carry out the sequencing (Figure 1.8). In the Ion PGM™ sequencer, all four
nucleotides are provided consecutively during DNA synthesis. If a com-
plementary nucleotide was added, the synthesized strand becomes one
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base longer causing an increase in negative charge resulting in a single H+
ion release that alters the surrounding pH by 0.02 pH units (Pourmand
et al., 2006; Rothberg et al., 2011). This shift in the pH is detected by a
sensor in the bottom of the wells. Through electronic reads and micropro-
cessor software, these changes will be converted to electrical signals which
are converted to base calls by using signal processing software (Rothberg
et al., 2011). Generated data can then be assembled with a reference se-
quence or de novo and analysed using computer software.
1.13 Third Generation Sequencing (TGS)
Genomics was radically reshaped during the past two decades by the in-
troduction of the first and then the second generation sequencing (Lu et al.,
2016). Next generation sequencing is a high-throughput sequencing, de-
pends on PCR amplification, that generates a vast amount of data in a low
cost. However, short reads generated during library preparation made de
novo assembly for large genomes difficult due to repetitive DNA sequence
(Lu et al., 2016; Zhang et al., 2011; Schatz et al., 2010), which brought the
need for a new sequencing approach that uses longer reads later named
TGS and also called single molecule sequencing (SMS) (Lu et al., 2016).
Unlike NGS, TGS technology does not rely on PCR and aims for DNA SMS
with real time sequencing and data analysis. The PCR free approach in
TGS abolished sequencing biases introduced by PCR (Schadt et al., 2010)
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Figure 1.8: Sequencing chemistry of the Ion PGM™. Well, DNA template captured in a
bead, an underneath sensor, and electronics are the main elements for sequencing in the
Ion PGM™. When a nucleotide is incorporated, a proton H+ is released altering the pH
of the well. Off-chip electronics transform the voltage changes to digital data. Image
courtesy Rothberg et al. (2011).
and allowed the detection of epigenetic modifications in the DNA. The
advancement of TGS reduced time of library preparation and sequencing
from days to hours (Lu et al., 2016).
The first successful single-molecule real time (SMRT) sequencer was estab-
lished by Pacific Biosciences that produced 0.5-1 gigabytes (GB) per SMRT
cell with read lengths of about 10 kb. However, error rate is about 13-15%
higher than NGS (Nagarajan and Pop, 2013; Ardui et al., 2018).
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1.13.1 Nanopore MinION™
MinION™ introduced by Oxford Nanopore Technologies in 2014 (Meller
et al., 2000, 2001) is the smallest portable nanopore based sequencing de-
vice on the market that offer different cost-efficient sequencing kits to meet
various sequencing needs. MinION™ sequencer technology is based on
flowcell containing 512 pores that are derived from Escherichia coli Curli
(Goyal et al., 2014; Rang et al., 2018). Curli are the main proteinaceous el-
ements of the extracellular matrix produced by different Enterobacteriaceae
which play essential roles in the pathogenicity of the bacteria (Barnhart
and Chapman, 2006). These Curli-derived nanopores are embedded in a
synthetic membrane submerged in ionic solution (Meller et al., 2000; Ple-
sivkova et al., 2019). Applying a voltage, DNA molecule is driven through
the pores causing changes in the ionic current running through the pores
in a distinctive manner, described as "squiggle" (Rang et al., 2018; Ple-
sivkova et al., 2019). These changes are measured by a sensor thousands
of times per second (Eisenstein, 2017), which are then translated to nu-
cleotides using software in a process known as basecalling, (Figure 1.9).
MinION™, when first introduced, had a 65-88% accuracy rate (Laver et al.,
2015; Lu et al., 2016), however, recent advancement in sequencing chem-
istry and computational software led error rate to decrease significantly to
5-15 % Rang et al. (2018). Sequencing yield and accuracy, when used for
whole microbial genome sequencing, reached 97% for 2D chemistry ex-
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periments, and 94% for 1D experiments (Tyler et al., 2018).
MinION™ sequencer has captivated researchers interest, specifically in in-
fectious agent surveillance and clinical diagnosis as they would benefit the
most from real-time sequencing technology (Lu et al., 2016). Studies have
shown the great potential of the MinION™, for example, during the Ebola
virus breakout in Guinea (Quick et al., 2016) and Zika virus epidemic in
Brazil in 2015 (Faria et al., 2017). MinION™ was also utilised to sequence
the SARS-CoV-2 during COVID-19 pandemic from infected individuals in
Ecuador and Colombia (Marquez et al., 2020; Lopez-Alvarez et al., 2020).
Different studies have utilised the Nanopore sequencer to detect DNA
and RNA modification, such as methylation in bacterial and mammalian
genome (Rand et al., 2017; Simpson et al., 2017; Garalde et al., 2018; Xu
and Seki, 2020). Although the use of nanopore sequencing has not been
widely investigated in blood group genotyping (BGG), it has been utilised
and proven effective for clinical genotyping of human HLA in different
studies (Lang et al., 2018; Ton et al., 2018; Matern et al., 2020; De Santis
et al., 2020). Matern et al. (2017) utilised MinION™ in ABO genotyping by
sequencing a 7 kb amplicon, covers the region of exons 6 and 7, which was
successful in differentiating between six ABO genotypes (AA, AO, BB, BO,
AB, OO).
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Figure 1.9: MinION™ sequencing chemistry. Protein nanopores are imbibed in a mem-
brane and a voltage is applied to drive a single stranded DNA through the pore. As the
DNA passes through the pore, changes in the current are measured by a sensor thousands
time per second and recorded as "squiggle" (bottom right image) which is then translated
to nucleotides in a process known as basecalling. Image courtesy Eisenstein (2017).
1.14 Study Aims and Objectives
Unlike serological testing, BGG provides the freedom to analyse a wider
range of blood antigens including low frequency antigens that are clini-
cally significant and can lead in the case of discrepancy to clinical compli-
50
STUDY AIMS AND OBJECTIVES
cations. BGG could be widely used in transfusion practice, and is specially
beneficial to transfusion dependent patients to minimize the risk of sensi-
tisation and risks associated with that. NGS is a powerful technique to
be used for BGG as it provides high throughput data and allows explor-
ing the novel alleles of blood group genes. TGS is the new sequencing
technology that directly sequences the DNA molecule allowing real time
sequencing and data analysis, while reducing preparation time and cost.
This study aimed to use NGS (Ion PGM™) to develop a methodology to
fully sequence the Rh genes including RHD, RHCE and RHAG to study
variants present in the population and establish Rh haplotype specific ref-
erence sequences through studying intronic SNPs suspected to be Rh hap-
lotype specific. We also aimed to use TGS (MinION™) to sequence the
RHD gene to compare between the two sequencing technologies and as-
sess the use of TGS for BGG. To achieve these aims, objectives were as
follow:
1. Design target specific long range-polymerase chain reaction (LR-PCR)
primers to amplify the complete RHD and RHCE genes including
promoter, introns and all exons for sequencing. Complete sequenc-
ing of the Rh genes will enable the identification of known and novel
variants encoded by exonic and/or intronic mutations.
2. All primers will be assessed for specificity to ensure that amplifi-
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cation is target specific and not from the other homologous gene.
Primers are tested with different Rh alleles for the optimisation of
LR-PCR conditions to ensure adequate amplification is achieved from
different Rh alleles.
3. Prepare sequencing libraries and sequence the target genes using
NGS on Ion PGM™ platform.
4. Map sequence reads to the human genome reference sequence (hg38)
and analyse data. Call variants to identify exonic and intronic muta-
tions in the sequence to assess for allele determination.
5. Analyse intronic SNPs and their relation to a specific Rh haplotype
and create intronic SNP patterns for these haplotypes to establish Rh
allele specific refernce sequences.
6. Use MinION™ to fully sequence the RHD gene to test the suitability
and efficiency of the MinION™ sequencer in BGG. Data generated
from samples sequenced using MinION™ will be compared to the
sequence data for the same samples generated by Ion PGM™ which
will allow assessment of the MinION™ ability to achieve high qual-
ity reads and efficiency in calling variants to aid allele determination.
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2.1 Blood Sample Collection
Donor blood samples (n=146) were supplied in anti-coagulation ethylene-
diaminetetraacetic acid (EDTA) tubes by the NHSBT, Bristol, United King-
dom. Inclusion criteria for blood samples was either their Rh haplotype
(R1, R2, R0, Rz, r, r’, r”) (n=118) or by their D reactivity (weak D) (n=28).
Samples were serologically phenotyped for ABO, Rh and other blood groups
by the NHSBT and were properly consented, anonymised, and supplied
with a full ethical approval. Blood was processed in our laboratory after
about 96 hours post collection. Blood tubes were centrifuged at 2500 xg
for 10 minutes at room temperature. Plasma on the top layer was care-
fully disposed and buffy coat was collected into a 1.5 mL tube while the
remaining content was discarded.
Genomic DNA (gDNA) samples (n=23) were from the ISBT 1996 work-
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shop (ISBT, 1996). These samples were identified as RHD variants and
were included in this work to determine and compare their sequence to
other RHD variant alleles. All samples are listed in Table 2.1 including in-
formation supplied with them.
gDNA samples (n=35) were supplied by the Finnish Red Cross Blood Ser-
vice (Helsinki, Finland) by Silja Tammi, Susanna Sainio, and Katri Haim-
ila. Samples were collected from pregnant females who participated in the
national screening program for HDFN in Finland between February 2014
and December 2016 (Haimila et al., 2017). Samples tested serologically
as D-negative, very weak D or showed inconsistent RhD serology results.
Pregnant women with partial D variants and certain weak D variants, as
well as those that have inconsistent phenotyping and genotyping results,
were considered D-negative, so that they are included in the prophylaxis
program, due to the risk of immunisation. The samples were assessed us-
ing the SSP-PCR test which showed that all 35 samples were RHD gene
positive (Tammi, 2019). Figure 2.1 shows the number of samples supplied
by NHSBT, ISBT 1996 workshop, and the Finnish Red Cross Blood Ser-




Figure 2.1: Flowchart illustrates the number of samples supplied by NHSBT, ISBT 1996
workshop, and the Finnish Red Cross Blood Service.
Table 2.1: Ethnicity of donors, Rh serology results, and predicted Rh genotype for sam-
ples included in the study as supplied.
Rh Serology Results
Sample no. Ethnicity D C c E e Rh haplotype RHD allele
004_01 Caucasian + + - - + R1R1 ND
004_02 Caucasian + + - - + R1R1 ND
004_03 Other + + - - + R1R1 ND
004_04 Caucasian + + - - + R1R1 ND
004_05 Caucasian + + - - + R1R1 ND
004_06 Caucasian + + - - + R1R1 ND
004_07 Caucasian weak D+ + - - + R1R1 ND
004_08 Caucasian + + + - + R1r ND
004_09 Caucasian + + + - + R1r ND
004_10 Chinese + + + - + R1r ND
004_11 Caucasian + + + - + R1r ND
004_12 Caucasian + + + - + R1r ND
004_13 Caucasian + + + - + R1r ND
004_14 Caucasian weak D+ + + - + R1r ND
004_15 Caucasian + + + - + R1r ND
004_16 Caucasian weak D+ + + - + R1r ND
continued . . .
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Sample no. Ethnicity D C c E e Rh haplotype Rh Genotype
004_17 Caucasian weak D+ + + - + R1r ND
004_18 Caucasian weak D+ + + - + R1r ND
004_19 Caucasian weak D+ + + - + R1r ND
004_20 Caucasian weak D+ + + - + R1r ND
004_21 Caucasian weak D+ + + - + R1r ND
004_22 Caucasian weak D+ + + - + R1r ND
004_23 Caucasian weak D+ + + - + R1r ND
004_24 Caucasian weak D+ + + - + R1r ND
004_25 Caucasian weak D+ + + - + R1r ND
004_26 Caucasian weak D+ + + - + R1r ND
004_27 Caucasian weak D+ + + - + R1r ND
004_28 Caucasian weak D+ + + - + R1r ND
004_29 Caucasian + + + + + R1R2 ND
004_30 Caucasian + + + + + R1R2 ND
004_31 Caucasian + + + + + R1R2 ND
004_32 Caucasian + + + + + R1R2 ND
004_33 Caucasian + + + + + R1R2 ND
004_34 Caucasian + + + + + R1R2 ND
004_35 Caucasian weak D+ + + + + R1R2 ND
004_36 Caucasian + + + + + R1R2 ND
004_37 Caucasian + + + + + R1R2 ND
004_38 Caucasian + + + + + R1R2 ND
004_39 Caucasian + + + + + R1R2 ND
004_40 Caucasian + + + + + R1R2 ND
004_41 Caucasian + - + + - R2R2 ND
004_42 Not disclosed weak D+ - + + - R2R2 ND
004_43 Caucasian + - + + - R2R2 ND
004_44 Caucasian + - + + - R2R2 ND
004_45 Caucasian + - + + - R2R2 ND
004_46 Caucasian + - + + - R2R2 ND
004_47 Caucasian + - + + - R2R2 ND
004_48 Caucasian + - + + + R2r ND
004_49 Caucasian + - + + + R2r ND
004_50 Caucasian + - + + + R2r ND
004_51 Caucasian + - + + + R2r ND
004_52 Caucasian + - + + + R2r ND
004_53 Caucasian + - + + + R2r ND
004_54 Caucasian weak D+ - + + + R2r ND
004_55 Caucasian weak D+ - + + + R2r ND
004_56 Caucasian weak D+ - + + + R2r ND
continued . . .
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Sample no. Ethnicity D C c E e Rh haplotype Rh Genotype
004_57 Caucasian weak D+ - + + + R2r ND
004_58 Caucasian + - + + + R2r ND
004_59 Caucasian + - + + + R2r ND
004_60 Caucasian weak D+ - + + + R2r ND
004_61 Caucasian weak D+ - + + + R2r ND
004_62 Caucasian weak D+ - + + + R2r ND
004_63 Caucasian + - + - + R0r ND
004_64 Caucasian + - + - + R0r ND
004_65 Caucasian + - + - + R0r ND
004_66 Caucasian + - + - + R0r ND
004_67 Caucasian + - + - + R0r ND
004_68 Caucasian + - + - + R0r ND
004_69 Caucasian weak D+ - + - + R0r ND
004_70 Caucasian weak D+ - + - + R0r ND
004_71 Caucasian + - + - + R0r ND
004_72 Caucasian + - + - + R0r ND
004_73 Caucasian + - + - + R0r ND
004_74 Caucasian weak D+ + + + - R2Rz ND
004_75 Caucasian - - + - + rr ND
004_76 Caucasian - - + - + rr ND
004_77 Caucasian - - + - + rr ND
004_78 Caucasian - - + - + rr ND
004_79 Caucasian - - + - + rr ND
004_80 Caucasian - - + - + rr ND
004_81 Caucasian - + + - + r’r ND
004_82 Caucasian - + + - + r’r ND
004_83 Caucasian - + + - + r’r ND
004_84 Caucasian - + + - + r’r ND
004_85 Caucasian - + + - + r’r ND
004_86 Black - + + - + r’r ND
004_87 Black - + + - + r’r ND
004_88 Caucasian - - + + + r”r ND
004_89 Caucasian - - + + + r”r ND
004_90 Caucasian - - + + + r”r ND
004_91 Caucasian - - + + + r”r ND
004_92 Caucasian - - + + + r”r ND
004_93 Caucasian - - + + + r”r ND
004_94 ND ND ND ND ND ND ND DIII
004_95 ND ND ND ND ND ND ND DIII
continued . . .
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Sample no. Ethnicity D C c E e Rh haplotype Rh Genotype
004_96 ND + + + - + R1r DIII
004_97 ND ND ND ND ND ND ND DVII
004_98 ND ND ND ND ND ND ND DIIIb
004_99 ND ND ND ND ND ND ND DIVb
004_100 ND ND ND ND ND ND ND DIVb
004_101 ND + + + - + R1r DVa
004_102 ND + + + - + R1r DVI
004_103 ND + + + - + R1r DVI
004_104 ND + - + + + R2r DVI
004_105 ND + - + + + R2r DVI
004_106 ND ND ND ND ND ND ND DVI
004_107 ND ND ND ND ND ND ND DVII
004_108 ND + + + - + R1r DVII
004_109 ND + + + - + R1r DVII
004_110 ND + + + - + R1r DVII
004_111 ND + + + - + R1r DFR
004_112 ND ND ND ND ND ND ND DFR
004_113 ND ND ND ND ND ND ND Cw
004_114 ND ND ND ND ND ND ND Cw
004_115 ND ND ND ND ND ND ND Cx
004_116 ND ND ND ND ND ND ND Cx
004_117 ND - + + - + ND ND
004_118 ND - + + - + ND ND
004_119 ND - + + - + ND ND
004_120 ND - + + - + ND ND
004_121 ND - + + - + ND ND
004_122 ND - + + - + ND ND
004_123 ND - + + - + ND ND
004_124 ND weak D+ + + - + ND ND
004_125 ND weak D+ + + - + ND ND
004_126 ND - + + - + ND ND
004_127 ND - + + - + ND ND
004_128 ND - + + - + ND ND
004_129 ND - + + - + ND ND
004_130 ND - + + - + ND ND
004_131 ND - + + - + ND ND
004_132 ND weak D+ + + - + ND ND
004_133 ND - + + - + ND ND
004_134 ND - + + - + ND ND
004_135 ND - + + - + ND ND
continued . . .
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Sample no. Ethnicity D C c E e Rh haplotype Rh Genotype
004_136 ND - + + - + ND ND
004_137 ND - + + - + ND ND
004_138 ND - + + - + ND ND
004_139 ND - + - - + ND ND
004_140 ND weak D+ + - - + ND ND
004_141 ND weak D+ + - - + ND ND
004_142 ND - + + + + ND ND
004_143 ND -* + + + + ND ND
004_144 ND - - + + + ND ND
004_145 ND - - + + + ND ND
004_146 ND - - + + + ND ND
004_147 ND weak D+ - + + + ND ND
004_148 ND + - + - + ND ND
004_149 ND - - + - + ND ND
004_150 ND - - + - + ND ND
004_151 ND - - + - + ND ND
004_152- Multiple + + + + + R1R2 ND
004_205
Grey highlight indicates samples were supplied by the NHSBT, Bristol, United
Kingdom.
Green highlight indicates samples were from the ISBT workshop 1996.
Blue highlight indicates samples were supplied by the Finnish Red Cross Blood
Service, Helsinki, Finland.
ND = No data available.
* Very weak D reaction in serology testing.
** RhD antigen titre after elution +1 as reported by the Finnish research group
(Tammi, 2019).
2.2 Genomic DNA Extraction
gDNA was extracted from blood donor samples using the QIAamp DNA
Blood Mini kit (Qiagen Ltd, United Kingdom) following manufacturer’s
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guidelines. All samples were centrifuged on 2500 ×g for 10 minutes to
separate blood to three layers; plasma, buffy coat, and packed RBCs. In
a 1.5 ml tube, 200 μL of the extracted buffy coat was added to 20 μL of
Qiagen Proteinase K. A volume of 200 μL of AL buffer was added, mixed
vigorously and incubated at 56 ◦C for 10 minutes and then centrifuged.
200 μL of absolute ethanol (Fisher Scientific UK, United Kingdom) was
added to the mixture and mixed vigorously for 15 seconds. The mixture
was transferred to the QIAamp mini spin column, and centrifuged at full
speed xg for 1 minute. The filtrate was discarded and the spin column
was placed in a new collection tube. Next, 500 μL of AW2 buffer was
added to the QIAamp mini spin column tube and was spun at 6000 xg
for 3 minutes; the filtrate was discarded afterwards and the QIAamp mini
spin column was placed in a clean 2 mL tube. Lastly, gDNA was eluted
with 200 μL with nuclease-free water following a 1 minute incubation to
increase the yield of gDNA. The tube was centrifuged at 6000 xg for 1
minute. Purified gDNA concentration was determined using Qubit assay
(section 2.3). gDNA was finally stored at -20 ◦C.
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2.3 Qubit® dsDNA HS Assay
After gDNA extraction, gDNA concentration was determined using Qubit®
dsDNA HS Assay kit (Thermo Fisher Scientific, United Kingdom). The kit
included Qubit® dsDNA HS reagent buffer, and two standards, one and
two. Qubit™ reagent was diluted with Qubit™ buffer in 1:200 ratio to
create the working solution. In a clean Qubit™ assay tube, 190 μL of the
working solution was added for each of the standards, and 199 μL for each
of the samples. A volume of 10 μL for each standards and 1 μL for each
sample were added to reach a total volume of 200 μL. All tubes were mixed
vigorously, and incubated for 3 minutes at room temperature. Qubit™ 2.0
Fluorometer (Invitrogen, United Kingdom) instrument was used for read-
ing the standards 1 and 2 (ng/μL), followed by the samples. Using read-
ings acquired from the Qubit™ 2.0 fluorometer, gDNA concentration was
calculated. All samples were then diluted to 20 ng/μL using nuclease-free
water (Ambion®, Thermo Fisher Scientific, United States) and stored at




All primers in this study were designed using Primer3 software (Unter-
gasser et al., 2012) and the CLC Main Workbench 9 software (Qiagen Ltd,
United Kingdom) to visualize an alignment of the RHD and RHCE genes
to aid in locating primers positions. To ensure primer specificity to the
target of interest, primers were assessed using Primer- BLAST on the Na-
tional Centre for Biotechnology Information (NCBI) website (Altschul et al.,
1997).
To investigate 8 RHD intronic SNPs detected by Halawani (2015), that
were suspected to be R2 haplotype specific including 2 SNPs in intron
2 (25,611,580 G>A; 25,614,400 C>G), 3 SNPs in intron 3 (25,621,980 C>T;
25,625,471 T>C; 25,627,066 C>G), and 2 SNPs located in intron 8 (25,646,933
T>G; 25,648,349 T>C), RHD specific primers were designed to amplify re-
gions of interest for sequencing. SNPs numbers are the position they corre-
late to in hg19 reference sequence. Six sets of primers were designed, and
one pair of primers for SNP (25,646,933) was adapted from Clarke (2016),
listed in Table 2.2.
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LR-PCR primers for RHD, RHCE, and RHAG are listed in Tables 2.3, 2.4
and 2.5, respectively. Multiple overlapping amplicons were designed to
amplify the target gene for sequencing (Figure 2.2). The RHD gene was
amplified in six PCR amplicons ranging from 9 to 13 kb in size, with ap-
proximately 1 kb overlap between each of them. To eliminate amplifica-
tion from the RHCE gene, primers were designed around intronic differ-
ences between the RHD and the RHCE genes positioned at the 3’ end to
create RHD specific primers. Even though exons 8 and 10 for the RHD
and the RHCE are identical, there are intronic differences between the two
genes that have been utilised to create RHD specific primers.
In a similar manner, the RHCE gene was amplified in eight overlapping
amplicons (Figure 2.2) listed in Table 2.4, in which RHCE-2 reverse primer
was designed by Kelly Sillence and RHCE-3 and RHCE-4 primer sets were
adapted from Halawani (2015).
For the RHAG gene amplification, three sets of primers were designed to
amplify the gene in three overlapping amplicons (Table 2.5).
Another set of LR-PCR RHD primers were adopted from Hyland et al.
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(2017) (forward primer: 5’-GCTTGGGCTTCCTCACCTCG-3’ ; reverse primer:
5’-TGCCGGCTCCGACGGTATC-3’). Primers were used to amplify one
LR-PCR amplicon that covers the region from exon 2 to exon 7 in the RHD
gene for samples that failed to amplify one or more of the LR-PCR RHD
amplicons designed in this study. All primers were ordered in a high per-
formance liquid chromatography (HPLC) purified form from Eurofins Ge-
nomics (Ebersberg, Germany).
Figure 2.2: The RHD, RHCE, and RHAG genes amplified in LR-PCR amplicons. (a) Six
overlapping RHD LR-PCR amplicons. (b) The RHCE gene amplified in 8 overlapping
amplicons. (c) Three overlapping RHAG LR-PCR amplicons.
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2.5 Polymerase Chain Reaction (PCR)
2.5.1 Conventional PCR
Seven RHD intronic SNPs, 2 in intron 2 (25,614,400 C>G, 25,611,580 G>A);
3 in intron 3 (25,621,980 C>T, 25,627,066 C>G, 25,625,471 T>C); and 2 in
intron 8 (25,648,349 T>C, 25,646,933 T>G) were suspected to be linked to
the R2 haplotype (Halawani, 2015). All seven SNPs were tested to confirm
if they are R2 haplotype specific. gDNA samples from blood donors of dif-
ferent phenotypes were tested (6 R2R2, 6 R1R1, 1 R2r, 1 R1r, 6 R1R2, and
8 R0r). RHD -specific primers were used to amplify the region of interest
listed in Table 2.2.
Two different enzymes were used, BioMix™ 2X master mix (Bioline Reagents
Limited, United Kingdom) for (25,621,980), (25,625,471), (25,648,349), (25,646,933)
(25,648,349), and (25,646,933); and Q5® Hot Start High-Fidelity 2X Mas-
ter Mix, (New England Biolabs®, United Kingdom) for SNP (25,627,066).
Fifty μL PCR reaction contained a 1X master mix, 200ng of gDNA tem-
plate, 400 nM of the forward primer, and 400 nM of the reverse primer.
Veriti thermocycler program was set as following: denaturation at 95 ◦C
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for 10 min, 35 cycles of 95 ◦C for 30 seconds, annealing temperature (Ta)
varied for each primer set (Table 2.2), and 72 ◦C for 30 seconds. The last ex-
tension was at 72 ◦C for 10 min; finally, samples were held at 4 ◦C. Agarose
Gel Electrophoresis was used to validate the success of PCR amplification,
(section 2.6).
Table 2.2: Sequence, annealing temperature (Ta), and product sizes for all primers used
for RHD intronic SNPs amplification.
Primer name Sequence 5’-3’ Size (bp) Ta, ◦C
25,611,580-Forward TTTTACTGGACAGCCCTACTCC 558 62
25,611,580-Reverse CATGGCTATTTATTGTCTAGCAGCA
25,614,400-Forward GCTACCATGCCCTGCTAAT 417 63
25,614,400-Reverse TCCAGTACTTTTCAGAGCC
25,621,980-Forward GACCGAACACTTGTTCAATTTTGAAC 442 60
25,621,980-Reverse CTCTCCCTTTCTTGCTGTGG
25,625,471-Forward GGGGCAGCTTCATCTTATCAAGAG 419 62
25,625,471-Reverse CTCACTGCAACCTCCACCCGTT
25,627,066 Forward TGGGATTACAGGCAAAATTAG 834 60
25,627,066-Reverse AGGTGTGACTTGAAGCCAT
25,646,933-Forward* CTTGGGCTGCTGAGAGATTAGAA 507 57
25,646,933-Reverse* CATATGTATTCCTCCAGCTTCCT
25,648,349-Forward TCCAGGAATGACAGGGCT 525 63
25,648,349-Reverse TGAGGACTGCAGATAGGG
* Adapted from Clarke (2016).
2.5.2 Long Range-PCR (LR-PCR)
To optimize PCR conditions for LR-PCR, different Ta and primer concen-
trations were tested to ensure specific amplification from the target gene.
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In a 50 μL reaction, 1X master mix of LongAmp Hot Start Taq 2X Master
Mix (New England Biolabs, United Kingdom) was used with 200 ng of
gDNA template. One μM of the forward and reverse primers was used
for all amplicons except for RHD amplicon 3, where 0.2 μM of the for-
ward and reverse primers was used. Each RHD amplification cycle run
included RHD positive hemizygous control, RHD positive homozygous
control, RHD negative control, and non-template control.
The Veriti Thermal Cycler (Applied Biosystems, United Kingdom) pro-
gram was set as follows: denaturation at 95 ◦C for 5 minutes, 30 cycles of
95 ◦C for 30 seconds, annealing for 30 seconds, and extension at 65 ◦C 1
minute / kb. Ta varied for each primer set (Tables 2.3, 2.4, 2.5). The last
extension was at 65 ◦C for 10 minutes; finally, samples were held at 4 ◦C.
To validate PCR amplification, PCR products were tested on agarose gel
electrophoresis (section 2.6).
Hyland et al. (2017) primers were used to amplify the RHD gene from
exon 2 to exon 7 in a 22,117 bp LR-PCR amplicon. A final volume of 50
μL reaction contained: 1X master mix of 5X TaKaRa LA Taq Hot Start
(Takara, Japan), 100 ng of gDNA template, 1 μM of the forward and re-
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verse primers. The reaction was placed on 94 ◦C for initial denaturation
for 30 seconds followed by two-step PCR protocol (30 cycles at 98 ◦C for
10 seconds followed by 68 ◦C for 10 minutes) (Hyland et al., 2017).
Table 2.3: Sequence, exons covered, product sizes, and annealing temperature (Ta) for
primers used for RHD LR-PCR.
Primer name Sequence 5’-3’ Exons Size, bp Ta, ◦C
RHD-1 Forward ATCCACTTTCCACCTCCCTGC 1 10,326 62
RHD-1 Reverse TCTTTGCACTTCTTCTGACAACA
RHD-2 Forward CTGGGAGAGTGAAGCTGGGTGTGA 2, 3 13,709 62
RHD-2 Reverse TTCATACACATCTCTACCCCCCCTC
RHD-3 Forward GTTTGAGCCCAGGAGTTAGGGACCGAG 4 10,789 66
RHD-3 Reverse CCCACTGTGACCACCCAGCATTCTA
RHD-4 Forward CATACCTTTGAATTAAGCACTTCAC 5, 6, 7 9,895 66
RHD-4 Reverse CAGAATGGCCTTTACCAGCCAT
RHD-5 Forward GTTCAAGCTGTCAAGGAGACATCACTATACA 8 11,628 65
RHD-5 Reverse CCAGTTTTAAGAATTTGTCGGCCGGTCG
RHD-6 Forward ATACATTCCATCCAGAACTGTTCACC 9, 10 11,284 64
RHD-6 Reverse AGGCCAAGAGATCCTGGTGAAACTATCC
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Table 2.4: Sequence, exons covered, product sizes, and annealing temperature (Ta) for
primers used for RHCE LR-PCR.
Primer name Sequence 5’-3’ Exons (Intron) Size, bp Ta, ◦C
RHCE-1 Forward TCTTTGCACTTCTTCTGACAGCA 1 10,599 62
RHCE-1 Reverse GCTAGCGGACATTTAGGTTAGTCTC
RHCE-2 Forward AGGTCTTGCTATATTGCCCAGGTTCA 2 10,419 64
RHCE-2 Reverse* GCTGCTGGAGTATAGTGATGTGATCGTG
RHCE-3 Forward† CTACTATCAAGCTCACTGCCCGATTT 3, 4 11,215 62
RHCE-3 Reverse† ATCCTGGCTCTCCTTCTCA
RHCE-4 Forward† CAAGTCCATGTGCAGTGAC 4, 5, 6, 7 17,856 60
RHCE-4 Reverse† ACAGCCAGCATCTTCTTTCAGTCAG
RHCE-5 Forward TTACAGGTGTGCGCCAGAGT 7 3,881 62
RHCE-5 Reverse GACACGAAATCTTCTGTGACCC
RHCE-6 Forward GGCTGAAGTATGAGAATTGCTTGAAC (7) 6,032 62
RHCE-6 Reverse GTCACTGCACATGGACTTG
RHCE-7 Forward GTAGAGATGGGGTCTCACTATAGGA 8 5,333 64
RHCE-7 Reverse ATATGCCTAGAAGTGAAATTGTTGAG
RHCE-8 Forward GTACTGTTTCCTGTCCCCGA 9, 10 13,966 60
RHCE-8 Reverse TGTGGTGACATTGGGCATG
*Designed by Kelly Sillence.
† Adapted from Halawani (2015).
Table 2.5: Sequence, product sizes, and annealing temperature (Ta) for primers used for
RHAG LR-PCR.
Primer name Sequence 5’-3’ Exons Size, bp Ta, ◦C
RHAG-1 Forward TGGTAGGGCTGATTTCCTTGT 6, 7, 8, 9, 10 10,003 62
RHAG-1 Reverse TGGATGTTTTGGCCCAGCTT
RHAG-2 Forward GCTGATCTGAGGGTTACTCCTTT 2, 3, 4, 5 10,519 62
RHAG-2 Reverse AGGAGGATGGGAACGCTAAG
RHAG-3 Forward AATTATTCTGCAGATTTCACCCC 1 15,083 62
RHAG-3 Reverse GGAGACAAGAATTCCTCCACCTAT
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2.5.3 Droplet Digital PCR (ddPCR)
All samples were tested for zygosity with the aim of knowing the num-
ber of RHD alleles present for subsequent sequence analysis. The RHD
zygosity was determined for all samples using droplet digital polymerase
chain reaction (ddPCR) to determine if a sample was hemizygous (one
copy of the RHD gene) or homozygous (two copies of the RHD gene) (Sil-
lence et al., 2015, 2017). Samples were tested for RHD exon 5 (RHD5) and
RHD exon 7 (RHD7) against the reference gene Argonaute RISC component
1 (AGO1) on chromosome 1 (Sillence et al., 2015, 2017). Primers and probes
used in ddPCR zygosity testing were adapted from Finning et al. (2008);
Fan et al. (2009), (Table 2.6). Probes used for the two RHD gene targets,
RHD5 and RHD7, were labelled with 6-carboxyfluorescein (FAM) on the 5’
end and Black Hole Quencher 1 (BHQ-1) on the 3’ end, while the reference
sequence AGO1 probe was labelled with Hexachlorofluorescein (HEX) on
the 5’ end and BHQ-1 on the 3’ end.
Each PCR reaction was prepared in 20 μL final volume, which contained:
1X ddPCR™ Supermix for probes (Bio-Rad, United Kingdom), 300 nmol
\L of primers, 250 nmol \L probes, and 20 ng of template. To generate
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droplets, the 20 μL PCR reaction was transferred to the centre row labelled
with “sample” of a DG8™ cartridge (Bio-Rad). To the row labelled with
“oil”, 70 μL of QX100™ droplet generator oil for probes was placed (Bio-
Rad). The cartridge was sealed using DG8™ gaskets (Bio-Rad) and then
placed onto the QX100™ droplet generator (Bio-Rad) to generate droplets
through oil emersion chemistry.
After the generation of the droplets, 40 μL solution containing droplets
was transferred to a 96-well PCR Plate (Sigma-Aldrich, UK). The plate was
then sealed using a pierceable foil heat seal (Bio-Rad) on the PX1™ PCR
plate sealer (Bio-Rad). The plate was then placed in the C1000 Touch™
Thermal Cycler (Bio-Rad). PCR protocol was as follows; 95 ◦C for 10 mins,
40 cycles of 95 ◦C for 30 seconds and 58 ◦C for 1 minute. Final step was
carried out at 98 ◦C for 10 minutes. Samples were finally held at 12 ◦C.
Following manufacturer’s guidelines, a new experiment was set up using
the QuantaSoft™ Software v1.7 (Bio-Rad). After the thermal cycling had
finished, the plate was placed into the QX100™ droplet reader (Bio-Rad).
The droplet reader in combination with the QuantaSoft™ Software v1.7
analyses the droplets’ signals and differentiates between negative and pos-
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itive ones creating absolute concentration of desired DNA. The number of
RHD copies/μL present in a sample was compared to the reference gene
AGO1 copies/μL. A sample presenting RHD5 or RHD7/ AGO1 ratios ≈ 1
was considered to be homozygous RHD-positive, and a sample with ratios
≈ 0.5 were classified as hemizygous RHD-positive, and samples showing
a ratio ≈ 0 were classified as RHD-negative.
Table 2.6: Sequences for primers and probes used in the RHD zygosity testing using
dPCR.
Gene Sequence 5’-3’ Size, bp
AGO1* Forward: GTTCGGCTTTCACCAGTCT 82
Reverse: CTCCATAGCTCTCCCCACTC
Probe: HEX-CTGCCATGTGGAAGATGATG-BHQ1
RHD5** Forward: CGCCCTCTTCTTGTGGATG 75
Reverse: GAACACGGCATTCTTCCTTTC
Probe: FAM-TCTGGCCAAGTTTCAACTCTGCTCTGCT-BHQ1
RHD7** Forward: CAGCTCCATCATGGGCTACAA 81
Reverse: AGCACCAGCAGCACAATGTAGA
Probe: FAM-AGCTTGCTGGGTCTGCTTGGAGAGATC-BHQ1
*Adapted from Fan et al. (2009). **Adapted from Finning et al. (2008).
2.6 Agarose Gel Electrophoresis
To validate PCR amplification, PCR products were run on 1% (w/v) agarose
gel for RHD introns PCR products and on 0.7% (w/v) agarose gel for
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LR-PCR products. High resolution standards agarose (AGTC Bioprod-
ucts Ltd, Yorkshire, UK) was mixed with 1X Tris-acetate-EDTA (TAE) elec-
trophoresis buffer [40 mM Tris-acetate and 1 mM EDTA pH 8.0] (Sigma-
Aldrich Company Ltd, United Kingdom), and with the addition of flu-
orescent nucleic acid dye (GelRed) 1:10000 dilution (Biotium Inc, United
States).
A volume of 5 μL of each sample was mixed with 1 μL of loading buffer [10
mM Tris-hydrochloric acid (pH 7.6), 0.03% (v/v) bromophenol blue, 0.03%
(v/v) xylene cyanol FF, 60% (v/v) glycerol, and 60 mM EDTA] and then to
a well. Quick-Load® 1 kb Extend DNA Ladder (New England Biolabs®,
United Kingdom) was used to assess the amplicon size for LR-PCR prod-
ucts, and 100 bp DNA ladder (NORGEN, Thorold, Canada) was used for
RHD introns PCR products. The samples were subjected to electrophoresis
for 1 hour and 1 hour 30 minutes for RHD introns and LR-PCR products,
respectively; on 110V constant voltage. The gel was then removed to an
EC3 imaging system (Ultra Violet Products Ltd, United Kingdom), and
was visualized using the Launch Vision WorksLS.
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2.7 QIAquick Gel Extraction
QIAquick Gel Extraction kit (Qiagen Ltd, United Kingdom) was used to
purify RHD introns amplicons. Fifty μL of PCR reaction was mixed with
10 μL of the loading agent [10 mM Tris-hydrochloric acid (pH 7.6), 0.03%
(v/v) bromophenol blue, 0.03% (v/v) xylene cyanol FF, 60% (v/v) glyc-
erol, and 60 mM EDTA] and then subjected to electrophoresis (section 2.6).
After the electrophoresis was finished and all bands were clearly sepa-
rated, the size specific band was excised using a sharp scalpel and placed
in a clean 2 ml tube. The weight of the band was then measured on a
balance to determine the required of the QIAquick buffer QG. For each
volume of the gel (100 mg), 3 volumes of QIAquick buffer QG were added
(300 μL). The mixture was then incubated at 50 ◦C for 10 minutes or until
the gel had dissolved completely. After the gel slice had dissolved, one
volume of isopropanol (Fisher Scientific UK, United Kingdom) was added
to the sample and mixed vigorously. The mixture was then filtered using
the provided QIAquick spin column which was centrifuged at 6000 rpm
for 1 minute and filtrate was discarded; this step was repeated as needed
to filter the complete volume of mixture. The filter spin column (contain-
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ing DNA) was placed back to the collection tube for the washing steps.
Because PCR products were for direct sequencing, a wash with 500 μL of
QIAquick buffer QG was recommended, the spin column was centrifuged
and filtrate was discarded. A volume of 750 μL of the QIAquick buffer
PE was added to the column and incubated at room temperature for 5
minutes. The column was then centrifuged and filtrate was discarded,
additional centrifugation was recommended to thoroughly remove the
ethanol. The QIAquick spin column was placed in a clean 1.5 ml collection
tube for elution. The gDNA was eluted with 50 μL of QIAquick buffer EB
and then incubated at room temperature for 1 minute to increase the yield
of DNA. The samples were then subjected to agarose gel electrophoresis
to validate the success of the extraction and purification (section 2.6). One
hundred bp DNA ladder (NORGEN, Thorold, Canada) is provided with
an estimated concentration for each band which enabled the gDNA con-
centration for the PCR amplicons to be estimated by comparing the band




For RHD intronic SNPs investigation, purified amplicons were sent for
Sanger sequencing to Eurofins MWG Operon (Ebersberg, Germany) by
using Mix2Seq kit. Each sample was distributed into two barcoded tubes,
15 μL in each. A volume of 2 μL of each of the primers was added to a
single tube in 10 pmol/μL concentration. Sequencing data was received in
(ab1) format, which was then mapped and analysed using the CodonCode
Aligner 6 (Aligner, United States). Data was aligned to the GRCh37 chro-
mosome assembly RefSeq (NC_000001.10) which is the genome reference
consortium human genome build 37 (known as hg19) (NCBI, 2009). Each
trace chromatogram was analysed to determine intronic SNPs zygosity
and links to Rh specific haplotype.
2.9 NGS Library Preparation
2.9.1 Agencourt® AMPure® XP
Agencourt® AMPure® XP reagent (Beckman Coulter, United Kingdom)
was used to purify LR-PCR products. For each volume of the sample,
1.8 X volume of the purifying agent was added. The mixture was mixed
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thoroughly and then incubated at room temperature for 5 minutes. The
samples were then placed on the magnetic field (Alpaqua Engineering
LLC, United States) for 3 minutes to isolate smaller amplicons, and primer-
dimers. After 3 minutes, the supernatant was discarded and the remaining
bead pellets were washed two times with 70% ethanol (Fisher Scientific
UK, United Kingdom). After the second wash, the bead pellet was left
to air dry for 4 minutes. Finally, the samples were eluted with 20 μL of
nuclease-free water (Ambion®, Thermo Fisher Scientific, United States).
Samples were then quantified using Qubit® dsDNA HS Assay kit, (sec-
tion 2.3).
2.9.2 Pooling and Fragmentation
An equimolar pool for purified amplicons was created to ensure an equal
depth of coverage for the targeted gene. The pooling was prepared with
a final concentration of 100 ng in a total volume of 35 μL. One hun-
dred ng was divided by the number of amplicons for each sample, which
meant, for example, 16.67 ng of each of the RHD amplicons was required
to achieve the 100 ng concentration. Final volume was brought to 35 μL by




After pooling of the different amplicons, samples were fragmented to cre-
ate a 200 bp read library using the Ion Xpress™ Plus Fragment Library
kit (Life Technologies). In an Eppendorf LoBind™ tube, each sample was
mixed with 5 μL of Ion Shear™ Plus 10X Reaction Buffer and nuclease-free
water (Ambion®, Thermo Fisher Scientific, United States) to bring the fi-
nal volume to 40 μL, tubes were mixed for 5 seconds, vigorously. Ten μL of
the Ion Shear™ Plus Enzyme Mix II was added to each sample to bring the
total volume to 50 μL. The mixture was mixed by pipetting up and down
8-10 times. The reaction tube was then incubated on a heat block at 37
◦C for 15 minutes. Immediately after incubation, 5 μL of Ion Shear™ Stop
Buffer was added to stop the reaction. The fragmented amplicons were
purified by Agencourt® AMPure® XP reagent using 1.2X volume of the
samples (refer to section 2.9.1). However, in final elution the samples were
treated differently. Samples were eluted in 25 μL instead of 50 μL of Low
TE (10 mM Tris-HCl (pH 8.0), 0.1 mM EDTA). To check the fragment size,
1 μL of the eluted DNA was tested using the Agilent™ 2100 Bioanalyzer™
instrument and Agilent™ High Sensitivity DNA kit, (section 2.9.3).
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2.9.3 Agilent® 2100 Bioanalyzer System
The 2100 Bioanalyzer™ instrument with an Agilent™ High Sensitivity
DNA kit (Agilent™ Technologies UK Limited, United Kingdom) were used
to determine the size distribution and the concentration of the samples.
To prepare the gel-dye mix, 15 μL of the dye concentrate was added to
the light sensitive DNA gel matrix vial and then was mixed for 10 sec-
onds. The mixture was then placed in a spin filter, and centrifuged at
6000 rpm for 10 minutes. A High Sensitivity DNA chip was placed on the
chip priming station, and the plunger was placed at 1 ml. A volume of
9 μL of the gel-dye mix was pipetted into the third well marked with G,
the priming station was closed and the plunger was then pressed down
until it was held by the clip; a timer was then started for 60 seconds. The
plunger was released after 60 seconds and the priming station was opened
once the plunger reached 1 mL. A volume of 9 μL of the gel-dye mix was
placed into the remaining three wells marked with G. Five μL of the High
Sensitivity DNA marker was dispensed into all sample wells including
the ladder marked well. One μL of the High Sensitivity DNA ladder was
placed in the ladder position. In each sample well, 1 μL of each sample
was loaded. The chip was placed in the IKA vortex mixer (IKA®, United
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Kingdom) for 60 seconds at 2400 rpm. The chip was then placed in the Ag-
ilent 2100 Bioanalyzer, and a run was started following the manufacturer’s
guidelines.
2.9.4 Adaptor Ligation and Nick Repair
After amplicons fragmentation, fragments were ligated to adaptors and
nick-repaired using the Ion Xpress™ Barcode Adapters kit (Life Technolo-
gies) for barcoding materials and Ion Plus Fragment Library kit for nick
repair. In 0.2 mL PCR tubes, 25 μL of the fragmented amplicons were
mixed with 10 μL of 10X Ligase Buffer, 2 μL of Ion P1 adapter, 2 μL of Ion
Xpress™ Barcode X , 2 μL of deoxynucleotide triphosphates (dNTPs) Mix,
49 μL of nuclease-free water (Ambion®, Thermo Fisher Scientific, United
States), 2 μL of DNA ligase, and 8 μL of Nick Repair Polymerase. Veriti
thermocycler was programmed as follows: 25 ◦C for 15 minutes, then 72
◦C for 5 minutes and finally the samples were held at 4 ◦C for up to 1 hour.
The product was then purified using the 1.2X volume of the Agencourt®
AMPure® XP reagent (section 2.9.1). The samples were eluted with 20
μL of Low TE (10 mM Tris-HCl (pH 8.0), 0.1 mM EDTA). To validate the





After ligation and nick repair, samples were subjected to size selection us-
ing Agencourt® AMPure® XP. Right and left sides size selection was per-
formed using different ratio of the SPRIselect (Figure 2.3). The ratio of
SPRIselect reagent used dictate the size of the DNA fragments binding.
For the left side size selection, 0.8X of the Agencourt® AMPure® XP was
mixed with each sample and incubated at room temperature for 1 minute
then placed on the magnetic plate for 3-4 minutes to separate. Magnetic
beads in this stage bind to small fragments because increasing the ratio
of SPRIselect to sample increases the efficiency of binding smaller frag-
ments. The supernatant was removed carefully without disrupting the
beads. Two 85% ethanol washes were performed with discarding the su-
pernatant after each wash. After the last wash, the beads were left to dry
at room temperature for 5 minutes and then eluted with 50 μL of nuclease-
free water (Ambion®, Thermo Fisher Scientific, United States).
For the right side size selection, 0.7X of the SPRIselect was used as decreas-
ing the SPRIselect volume will increase the efficiency of binding larger
fragments. After mixing the samples with the SPRIselect, they were in-
81
TEMPLATE AMPLIFICATION AND ENRICHMENT
cubated at room temperature for 1 minute then placed on the magnetic
plate for 3-4 minutes to separate. The supernatant was then collected and
placed in a new well, leaving the beads with large fragments behind. At
this stage, the supernatant contains the right side size selected sample. To
the supernatant, 1.1X of the SPRIselect was mixed with each sample, incu-
bated for 1 minute and then placed on the magnetic rack to separate. The
supernatant was discarded and two 85% ethanol washes were performed.
After the final wash, the beads were left to air dry at room temperature for
5 minutes. Finally, samples were eluted with 20 μL of nuclease-free water
(Ambion®, Thermo Fisher Scientific, United States). The final product was
then analysed using Agilent™ 2100 Bioanalyzer™ instrument and Agi-
lent™ High Sensitivity DNA kit, (section 2.9.3). Data obtained from 2100
Bioanalyzer™ included size distribution and molar concentration which
were used to calculate the template dilution factor.
2.10 Template Amplification and Enrichment
2.10.1 Pooling of the Libraries and Amplification
To guarantee an equivalent representation of each of the libraries in the
sequencing run, sequencing libraries were diluted to a concentration of 26
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Figure 2.3: Left and right sides size selection using the Agencourt® AMPure® XP. (a)
Left side size selection was performed using 0.8X Agencourt® AMPure® XP to eliminate
smaller than 200 bp fragments; and (b) 0.7X Agencourt® AMPure® XP was used for right
side size selection to eliminate fragments larger than 200 bp. Image courtesy of Coulter
(2012).
pM. Dilution factor was determined by dividing the library concentration
in pM by 26. For instance, if the library concentration was 130 pM, the
dilution factor would be 5. Thus, 1 μL of the sequencing library would be
diluted in 4 μL of nuclease-free water. If a sample had less than 26 pM con-
centration, a higher volume of the library was added to reach the required
amount. For example, if a sample has 10 pM, then 2.6 μL was added to
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reach the amount of DNA required.
For library enrichment, the Ion OneTouch™ was used with the Ion PGM™
Template OT2 200 kit (Thermo Fisher Scientific). Dr. Michele Kiernan con-
ducted this step and subsequent sequencing protocols. The Ion PGM™
OneTouch Plus reaction filter was assembled according to the manufac-
turer’s guidelines. To prepare the amplification solution, 2 μL of the pooled
sequencing library was diluted in 23 μL of nuclease-free water. To the di-
luted library, subsequent solutions were added as follows: (25 μL of nucle-
ase free water, 500 μL of Ion PGM™ Template OT2 200 Reagent Mix, 300
μL of the Ion PGM™ Template OT2 200 PCR Reagent B, 50 μL of the Ion
PGM™ Template OT2 200 Enzyme Mix) to bring the final volume to 900
μL. The mixture was then mixed and 100 μL of the Ion PGM™ Template
OT2 200 Ion Sphere™ Particles were added and mixed thoroughly. Fol-
lowing the protocol instructions, 1000 μL of the amplification solution was
placed into the sample port in the reaction filter, followed by the addition
of 1.5 mL of the Ion OneTouch™ Reaction Oil. The reaction filter was then
placed in the Ion OneTouch™ 2 instrument and the run was started.
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2.10.2 Positive ISPs Recovery and Enrichment
After the completion of the Ion OneTouch™ 2 run, two Ion OneTouch™
recovery tubes were placed in the centrifuge in the Ion OneTouch™ 2 in-
strument, and were centrifuged for 10 minutes. The Ion OneTouch™ re-
covery router was discarded at the end of the centrifugation and the tubes
were placed in a rack. From each tube, all but 50 μL of the recovery so-
lution was removed carefully without disturbing the ion sphere particles
(ISPs) pellet, which was re-suspended in the remaining solution. The ISPs
suspension from both tubes was combined in a 1.5 mL tube and 1 mL of
the Ion OneTouch™ wash solution was added. In an 8-well strip from the
Ion OneTouch™ ES supplies kit, 100 μL of the ISPs-suspension was placed
in well 1.
On the Ion OneTouch™ ES, template enrichment was performed to in-
crease template numbers for sequencing. Melt-off reagent was prepared
by mixing 280 μL of the Tween™ solution with 40 μL of 1 M sodium hy-
droxide (NaOH), which was then placed into well 7 in the 8-well strip.
13 μL of the Dynabeads™ MyOne™ Streptavidin C1 Beads was placed
in a 1.5 mL tube, which was then placed on DynaMag™-2 magnet for 2
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minutes to separate the beads. After two minutes, the supernatant was
removed with caution to not disturb the beads pellet. To the beads, 130
μL of MyOne™ beads wash solution was added and then mixed by vortex
for 30 seconds. In the 8-well strip, where 100 μL of the ISPs-suspension
was placed in well 1, 130 μL of the re-suspended MyOne™ beads in the
wash solution was placed in well 2. Wells 3, 4, and 5, were filled with
300 μL of the Ion OneTouch™ wash solution, while wells 6 and 8 were left
empty. Following user guidelines, the Ion OneTouch™ ES was prepared
for template enrichment. The run was started following user instruction.
2.11 Ion PGM™ Sequencing
After completion of the enrichment stage, the PCR tube containing the en-
riched ISPs was removed and quality assessment was performed using the
Qubit® 2.0 Fluorometer, (section 2.3). Finally, a sequencing run was car-
ried on the Ion PGM™ on Ion 316™ Chip v2 by Dr. Michele Kiernan in the
Genomics Facility of the Systems Biology Centre, University of Plymouth.
A run is started with creating a planned run in the Torrent Browser con-




The enriched ISPs were prepared for sequencing using the Ion PGM™ Se-
quencing 200 Kit v2. In a PCR tube, 5 µL of Control Ion Sphere™ Par-
ticles was added directly to the whole amount of the enriched ISPs and
mixed thoroughly by pipetting, followed by centrifugation for 2 minutes
at 15,500 × g. Supernatant was carefully removed to not disturb the pellet
leaving about 15 µL of liquid in the tube. To the pellet, 12 µL of the Se-
quencing Primer was added and was mixed by pipetting. The tube was
placed in Veriti thermal cycler programmed with 95°C for 2 minutes; 37°C
for 2 minutes to anneal sequencing primers.
After thermal cycler, 3 µL of Ion PGM™ Sequencing 200 v2 Polymerase
was added, mixed by pipetting, and incubated for 5 minutes at ambient
temperature while sequencing Ion 316™ Chip v2 was inspected for any
physical damages before loading library. Sequencing chip was prepared
and library was loaded following carefully the user guide. The chip was
loaded into the Ion PGM™ and a sequencing run was initiated on the Ion
PGM™ system. Sequencing programme runs over night (about 8 hours)




Samples genotyped for RHD, RHCE, and RHAG using Ion PGM™ are
shown in Figure 2.4. Samples genotyped for the RHD gene included 75
blood donor samples that were either hemizygous for the RHD gene or
phenotyped as weak D by serology. Other homozygous samples were
also sequenced for comparison. Thirty-five gDNA samples from D nega-
tive pregnant females with inconclusive results were also included in RHD
genotyping to identify genetic background of RHD variants. A further
23 gDNA samples from the ISBT 1996 workshop (ISBT, 1996), previously
genotyped as variant RHD allele, were included to study the full sequence
of different variant alleles and intronic SNPs variations might be associ-
ated with these variants.
2.12 MinION™ Library Preparation
The RHD gene from gDNA samples (n=12) from Finnish pregnant fe-
males with variant RHD gene, supplied by the Finnish Red Cross Blood
Service (Helsinki, Finland) were sequenced using the MinION™ (Oxford
Nanopore Technologies, UK), and one blood donor sample (Figure 2.4).
Library preparation was performed following the 1D Native barcoding
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gDNA (Oxford Nanopore Technologies, UK) protocol using the Native
Barcoding kit 1-12 (Oxford Nanopore Technologies, UK) and the Ligation
Sequencing kit (SQK-LSK109) (Oxford Nanopore Technologies, UK) with
1D flow cells R9 version (Oxford Nanopore Technologies, UK).
Six RHD LR-PCR amplicons were pooled for each sample to yield a final
amount of 1800 ng at 48 μL final volume. For end repair and dA-tailing, 3.5
μL of NEBNext FFPE DNA Repair Buffer (New England Biolabs®, United
Kingdom), 2 μL of NEBNext FFPE DNA Repair Mix (New England Bi-
olabs®, United Kingdom), 3.5 μL of Ultra II End-Prep buffer (New Eng-
land Biolabs®, United Kingdom), and 3 μL of Ultra II End-Prep enzyme
mix (New England Biolabs®, United Kingdom) was added and mixed by
pipetting. Using a Veriti Thermal Cycler, the reaction was incubated at 20
◦C for 5 min and then at 65 ◦C for 5 minutes, and was then purified using
AMPure XP beads (section 2.9.1) and eluted in 25 μL nuclease free water.
Recovered samples were then quantified using Qubit® dsDNA HS Assay
Kit (section 2.3). Samples were then diluted to 500 ng in a 22.5 μL final vol-
ume in preparation for barcode ligation. To each sample, 2.5 μL of unique
barcode and 25 μL of Blunt/TA Ligase Master Mix (New England Bio-
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labs®, United Kingdom) was added and mixed by flicking the tube which
was then incubated for 10 minutes at ambient temperature. The reaction
was then purified using AMPure XP beads (section 2.9.1) and eluted in
26 μL nuclease free water and quantified using Qubit® dsDNA HS assay
(Thermo Fisher Scientific, United Kingdom) explained in (section 2.3) be-
fore pooling to ensure equal coverage for all samples.
Samples were then pooled in equimolar amount to yield a final concen-
tration of 700 ng in 65 μL final volume. To pooled libraries, 5 μL of the
Adapter mix II, 20 μL of NEBNext Quick Ligation Buffer (New England
Biolabs®, United Kingdom), and 10 μL of Quick T4 DNA Ligase (New
England Biolabs®, United Kingdom) were added and mixed by flicking
the tube, which was then incubated for 10 minutes at ambient tempera-
ture. Last step purification was carried out using 50 μL of AMPure XP
beads. After discarding the supernatant, pellet was washed twice with
250 μL of Long Fragment Buffer. Library was then eluted in 15 μL Elution
Buffer. Eluted library was then quantified using Qubit® dsDNA HS Assay
Kit, (section 2.3). Prepared library was stored in ice until the sequencing




A flow cell was placed in the MinION™ which is then plugged directly
into USB3 port on laptop running Windows 10. MinKNOW software (Ox-
ford Nanopore Technologies, United Kingdom) connects to the MinION™
and runs control checks. To prepare priming solution, 30 μL of the flush
tether was added to a full tube of flush buffer. To prime flow cells, 800 μL
of the priming solution was loaded to the flow cells through the priming
port. After 5 minutes, 200 μL of the priming solution was loaded to the
flow cells through the priming port while the SpotON cover was open. In
preparation for sequencing, 12 μL of DNA library was mixed with 37.5 μL
of sequencing buffer, and 25.5 μL of loading beads. The library was loaded
drop by drop to the flow cell via the SpotON port. On the MinKNOW soft-
ware (MinION™ Release 18.12.6), the sequencing run was started and was





2.14.1 NGS Data Analysis
Data generated from the NGS (FASTQ) was analysed using the CLC Main
Workbench 10 software (Qiagen Ltd, United Kingdom). Short reads were
aligned to the human reference sequence hg38 downloaded from the NCBI
database (NC_000001.11) (Tatusova et al., 2016). The RHCE gene was masked
in the RHD gene analysis by converting it into trimmed track i.e (blocked-
out) to prevent reads from scattering by mapping to a different region
or gene in the chromosome assembly, and vice versa for the RHCE data
analysis. Variant detection was performed on a minimum coverage of
30 i.e (the numbers of overlapping reads over a single base) and variants
detected were analysed on a single base basis considering different pa-
rameters including number and percentage of reads and nucleotide count
(Nielsen et al., 2011). Variant tracks created were annotated with the exon
numbers and compared with known variants for prediction of amino acid
changes and splice site alterations. For allele determination, SNPs de-
tected that predicted amino acid changes or splice site changes were com-
pared to known alleles on RhesusBase (Wagner and Flegel, 2014), Erythro-
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gene (Möller et al., 2016) and the Blood Group Antigen FactsBook (Reid
et al., 2012). The reference SNP number was then found for each SNP de-
tected in the database of SNPs (Sherry et al., 2001).
2.14.2 MinION™ Data Analysis
The MinION™ was run for about 12 hours which produced 49 FAST5 files
each containing about 4000 reads. The data analysis workflow is illus-
trated in Figure 2.5. Guppy basecaller v3.2.4 (Oxford Nanopore Technolo-
gies, United Kingdom) was used to call the bases of the raw data (FAST5)
files, which divided the read into pass and fail FASTQ files based on qual-
ity score determined. Only pass reads were used to carry on the analysis.
Files were subjected to sequencing quality analysis using EPI2ME soft-
ware (Oxford Nanopore Technologies, United Kingdom).
FASTQ files were then concatenated into one FASTQ file for barcoding
using Samtools v.1.4.1. Porechop software v.0.2.1 was used for barcod-
ing, which divided reads by barcodes 1-12. Barcodes were then trimmed
using SeqKit software v0.7.1. A bash loop script, a programming lan-
guage that executes command codes subsequently, (Figure 2.6) was cre-
ated by Dr Vasileios Lenis to analyse the data. Nanopolish software v.0.9.0
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was used to index the reference (hg38 chromosome 1 reference sequence
(NC_000001.11)), index the FASTQ files, and then map the reads to the
reference which generated BAM files. BAM files were then sorted using
Samtools v.1.4.1 to generate BAI files. Variants were then called using Na-
nopolish software v.0.9.0. (Loman et al., 2015). BAM and BAI files were
visualised using Integrated Genome Viewer (IGV) v.2.5.3 (Broad Institute
and the Regents of the University of California, United States) and CLC
Main Workbench 10 software (Qiagen Ltd, United Kingdom). Variant call-
ing was also performed using CLC Main Workbench 10 software at 100x
minimum coverage. The data was then compared to the sequencing data
obtained from Ion PGM™. Exonic and intronic mutations detected from




Figure 2.4: Flowchart illustrates the number of samples genotyped on Ion PGM™ for
each target gene including RHD, RHCE, and RHAG, and number of samples genotypes
for the RHD gene using MinION™.
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Figure 2.5: MinION™ data analysis workflow. Analysis started with calling bases of the
raw data (FAST5) using Guppy basecaller v3.2.4. Pass FASTQ files were subjected to qual-
ity assessment using EPI2ME software which were then concatenated into one FASTQ
file for barcoding using Samtools software v.1.4.1. Barcoding was then performed using
Porechop software v.0.2.1 to divide reads into 12 barcoded files. The reads were then
mapped to the RHD reference sequence hg38 which were visualised using IGV software
v.2.5.3 and CLC Main Workbench 10 software. Calling variants was performed using




Figure 2.6: A bash loop script used for MinION™ data analysis. Bash is a programming
language that enables command execution subsequently. Passed raw files (fast5) were
barcoded and then mapped to the human genome reference sequence (hg38) generating





3. RHD & RHAG Next Generation
Sequencing and Single Molecule
Sequencing in Blood Group
Genotyping
3.1 Introduction
The Rh blood group system (ISBT004) is the second most important blood
group after ABO (Avent and Reid, 2000; Avent et al., 2006) and one of
the most polymorphic blood group systems. The RHD and RHCE genes
located on chromosome 1 (1p33.1_1p36) encode the RhD protein and RhC-
cEe protein, respectively (Colin et al., 1991; Wagner and Flegel, 2000). The
RhD antigen is the most clinically significant antigen in the Rh system due
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to its high immunogenicity and being the main cause of HDFN (Le van
Kim et al., 1992). The RHD and the RHCE genes show 93.8% homology
in their introns and coding exons (Okuda et al., 1999). The similarities be-
tween these two genes give an indication to their evolutionary rise from
the same ancestral gene through duplication (Carritt et al., 1997; Okuda
et al., 1999, 2000). Recombination, deletion, and point mutations in these
two genes generate the eight most common Rh haplotypes which include:




(dcE) (Noizat-Pirenne et al., 1998).
Serological testing is fast, cost friendly, and efficient; however, it is lim-
ited by many factors; for instance, the availability of antisera (Jungbauer,
2011a; Orzińska et al., 2018), reactivity of the antibodies, and the antigen
status like weak or partial expression. Current assignment of a partial
or a weak D phenotype would require an extensive collection of mono-
clonal anti-D. Monoclonals to low frequency Rh antigens, such as Goa,
BARC, and Tar, to identify specific partial D phenotypes are still unavail-
able. Serological testing also leads to predicting the Rh genotype based on
the most common haplotype present in the population, which for some
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cases is incorrect (Sillence et al., 2017).
Unlike serological testing, genotyping provides the freedom to analyse a
wider range of blood group antigens including low frequency antigens, for
instance: Goa, BARC, and Tar which can cause HDFN and allo-immunisation
(Avent and Reid, 2000; Daniels, 2013c). Complete BGG could be widely
used in transfusion practice where serology tests may fail to clarify issues
or resolve discrepancies.
Extensive efforts have been made to use molecular genotyping tests, as
an alternative to serological testing, ranging from low to high throughput
assays (Fichou et al., 2014). Different DNA microarray-based tests were
introduced that enable genotyping of variant blood groups by targeting
specific SNPs (Hashmi et al., 2005; Avent et al., 2009; Goldman et al., 2015;
Chang et al., 2016; Fichou and Férec, 2017; López et al., 2018; Bub and
Castilho, 2019). Although these assays are very accurate, they have some
limitations. They are designed to target certain nucleotides or DNA re-
gions through PCR, while novel variants remain unknown (Fichou et al.,
2014; Avent et al., 2015). Complete DNA sequencing could be the most
relevant technique to thoroughly study blood group variations and over-
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come limitations in other assays (Avent et al., 2015; Lane et al., 2016).
Genomics was radically reshaped during the past decades by the introduc-
tion of the first generation sequencing in the 1970s (Sanger et al., 1977), and
then the introduction of the second (Anderson and Schrijver, 2010; Pareek
et al., 2011) and third generation sequencing (Nagarajan and Pop, 2013;
Lu et al., 2016; Ardui et al., 2018) less than three decades later. Since it
was introduced in 2005, NGS has greatly impacted the genetic research
field by elevating both throughput and data generated, and at the same
time lowering significantly the cost of sequencing per nucleotide (Fichou
and Férec, 2017; Fichou et al., 2014; Pareek et al., 2011; Tilley and Grims-
ley, 2014; Zhang et al., 2011). NGS is used in HLA testing (Profaizer et al.,
2016), which creates a strong impetus to introduce NGS for BGG (Möller
et al., 2016). Genotyping could be utilized to genotype blood transfusion
dependent patients who are at risk of allo-sensitisation (Bakanay et al.,
2013; Fichou et al., 2016; Chou et al., 2017; Dezan et al., 2017). It could also
be used to genotype donors and create a database that would make find-
ing and recall of compatible donors for transfusion easier (Denomme and




Different studies have aimed to use NGS in BGG using a variety of ap-
proaches. Dezan et al. (2017), Chou et al. (2017) and Schoeman et al. (2018)
used whole exome sequencing (WES) to identify Rh variation but the high
similarity between the RHD and RHCE genes could make it challenging
to analyse data especially in exons 8 and 10 where there are no differences
between the two genes. Hyland et al. (2017) used LR-PCR using primers
described by Gassner et al. (1997) to amplify the RHD gene from exon 2 to
exon 7 but omitting exons 1, 8, 9 and 10.
NGS is a high-throughput sequencing, depends on PCR amplification,
that generates a vast amount of data at a low cost. However, short reads
generated during library preparation made de novo assembly for large genomes
difficult due to repetitive DNA sequence (Schatz et al., 2010; Zhang et al.,
2011; Lu et al., 2016), which initiated the need for a new sequencing ap-
proach that uses longer reads, later called the TGS (Lu et al., 2016).
MinION™ sequencer offered by Nanopore Technologies (Oxford, United
Kingdom) is the only sequencing technology that offers direct DNA se-
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quencing using long reads up to 2 Mb and real time data analysis while re-
ducing the cost to about $ 1,000 (Branton et al., 2008). MinION™ sequenc-
ing chemistry depends on driving the DNA through nanopores, which
are embedded in a membrane submerged in ionic solution. By applying a
voltage, a DNA molecule passes through the pores which causes changes
in the ionic current running through the pores. These changes in the flow-
ing current occur in a distinctive manner which are recorded and then
translated to bases (Meller et al., 2000, 2001; Branton et al., 2008).
MinION™ sequencer has been used in different studies including BGG
(Matern et al., 2017). Other studies have shown the great potential of the
MinION™ sequencer on spot sequencing for example, during the Ebola
virus outbreak in Guinea (Quick et al., 2016), Zika virus epidemic in Brazil
and the Americas in 2015 (Faria et al., 2017), and during COVID-19 pan-
demic (Marquez et al., 2020; Lopez-Alvarez et al., 2020).
3.2 Aim and Objectives
This study aimed to fully sequence the RHD gene using NGS (Ion PGM™)
to study alleles present in the population and identify novel variants. It
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also focused on establishing Rh allele specific reference sequences by in-
vestigating intronic SNPs and their relation to a specific Rh haplotypes.
We also aimed to assess the suitability and efficiency of MinION™ se-
quencer in BGG and its ability to enable RHD allele determination. The
RHAG gene was also investigated for mutations that might be linked to
disturbed RhD expression (weak or null D). To achieve these aims, objec-
tives were as follow:
1. Test all samples for RHD zygosity using dPCR to allow the use of
hemizygous RHD samples to unequivocally establish reference se-
quences for specific RHD alleles. Sequencing RHD hemizygous sam-
ples will ensure only one allele is amplified and sequenced to estab-
lish Rh allele specific reference sequences.
2. Investigate the relation of intronic SNPs to R2 haplotype which were
previously detected by Halawani (2015). The suspected intronic SNPs,
that could be haplotype specific, were not confirmed due to low cov-
erage and low number of samples tested in Halawani (2015) work.
Specific primers were designed to amplify target region of SNPs for
Sanger sequencing to confirm their relation to the R2 haplotype.
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3. Design LR-PCR RHD specific primers, to amplify the complete RHD
gene including promoter, introns and all exons, that would allow
specific amplification from the target gene without contamination
from the homologous RHCE gene.
4. Fully sequence the RHD gene using NGS on Ion PGM™ platform
and analyse the sequencing data and call variants to determine the
RHD alleles and intronic SNP patterns for different haplotypes.
5. Utilise RHD intronic SNPs to establish Rh haplotype specific refer-
ence sequences. Identifying intronic changes in different RHD alleles
is important as these SNPs could be a useful target to identify RHD
haplotypes. Intronic changes may also lead to allelic dropout when
attempting target sequencing; therefore, identifying these changes is
crucial.
6. Design primers to amplify and sequence the RHAG gene using Ion
PGM™, as mutations in RHAG can lead to weak or null D pheno-
type. The RHAG gene sequencing is targeted for samples that show




7. Use MinION™ to sequence the RHD gene to compare with data gen-
erated from Ion PGM™ to test the suitability and efficiency of the
MinION™ sequencer in BGG.
8. Analyse MinION™ data to achieve allele phasing (which referes to
the ability to segregate reads and assign alleles to different allele in
heterozygous samples) and accurate variant calling to determine al-
leles. Variant calling, a process to identify variants in a sequence set
when reads are aligned to the reference sequence, is crucial to assess






Samples (n=206) (Table 3.1) with different Rh genotypes presumed from
serology results were first tested using ddPCR to determine RHD zygos-
ity. An additional 12 samples (not shown) were also tested for RHD zy-
gosity which were included in the investigation of RHD intronic varia-
tion using Sanger sequencing, see section 3.3.2. The presence or absence
of the RHD amplification on the ddPCR platform was used to determine
whether the samples were hemizygous or homozygous RHD-positive or
RHD-negative, respectively (Figure 3.1). Samples showing RHD5 or RHD7/
AGO1 ratios ≈1 were determined to be homozygous RHD-positive, sam-
ples with ratios ≈0.5 were classified as hemizygous RHD-positive, and
samples showing a ratio ≈0 were classified as RHD-negative (Table 3.1).
Samples included 10 R1R1 (DCe/DCe), 22 R1r (DCe/dce), 10 R2R2 (DcE/DcE),
16 R2r (DcE/dce), 66 R1R2 (DCe/DcE), 13 R0r (Dce/dce), 1 R2Rz (DcE/DCE),
6 rr (dce/dce), 7 r’r (dCe/dce), 6 r”r (dcE/dce), as determined by serol-
ogy. RhD negative samples were collected for the purpose of RHCE se-
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Figure 3.1: Two-dimensional amplitude plot from two representative samples tested for
RHD zygosity using ddPCR. Blue plot represents RHD gene targets (exon5/exon7) posi-
tive droplets (FAM), green plot represents reference gene AGO1 positive droplets (HEX),
orange represents droplets positive for the RHD and reference gene AGO1 ,and grey plot
represents negative droplets. In A and B, samples were tested for RHD exon 5 (A.1/B.1)
and RHD exon 7 (A.2/B.2) against the reference gene AGO1. Sample in A presented a ra-
tio of 1 for both RHD targets against the reference gene AGO1 and was considered RHD
homozygous, and sample in B presented a ratio of 0.5 for both targets and was considered
hemizygous for the RHD gene.
quencing. Samples were therefore tested for the presence of the RHD gene
to confirm deletion. Twenty-three ISBT samples and 35 Finnish samples
(Section 2.1) were also tested for RHD zygosity.
Zygosity results were compatible with the serologically predicted geno-
type except for the samples listed in Table 3.2. Sample (004_14), previously
classified by serology as being phenotypically R1r (DCe/dce), expressed
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ratios of 1.06 and 0.99 for the RHD5 and RHD7 multiplex reactions, respec-
tively (Table 3.2). This result contradicted previous serological classifica-
tions and indicated that the sample expressed two copies of the RHD gene.
Sample (004_42), previously classified by serology as being phenotypically
R2R2, expressed ratios of 0.54 and 0.47 for the RHD5 and RHD7 multiplex
reactions, respectively (Table 3.2). This result contradicted previous sero-
logical classifications and indicated that the sample expressed one copy of
the RHD gene (hemizygous). In a similar manner, samples 004_35, 004_36,
004_37, 004_38, 004_39 and 004_40 were previously classified by serology
as being phenotypically R1R2. However, given the ratios from the RHD5
(average 0.51) and RHD7 (average 0.51) multiplex reactions, these sam-
ples only express one copy of the RHD gene and are therefore classified
as being RHD hemizygous. One R1R1sample (004_07) showed a discrep-
ancy between hemizygous RHD5 (ratio 0.54) and homozygous RHD7 (ra-
tio 1.01) indicating a possible deletion of exon 5 in one of the RHD alleles.
Blood donor sample (004_88) classified by serology as r”r showed a hem-
izygous RHD gene on ddPCR with 0.51 and 0.47 ratios for RHD5 and
RHD7 assays, respectively. Six ISBT samples (004_101- 004_106) showed a
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ratio of 0.5 for the RHD7 assay indicating a hemizygous RHD gene and a
ratio ≈0 for the RHD5 assay indicating a deletion in exon 5.
Finnish samples (004_117, 004_118, 004_119, 004_120, 004_121, 004_122,
004_123, 004_126, 004_127, 004_128, 004_129, 004_130, 004_131, 004_133,
004_134, 004_135, 004_136, 004_137, 004_138, 004_139, 004_142, 004_143,
004_144, 004_145, 004_146, 004_149, 004_150, 004_151) were serologically
classified as RhD negative presented a ratio ≈0.5 for RHD5 and RHD7
assays against the reference gene indicating the presence of a hemizy-
gous RHD gene. One Finnish sample (004_125) showed ratios of ≈1 for
both RHD5 and RHD7 assays against the reference sequence indicating
the presence of homozygous RHD gene.
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Table 3.1: Serologically predicted genotype (Rh serology), ethnicity of donors, dPCR RHD zygosity results, and RHD allele as
determined by NGS (Ion PGM™).
Lab no. Rh serologyγ Ethnicityγ RHD Zygosity Nucleotide Exon (Intron) Amino acid RHD Allele Linked haplotype ∇
004_01 R1R1 Caucasian Homozygous - - - RHD*01 NA
004_02 R1R1 Caucasian Homozygous - - - RHD*01 NA
004_03 R1R1 Other Homozygous - - - RHD*01 NA
004_04 R1R1 Caucasian Homozygous - - - RHD*01 NA
004_05 R1R1 Caucasian Homozygous - - - RHD*01 NA
004_06 R1R1 Caucasian Homozygous - - - RHD*01 NA
004_07 R1R1 Caucasian Discrepancy 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_08 R1r Caucasian Hemizygous - - - RHD*01 NA
004_09 R1r Caucasian Hemizygous - - - RHD*01 NA
004_10 R1r Chinese Hemizygous - - - RHD*01 NA
004_11 R1r Caucasian Hemizygous - - - RHD*01 NA
004_12 R1r Caucasian Hemizygous - - - RHD*01 NA
004_13 R1r Caucasian Hemizygous - - - RHD*01 NA
004_14 R1r Caucasian Homozygous - - - RHD*01 NA
004_15 R1r Caucasian Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_16 R1r Caucasian Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_17 R1r Caucasian Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_18 R1r Caucasian Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_19 R1r Caucasian Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_20 R1r Caucasian Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_21 R1r Caucasian Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_22 R1r Caucasian Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_23 R1r Caucasian Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_24 R1r Caucasian Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_25 R1r Caucasian Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_26 R1r Caucasian Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
continued . . .
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Lab no. Rh serologyγ Ethnicityγ RHD Zygosity Nucleotide Exon (Intron) Amino acid RHD Allele Linked haplotype ∇
004_27 R1r Caucasian Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_28 R1r Caucasian Hemizygous 8C>G 1 Ser3Cys RHD*01W.03 R1 (DCe)
004_29 R1R2 Caucasian Homozygous - - - RHD*01 NA
004_30 R1R2 Caucasian Homozygous - - - RHD*01 NA
004_31 R1R2 Caucasian Homozygous - - - RHD*01 NA
004_32 R1R2 Caucasian Homozygous - - - RHD*01 NA
004_33 R1R2 Caucasian Homozygous - - - RHD*01 NA
004_34 R1R2 Caucasian Homozygous - - - RHD*01 NA
004_35 R1R2 Caucasian Hemizygous 1154G>C 9 Gly385Ala RHD*01W.02 NA
004_36 R1R2 Caucasian Hemizygous - - - RHD*01 NA
004_37 R1R2 Caucasian Hemizygous - - - RHD*01 NA
004_38 R1R2 Caucasian Hemizygous - - - RHD*01 NA
004_39 R1R2 Caucasian Hemizygous - - - RHD*01 NA
004_40 R1R2 Caucasian Hemizygous - - - RHD*01 NA
004_41 R2R2 Caucasian Homozygous 1154G>C 9 Gly385Ala RHD*01W.02 R2 (DcE)
004_42 R2R2 Not disclosed Hemizygous 1154G>C 9 Gly385Ala RHD*01W.02 R2 (DcE)
004_43 R2R2 Caucasian Homozygous - - - RHD*01 NA
004_44 R2R2 Caucasian Homozygous - - - RHD*01 NA
004_45 R2R2 Caucasian Homozygous - - - RHD*01 NA
004_46 R2R2 Caucasian Homozygous - - - RHD*01 NA
004_47 R2R2 Caucasian Homozygous - - - RHD*01 NA
004_48 R2r Caucasian Hemizygous - - - RHD*01 NA
004_49 R2r Caucasian Hemizygous - - - RHD*01 NA
004_50 R2r Caucasian Hemizygous - - - RHD*01 NA
004_51 R2r Caucasian Hemizygous - - - RHD*01 NA
004_52 R2r Caucasian Hemizygous - - - RHD*01 NA
004_53 R2r Caucasian Hemizygous - - - RHD*01 NA
004_54 R2r Caucasian Hemizygous 1154G>C 9 Gly385Ala RHD*01W.02 R2 (DcE)
004_55 R2r Caucasian Hemizygous 1154G>C 9 Gly385Ala RHD*01W.02 R2 (DcE)
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004_56 R2r Caucasian Hemizygous 1154G>C 9 Gly385Ala RHD*01W.02 R2 (DcE)
004_57 R2r Caucasian Hemizygous 1154G>C 9 Gly385Ala RHD*01W.02 R2 (DcE)
004_58 R2r Caucasian Hemizygous 1154G>C 9 Gly385Ala RHD*01W.02 R2 (DcE)
004_59 R2r Caucasian Hemizygous 1154G>C 9 Gly385Ala RHD*01W.02 R2 (DcE)
004_60 R2r Caucasian Hemizygous 1154G>C 9 Gly385Ala RHD*01W.02 R2 (DcE)
004_61 R2r Caucasian Hemizygous 1154G>C 9 Gly385Ala RHD*01W.02 R2 (DcE)
004_62 R2r Caucasian Hemizygous 1154G>C 9 Gly385Ala RHD*01W.02 R2 (DcE)
004_63 R0r Caucasian Hemizygous - - - RHD*01 NA
004_64 R0r Caucasian Hemizygous - - - RHD*01 NA
004_65 R0r Caucasian Hemizygous - - - RHD*01 NA
004_66 R0r Caucasian Hemizygous - - - RHD*01 NA
004_67 R0r Caucasian Hemizygous - - - RHD*01 NA
004_68 R0r Caucasian Hemizygous - - - RHD*01 NA
004_69 R0r Caucasian Hemizygous 602C>G 4 Thr201Arg RHD*09.03.01 R0 (Dce)
667T>G 5 Phe223Val
819G>A 6 silent




004_71 R0r Caucasian Hemizygous - - - RHD*01 NA
004_72 R0r Caucasian Hemizygous - - - RHD*01 NA







004_74 R2Rz Caucasian Homozygous - - - RHD*01 NA
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Lab no. Rh serologyγ Ethnicityγ RHD Zygosity Nucleotide Exon (Intron) Amino acid RHD Allele Linked haplotype ∇
004_75 rr Caucasian Negative NA NA NA NA NA
004_76 rr Caucasian Negative NA NA NA NA NA
004_77 rr Caucasian Negative NA NA NA NA NA
004_78 rr Caucasian Negative NA NA NA NA NA
004_79 rr Caucasian Negative NA NA NA NA NA
004_80 rr Caucasian Negative NA NA NA NA NA
004_81 r’r Caucasian Negative NA NA NA NA NA
004_82 r’r Caucasian Negative NA NA NA NA NA
004_83 r’r Caucasian Negative NA NA NA NA NA
004_84 r’r Caucasian Negative NA NA NA NA NA
004_85 r’r Caucasian Negative NA NA NA NA NA
004_86 r’r Black/Caribbean Negative NA NA NA NA NA
004_87 r’r Black/Caribbean Negative NA NA NA NA NA
004_88 r”r Caucasian Hemizygous 399delG 3 Val134fs Novel variant 1 NA
004_89 r”r Caucasian Negative NA NA NA NA NA
004_90 r”r Caucasian Negative NA NA NA NA NA
004_91 r”r Caucasian Negative NA NA NA NA NA
004_92 r”r Caucasian Negative NA NA NA NA NA
004_93 r”r Caucasian Negative NA NA NA NA NA
004_94 No data No data Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)
004_95 No data No data Hemizygous 809T>G 6 Val270Gly RHD*01W.01 R1 (DCe)





004_97 No data No data Hemizygous 602C>G 4 Thr201Arg RHD*09.03.01 R0 (Dce)
667T>G 5 Phe223Val
819G>A 6 silent
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Lab no. Rh serologyγ Ethnicityγ RHD Zygosity Nucleotide Exon (Intron) Amino acid RHD Allele Linked haplotype ∇
004_98 No data No data Hemizygous 1063G>A 7 Gly355Ser RHD*25 R1 (DCe)





004_100 No data No data Hemizygous = = = RHD*04.04 R1 (DCe)














004_102 R1r No data Hemizygous = = = Undetermined⊗ NA
004_103 R1r No data Hemizygous = = = Undetermined⊗ NA
continued . . .
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004_105 R2r No data Hemizygous = = = Undetermined⊗ NA
004_106 No data No data Hemizygous = = = Undetermined⊗ NA
004_107 No data No data Hemizygous 8C>G 1 Ser3Cys RHD*01W.03 R1 (DCe)
004_108 R1r No data Hemizygous 329T>C 2 Leu110Pro RHD*07.01 R1 (DCe)
004_109 R1r No data Hemizygous 329T>C 2 Leu110Pro RHD*07.01 R1 (DCe)
004_110 R1r No data Hemizygous 329T>C 2 Leu110Pro RHD*07.01 R1 (DCe)
004_111 R1r No data Hemizygous 505A>C 4 Met169Leu RHD*17.01 multiple
509T>G 4 Met170Arg
514A>T 4 Ile172Phe
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004_113 No data No data Hemizygous - - - RHD*01 NA
004_114 No data No data Homozygous - - - RHD*01 NA
004_115 No data No data Hemizygous - - - RHD*01 NA
004_116 No data No data Homozygous - - - RHD*01 NA
004_117 D- No data Hemizygous 1227G>A 9 Splice site RHD*01EL.01 R1 (DCe)
004_118 D- No data Hemizygous 1227G>A 9 Splice site RHD*01EL.01 R1 (DCe)
004_119 D- No data Hemizygous 8C>G 1 Ser3Cys Novel variant 3 NA
49delG 1 Ala17fs
004_120 D- No data Hemizygous 952C>T 7 Arg318* RHD*01N.61 R1 (DCe)
004_121 D- No data Hemizygous 712delG 5 Val238Fs RHD*01N.33 R1 (DCe)
004_122 D- No data Hemizygous 885G>T 6 Met295Ile RHD*11 R0 (Dce)
004_123 D- No data Hemizygous 845G>A 6 Gly282Asp RHD*15 R2 (DcE)
004_124 Weak D+ No data Hemizygous 1212C>A 9 Asp404Glu RHD*01W.72 Not reported
004_125 Weak D+ No data Homozygous 48G>C 1 Trp16Cys Undetermined NA
602C>G 4 Thr201Arg
667T>G 5 Phe223Val
004_126 D- No data Hemizygous 147delA 1 fs, stop RHD*01EL.04 R1 (DCe)
IVS1+6delA (1)
004_127 D- No data Hemizygous 829G>A 6 Gly277Arg Novel variant 10 NA
004_128 D- No data Hemizygous 829G>A 6 Gly277Arg Novel variant 10 NA
004_129 D- No data Hemizygous 829G>A 6 Gly277Arg Novel variant 10 NA
004_130 D- No data Hemizygous 829G>A 6 Gly277Arg Novel variant 10 NA
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004_131 D- No data Hemizygous 784delC 5 Gln262fs Novel variant 5 NA
004_132 Weak D+ No data Hemizygous 782C>T 5 Pro261Leu Novel variant 8 NA
004_133 D- No data Hemizygous 421delG 3 Val141fs Novel variant 9 NA
422T>A 3 Val141Glu
004_134 D- No data Hemizygous 421delG 3 Val141fs Novel variant 9 NA
422T>A 3 Val141Glu
004_135 D- No data Hemizygous 421delG 3 Val141fs Novel variant 9 NA
422T>A 3 Val141Glu
004_136 D- No data Hemizygous 486+1G>A (3) splice site RHD*01EL.08 R1 (DCe)
004_137 D- No data Hemizygous - - - Undetermined./ NA
004_138 D- No data Hemizygous - - - Undetermined./ NA
004_139 D- No data Hemizygous 829G>A 6 Gly277Arg Novel variant 10 NA
004_140 Weak D+ No data Hemizygous 8C>G 1 Ser3Cys RHD*01W.03 NA
004_141 Weak D+ No data Hemizygous 782C>T 5 Pro261Leu Novel variant 8 NA
004_142 D- No data Hemizygous 1154G>C 9 Gly385Ala RHD*01W.02 R2 (DcE)
004_143 D- No data Hemizygous 1154G>C 9 Gly385Ala RHD*01W.02 R2 (DcE)
004_144 D- No data Hemizygous 1154G>C 9 Gly385Ala Novel variant 4 NA
1163T>G 9 Leu388Arg
004_145 D- No data Hemizygous 519C>G 4 Tyr173* Novel variant 6 NA
004_146 D- No data Hemizygous 845G>A 6 Gly282Asp RHD*15 R2 (DcE)
004_147 Weak D+ No data Hemizygous 1016G>C 7 Gly339Ala Novel variant 7 NA
004_148 D+ No data Hemizygous 602C>G 4 Thr201Arg RHD*09.03.01 R0 (Dce)
667T>G 5 Phe223Val
819G>A 6 silent
004_149 D- No data Hemizygous 330-331delGT 2 Phe111fs RHD*01N.35 Not reported




continued . . .
119
Lab no. Rh serologyγ Ethnicityγ RHD Zygosity Nucleotide Exon (Intron) Amino acid RHD Allele Linked haplotype ∇
004_151 D- No data Hemizygous 395_396 insGG 3 Lys133fs No designation assigned NA
004_152 R1R2 Multiple Homozygous NA NA NA Not sequenced NA
004_205
Blue highlight indicates samples show discrepant results between Rh serology predicted genotype and RHD zygosity results using dPCR.
*Termination codon.
γAs supplied by the NHSBT, Bristol, United Kingdom, and the Finnish Red Cross Blood Service, Helsinki, Finland.
∇Rh haplotype linked to the RHD allele as found in RhesusBase (Wagner and Flegel, 2014).
** RhD antigen titre after elution +1 as reported by the Finnish research group (Tammi, 2019).
- no SNPs detected.
NA= Not applicable.
= Similar to previous.
⊗ Samples previously genotyped as hybrid RHD*06.01 allele, but results remain inconclusive due to the lack of coverage in exon 6 (expected conversion).
ζ RHD NGS findings do not agree with existence genotyping data (DVa) provided by ISBT (1996).
./One or multiple failed amplicons in LR-PCR.
∝sample showed homozygous RHD gene using ddPCR indicating a compound heterozygote variant RHD alleles.120
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Table 3.2: Samples with discrepant results between the serology predicted Rh genotypes
and RHD gene zygosity results using dPCR.
Lab no. Rh serology* RHD5/AGO1 ratio RHD7/AGO1 ratio RHD zygosity
004_07 R1R1 0.54 1.01 Discrepancy (a)
004_14 R1r 1.06 0.99 Homozygous (b)
004_35 R1R2 0.46 0.51 Hemizygous (c)
004_36 R1R2 0.51 0.51 Hemizygous (c)
004_37 R1R2 0.53 0.49 Hemizygous (c)
004_38 R1R2 0.51 0.53 Hemizygous (c)
004_39 R1R2 0.52 0.51 Hemizygous (c)
004_40 R1R2 0.53 0.52 Hemizygous (c)
004_42 R2R2 0.54 0.47 Hemizygous (d)
004_88 r”r 0.51 0.47 Hemizygous(e)
004_101 R1r 0.0 0.45 Hemizygous(f )
004_102 R1r 0.0 0.49 Hemizygous(f )
004_103 R1r 0.0 0.53 Hemizygous(f )
004_104 R2r 0.0 0.53 Hemizygous(f )
004_105 R2r 0.0 0.50 Hemizygous(f )
004_106 No data 0.0 0.58 Hemizygous(f )
004_117 D- 0.50 0.50 Hemizygous(g)
004_118 D- 0.51 0.52 Hemizygous(g)
004_119 D- 0.51 0.50 Hemizygous(g)
004_120 D- 0.53 0.52 Hemizygous(g)
004_121 D- 0.45 0.52 Hemizygous(g)
004_122 D- 0.51 0.49 Hemizygous(g)
004_123 D- 0.51 0.49 Hemizygous(g)
004_125 Weak D+ 1.0 1.0 Homozygous(h)
004_126 D- 0.51 0.51 Hemizygous(g)
004_127 D- 0.51 0.52 Hemizygous(g)
004_128 D- 0.52 0.50 Hemizygous(g)
004_129 D- 0.51 0.53 Hemizygous(g)
004_130 D- 0.49 0.50 Hemizygous(g)
004_131 D- 0.47 0.50 Hemizygous(g)
004_133 D- 0.53 0.52 Hemizygous(g)
004_134 D- 0.52 0.49 Hemizygous(g)
004_135 D- 0.54 0.52 Hemizygous(g)
004_136 D- 0.52 0.51 Hemizygous(g)
004_137 D- 0.51 0.51 Hemizygous(g)
004_138 D- 0.51 0.53 Hemizygous(g)
004_139 D- 0.53 0.52 Hemizygous(g)
004_142 D- 0.51 0.50 Hemizygous(g)
004_143 D- 0.52 0.52 Hemizygous(g)
004_144 D- 0.55 0.50 Hemizygous(g)
004_145 D- 0.51 0.53 Hemizygous(g)
004_146 D- 0.53 0.50 Hemizygous(g)
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Lab no. Rh serology* RHD5/AGO1 ratio RHD7/AGO1 ratio RHD zygosity
004_149 D- 0.55 0.53 Hemizygous(g)
004_150 D- 0.52 0.54 Hemizygous(g)
004_151 D- 0.50 0.50 Hemizygous(g)
* As supplied by the NHSBT, Bristol, UK or Finnish Red Cross Blood Service, Helsinki, Finland. (a) Sample
shows discrepancy between hemizygous RHD5 and homozygous RHD7 meaning that it is likely one of the
RHD alleles has a deletion in exon 5. Samples showing incompatible dPCR results with serologically predicted
genotypes indicating incorrectly assigned genotype by serology include: (b) R1r sample shows homozygous
RHD gene, (c) R1R2 samples show hemizygous RHD gene, (d) R2R2 sample shows hemizygous RHD gene,
(e) r”r sample genotype predicted by serology as r”r found to be RHD hemizygous, (f) Samples presented
RHD5/AGO1 ratio = 0 and RHD7/AGO1 ≈0.5 indicating a hemizygous RHD gene but with a deletion in exon
5, and (g) Samples phenotyped by serology as RhD negative and tested as RHD hemizygous. (h) Sample
phenotyped by serology as RhD weak and tested as RHD homozygous indicating two variant RHD alleles.
3.3.2 Sanger Sequencing
Seven intronic RHD SNPs were detected through NGS (Halawani, 2015)
that were thought to be R2 haplotype specific. Two SNPs located in in-
tron 2 (25,611,580 G>A; 25,614,400 C>G), three SNPs located in intron
3 (25,621,980 C>T; 25,625,471 T>C; 25,627,066 C>G), and two SNPs lo-
cated in intron 8 (25,646,933 T>G; 25,648,349 T>C) (Halawani, 2015; Sil-
lence et al., 2017). RHD primers were designed to amplify regions of in-
terest. Samples with different Rh phenotypes were sequenced by Sanger
sequencing to test if these SNPs were R2 haplotype specific. The samples
tested included 6 R1R1, 1 R1r, 6 R2R2, 1 R2r, 8 R0r, and 6 R1R2.
Target intronic SNPs were not detected in samples genotyped by serol-
ogy as R1R1, and R1r. In contrast, all seven SNPs were detected in sam-
ples genotyped by serology as R2R2 and R2r samples. Samples geno-
typed by serology as R0r were included to test if they show R1 or R2 in-
tronic SNP patterns, and they were all missing the SNPs (R1 pattern). Six
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R1R2 samples were tested to confirm the previous results by the presence
of two peaks in the trace chromatogram at the SNP position, in which
one comes from the R1 allele and another from the R2 allele. For SNPs
(25,611,580 G>A), (25,614,400 C>G), (25,625,471 T>C), (25,627,066 C>G),
and (25,648,349 T>C), all samples but one R1R2 sample (004_38) have
shown two different peaks at the SNP positions. Sample (004_38), sero-
logically predicted as R1R2, was missing all intronic SNPs investigated
suggesting that R2 allele was assigned incorrectly for this sample. Figure
3.2 shows SNP position 25,614,400 C>G in 6 R1R2 samples showing two
peaks except sample (004_38) that shows one peak (C).
All 6 R1R2 samples were missing the SNP (25,621,980 C>T) showing only
C at the SNP position. For SNP (25,646,933 T>G), all samples except for
(004_38) present the SNP peak (G) in the SNP position while missing the
second peak (T); sample (004_38) showed only one peak (T) for that SNP.
Sample (004_38) tested as hemizygous for RHD gene showing a ratio of
0.51 and 0.53 for RHD5 and RHD7 against the reference sequence AGO1.
This indicates a discrepancy between serologically assigned Rh haplotype
and ddPCR zygosity results. Table 3.3 summarizes Sanger sequencing re-
sults for RHD intronic SNP investigations for R1, R2, R0, and R1R2 sam-
ples. Table 3.3 also gives the position of these SNPs corresponding to both
hg19 and hg38 reference sequences.
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Figure 3.2: Sanger sequence data from reverse primer for R1R2 samples for RHD intronic
SNP 25,614,400 C>G. All samples show two peaks (blue for C and black for G) in the




Table 3.3: Summary of RHD intronic SNPs results for R1, R2, R0, and R1R2 samples.
Position (hg19) Position (hg38)* SNP Intron R1 R2 R0 R1R2
25,611,580 25,285,089 G>A 2 - + - +/-**
25,614,400 25,287,909 C>G 2 - + - +/-**
25,621,980 25,295,489 C>T 3 - + - -@
25,625,471 25,298,980 T>C 3 - + - +/-**
25,627,066 25,300,575 C>G 3 - + - +/-**
25,646,933 25,320,442 T>G 8 - + - +$
25,648,349 25,321,858 T>C 8 - + - +/-**
* Position of SNPs for RHD intronic SNPs detected using the hg19 reference
sequence correlated to position in the hg38 reference sequence.
** All R1R2 samples except sample (004_38), that presented a hemizygous RHD
gene on dPCR, show two peaks at SNP positions.
$ All R1R2 samples show one SNP peak (G) except for sample (004_38), that
presented a hemizygous RHD gene on dPCR, shows (T) in SNP position (-).
@ SNP was negative in all 6 R1R2 samples indicating that SNP is not R2 allele
specific by Sanger sequencing.
125
RESULTS
3.3.3 RHD NGS Data Quality
To fully sequence the RHD gene, LR-PCR amplification was used to am-
plify the gene in six overlapping amplicons, Figure 3.3. Samples were pre-
pared for sequencing (section 2.9) and sequenced using Ion PGM™, each
sequencing run contained between 10 and 39 samples (Table 3.4). Figure
3.4 shows Ion PGM™ sequencing run summary from a single represen-
tative run, which indicates (a) high ISPs loading density in 316™ Chip of
80%, (b) recovered reads were over 3.9 million reads, and (c) reads length
distribution, which refers to the number of bases sequenced in a DNA
fragment, was around 120-130 bp. A higher percentage of polyclonal am-
plification was noticed in other runs with higher number of samples. ISPs
loading density refers to the percentage of chip wells that contain ISP, in
which red colour indicates adequate loading density, yellow indicates less-
than adequate loading density, and red indicates inadequate loading den-
sity or absence of beads.
NGS data was obtained in FASTQ files, which are raw text sequence data
with corresponding quality scores, was assessed for sequence quality. CLC
workbench 10 software was utilised to generate a quality sequence sum-
mary report. Quality analysis on reads included, but was not limited to,
reads lengths distribution (Figure 3.5 (A)), GC-content, quality distribu-
tion using PHRED score (Figure 3.5 (B)), per-base coverage (Figure 3.5 (C)),
and sequence duplication level. High PHRED sequence quality score was
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Figure 3.3: Gel electrophoresis of the 6 LR-PCR RHD amplicons. Six LR-PCR amplicons
RHD1-RHD6 from a single representative RHD positive sample next to 1 kb Extend lad-
der (New England Biolabs®, U.K) was used to indicate amplicon size. All PCR reactions




noticed across all the samples sequenced. Figure 3.5 shows a PHRED score
of over 30 for a representative sample that was sequenced indicating >99%
accuracy. PHRED score is an algorithmic integer value representing the es-
timated probability of an error in the identification of a nucleic acid base
(section 1.12). There is no recommended PHRED score for NGS; however,
higher PHRED score indicates lower probability of error, therefore, higher
accuracy.
Figure 3.4: Ion PGM™ sequencing run summary from a single representative run. (a) The
loading density in 316™ Chip was 80% of the chip capacity, giving a final throughput of
442 Mb. (b) Over 3.9 million reads were recovered after enrichment and polyclonal filters.
(c) A histogram shows the distribution of the read length mean around 112bp, where the
y-axis and x-axis represent the read count and the read length in bp, respectively.
Reads were mapped to the RHD gene in the hg38 reference sequence (Tatusova
et al., 2016). The homologous RHCE gene was masked in the mapping
process to prevent reads from scattering. Detailed mapping report was
generated using the CLC workbench 10 which included coverage analysis
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(Figure 3.6), mismatches analysis, read length distribution, insertion and
deletion level, and quality for match and mismatch distribution.
Variant detection was performed on a minimum coverage (i.e the num-
bers of overlapping reads over a single base) of 30 and variants detected
were analysed on a single base basis considering different parameters in-
cluding number and percentage of reads and nucleotide count (Nielsen
et al., 2011). Full coverage across the gene was achieved and depth of se-
quencing coverage was adequate at >50 and sufficient for calling variants
(Figure 3.7) (Stabentheiner et al., 2011; Sims et al., 2014; Fichou et al., 2014).
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Figure 3.5: RHD gene sequence quality summary report generated by the CLC work-
bench 10 software from a single representative sample. A. Distribution of reads sequence
lengths from a single representative sample; x axis: sequence length in base-pairs, y axis:
number of reads showing a specific length normalized to the total number of sequences.
B. PHRED score for RHD gene sequence from a single representative sample. x axis:
PHRED-score; y axis: percentage of sequences, normalized to the total number of reads,
noted at that quality. C. The number of sequences that cover the individual base positions
from a single representative sample, x axis: base position; y axis: number of sequences
covering individual base positions normalized to the total number of sequences.
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Figure 3.6: Level of coverage across the RHD gene from a single representative sample.
Level of coverage (x axis) and number of bases observed at that level (y axis). A total
of 57,317 positions (RHD gene) have coverage between 1 and 1,189. Positions of zero
coverage (248,898,842) (chr1 genome) were not included in the graph.
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Table 3.4: Ion PGM™ sequencing run summary report details for RHD sequencing runs.
Library No. of ISP loading Polyclonal Usable reads Total reads Average reads
no. samples (%) (%) (%) /sample
1 10 86 34 60 3,249,115 324,911
2 26 76 30 62 2,967,256 114,125
3 27 84 40 54 2,836,007 105,037
4 33 87 37 57 3,107,386 94,163
5* 36 91 51 39 2,224,525 61,792
6 39 80 18 79 3,951,879 101,330
*High loading density (91%) but lowest usable reads (39%) could be due to variations in
either library preparation and concentration of reads used or Ion OneTouch™
performance.
3.3.4 RHD Genotyping using NGS
In this study, we have collected (n= 205) samples, from which (n=133) sam-
ples were genotyped for the RHD gene, 53 R1R2 samples were excluded
from the sequencing as they tested homozygous for the RHD gene, and 18
samples (6 rr, 7 r’r, 5 r”r) tested as RHD negative on dPCR. Sequencing
RHD hemizygous samples will ensure only one allele is sequenced to es-
tablish Rh allele specific reference sequences. From (n=133) samples geno-
typed for the RHD gene, 75 were blood donor samples, 35 were from RhD
negative/weak Finnish pregnant females, and 23 from the ISBT workshop
1996 (ISBT, 1996), (Figure 3.8).
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Figure 3.7: Depth of coverage across the RHD gene from a single representative sample.
Six RHD amplicons are mapped to the RHD gene (top). Blue peaks indicate continuous
and high level of coverage.
In order to establish reference RHD allele sequences, we aimed to sequence
blood donor hemizygous RHD samples to avoid amplification from 2 dif-
ferent RHD alleles; nevertheless, RHD homozygous samples were also
included in the sequence analysis to detect weak D that could be unde-
tectable by serological testing due to the presence of a wild type copy of
the RHD allele. We also sequenced the RHD gene in RhD negative samples
or very weak D samples that tested RHD positive by ddPCR to determine
the genetic reasons behind the negative or weakened expression, this in-
cluded 1 blood donor sample (004_88) and 35 pregnant female samples
supplied by the Finnish Red Cross Blood Service (004_117- 004_151).
Donor samples (n=75) (Table 3.1) with different Rh serologically predicted
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RESULTS
Figure 3.8: Flowchart illustrates number of samples tested on each sequencing platform.
Blood donor samples not sequenced included 18 RHD negative samples and 53 R1R2
samples found to be homozygous for the RHD gene using ddPCR.
genotypes were sequenced on the Ion PGM™ including 7 R1R1 (DCe/DCe),
21 R1r (DCe/dce), 12 R1R2 (DCe/DcE), 7 R2R2 (DcE/DcE), 15 R2r (DcE/dce),
11 R0r (Dce/dce) and 1 R2Rz (DcE/DCE). One r”r (dcE/dce) sample which
showed hemizygous RHD gene on ddPCR was also sequenced. We pur-
posely included the 6 R1R2 samples (004_35, 004_36, 004_37, 004_38, 004_39,
004_40) that tested as hemizygous for the RHD gene and included an-
other set of 6 homozygous R1R2 samples (004_29, 004_30, 004_31, 004_32,
004_33, 004_34) for a comparison, which were randomly chosen from the
remaining 60 homozygous R1R2 samples.
The RHD gene was also sequenced from the ISBT workshop 1996 sam-
ples (n=23), however Rh serological data was available for only 10 sam-
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ples. RHD allele was determined and supplied for these samples (n=23).
Finnish samples (n=35) with negative and weak D phenotypes by serol-
ogy were also sequenced for the RHD gene to determine the genetic back-
ground for the RhD negative expression. Samples included 22 (dCe/dce),
3 (dCe/dCe), 2 (dCe/DcE), 4 (dcE/dce) and 4 (dce/dce).
Data was aligned to the hg38 reference sequence using the CLC work-
bench 10 software (Qiagen Ltd, United Kingdom). It is noteworthy that
the RHD reference sequence (NC_000001.11) (Tatusova et al., 2016) is RHD*DAU0
(RHD*10.00) that presents a SNP in exon 8 (1136C>T) causing amino acid
change Thr379Met; therefore, all samples sequenced presented a SNP in
exon 8 (1136T>C) Met379Thr, illustrated in Figure 3.9. Multiple exonic
SNPs linked to different known RHD alleles were detected across all the
samples sequenced (n=133) and are shown in Table 3.5.
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Figure 3.9: The RHD hg38 reference sequence is a variant allele. (A) RHD hg38 refer-
ence sequence is a variant allele that shows c.1136T (p.379Met) in exon 8 that encodes
RHD*DAU0. (B) All samples sequenced showed c.1136T>C (p.Met379Thr) when aligned
to the reference sequence.
Data analysis of the (n= 133) samples (Table 3.1) showed that 48 samples
carried the RHD wild type allele RHD*01. Other samples (n= 85) showed
a RHD variant allele, in which 59 samples linked to known RHD vari-
ant alleles, and 17 samples showed novel RHD variant alleles. Table 3.5
lists exonic changes and the predicted amino acid alterations they encode
for each allele. In the remaining 9 samples (004_102, 004_103, 004_104,
004_105, 004_106, 004_125, 004_137, 004_138, 004_150) the RHD genotyp-
ing results were inconclusive. Inconclusive genotyping results were due
to either the lack of a complete sequence, failure to amplify one or more of
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the amplicons, or the presence of two different possible variant alleles.
Known RHD variants detected include weak, partial, DEL and null RHD
alleles. Four different weak D alleles were detected in 24 samples in which:
16 samples (004_07, 004_15, 004_16, 004_17, 004_18, 004_19, 004_20, 004_21,
004_22, 004_23, 004_24, 004_25, 004_26, 004_27, 004_94, 004_95) were geno-
typed as RHD*01W.01, 14 samples (004_35, 004_41, 004_42, 004_54, 004_55,
004_56, 004_57, 004_58, 004_59, 004_60, 004_61, 004_62, 004_142, 004_143)
were genotyped as RHD*01W.02, 3 samples (004_28, 004_107, 004_140)
were genotyped as RHD*01W.03, and 1 sample (004_124) genotyped as
RHD*01W.72.
Eleven partial weak D alleles were found in 17 samples in which 1 sample
(004_101), genotyped previously by the ISBT (ISBT, 1996) as DVa, showed
SNPs that encode the hybrid allele RHD*06.01. Three samples (004_108,
004_109, 004_110) were genotyped as RHD*07.01, 3 samples (004_69, 004_97,
004_148) were genotyped as RHD*09.03.01, 2 samples (004_123, 004_146)
were genotyped as RHD*15 and 2 samples (004_99, 004_100) were geno-
typed as RHD*04.04. Sample (004_111) genotyped as RHD*17.01, sam-
ple (004_111) genotyped as RHD*17.02, sample (004_98) was genotyped as
RHD*25, sample (004_96) was genotyped as RHD*03.01, sample (004_70)




Three DEL alleles were detected in 4 samples in which: 2 samples (004_117,
004_118) were genotyped as RHD*01EL.01, 1 sample (004_126) was geno-
typed as RHD*01EL.04, and 1 sample (004_136) was genotyped as RHD*01EL.08.
Three negative RHD alleles were detected in 3 samples, in which: sam-
ple (004_149) was genotyped as RHD*01N.35, sample (004_120) was geno-
typed as RHD*01N.61, and sample (004_121) was genotyped as RHD*01N.33.
In 5 samples (004_102, 004_103, 004_104, 004_105, 004_106), genotyped
previously by the ISBT (ISBT, 1996) as RHD*06.01 (DVI), exonic changes
linked to RHCE4-5 insertion were detected. Lack of coverage in exon 6
was noted indicating a deletion of the exon. Adequate coverage was no-
ticed over exons 4 and 5 which are amplified by the same amplicon as
exon 6 (amplicon 4). Exon 5 SNP (c.676G>C) was detected in 3 samples
(004_104, 004_105, 004_106) but not in samples serologically genotyped as
R1r (004_102, 004_103). Genotyping results for theses 5 samples remain
inconclusive.
Sample (004_125) tested as RHD homozygous by dPCR and was serolog-
ically phenotyped as weak D. NGS data showed 4 heterozygous exonic
changes c.48G>C (p.Trp16Cys) in exon 1, c.602C>G (p.Thr201Arg) in exon
4, c.667T>G (p.Phe223Val) in exon 5, and c.819G>A (silent) in exon 6. Pos-
sible alleles encoded by these exonic changes are either RHD*09.03 and
RHD*01.01 or RHD*09.04 and RHD*01, however, both options include a
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wild type RHD allele that should produce normal RhD protein which does




Table 3.5: Molecular basis of the different RHD alleles detected by NGS.
no. of samples Nucleotide Exon (Intron) Amino acid Allele name Allele encodes Haplotype
48 NA NA NA RHD*01 Normal D
1 48G>C 1 Trp16Cys RHD*01.01 Normal D DCe
16 809T>G 6 Val270Gly RHD*01W.01 Weak D type 1 DCe
14 1154G>C 9 Gly385Ala RHD*01W.02 Weak D type 2 DcE
3 8C>G 1 Ser3Cys RHD*01W.03 Weak D type 3 DCe
1 1212C>A 9 Asp404Glu RHD*01W.72 Weak D type 72 NR



















3 602C>G 4 Thr201Arg RHD*09.03.01 DAR3.1 Dce
667T>G 5 Phe223Val
819G>A 6 Silent




3 329T>C 2 Leu110Pro RHD*07.01 DVII DCe
1 505A>C 4 Met169Leu RHD*17.01 DFR1 multiple
509T>G 4 Met170Arg
514A>T 4 Ile172Phe
continued . . .
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no. of samples Nucleotide Exon (Intron) Amino acid Allele name Allele encodes Haplotype












1 885G>T 6 Met295Ile RHD*11 Weak partial D 11 DCe
2 845G>A 6 Gly282Asp RHD*15 Weak partial D 15 DcE
1 1063G>A 7 Gly355Ser RHD*25 DNB DCe




‘ 1061C>A 7 Ala354Asn
2 1227G>A 9 Lys409Lys RHD*01EL.01 Del DCe
splice site
1 147delA 1 fs, stop RHD*01EL.04 Del DCe
IVS1+6delA (1)
1 486+1G>A (3) splice site RHD*01EL.08 Del DCe
1 712delG 5 Val238fs RHD*01N.33 D- DCe
1 330_331delGT 2 Phe111fs RHD*01N.35 D- NR
1 952C>T 7 Arg318* RHD*01N.61 D- DCe
1 399delG 3 Val134fs Novel variant 1 NA NA








1 8C>G 1 Ser3Cys Novel variant 3 NA NA
49delG 1 Ala17fs
1 1154G>C 9 Gly385Ala Novel variant 4 NA NA
1163T>G 9 Leu388Arg
1 784delC 5 Gln262fs Novel variant 5 NA NA
1 519C>G 4 Tyr173* Novel variant 6 NA NA
continued . . .
141
RESULTS
no. of samples Nucleotide Exon (Intron) Amino acid Allele name Allele encodes Haplotype
1 1016G>C 7 Gly339Ala Novel variant 7 NA NA
2 782C>T 5 Pro261Leu Novel variant 8 NA NA
3 421delG 3 Val141fs Novel variant 9 NA NA
422T>A 3 Val141Glu
5 829G>A 6 Gly277Arg Novel variant 10 NA NA
1 395_396dupGG 3 Lys133fs * NA NA
NA = Not applicable.
NR = Not reported.
*No designation assigned by ISBT.
Blue highlight indicates RHD alleles encode weak D.
Red highlight indicates RHD alleles encode weak partial D.
Green highlight indicates RHD alleles encode DEL phenotype.
Yellow highlight indicates RHD alleles encode null phenotype.
Gray highlight indicates novel RHD variant alleles.
3.3.4.1 NHSBT Blood Donor Samples
Of the NHSBT blood donor samples (n=75), one R1r sample (004_28) showed
a SNP in exon 1 (c.8C>G) Ser3Cys that encodes weak D type 3 (RHD*01W.03).
Thirteen R1r samples (004_15, 004_16, 004_17, 004_18, 004_19, 004_20, 004_21,
004_22, 004_23, 004_24, 004_25, 004_26, 004_27) and 1 R1R1 sample (004_07)
showed a SNP in exon 6, (c.809T>G) Val270Gly that encodes weak D type 1
(RHD*01W.01). Nine R2r samples (004_54, 004_55, 004_56, 004_57, 004_58,
004_59, 004_60, 004_61, 004_62), two R2R2 samples (004_41, 004_42), and
one R1R2 sample (004_35) showed the exon 9 (c.1154G>C) SNP that causes
amino acid change p.Gly385Ala which encodes weak D type 2 (RHD*01W.02).
Sample (004_69) showed c.186G>T in exon 2, c.410C>T in exon 3, c.455A>C
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and c.602C>G in exon 4, and c.667T>G in exon 5 mutations that predict
the following amino acid changes p.Leu62Phe, p.Ala137Val, p.Asn152Thr,
p.Thr201Arg, and p.Phe223Val, that encode RHD*09.03.01. Sample (004_70)
showed mutations that encode for the RHD*09.01.02 (DAR1.2) allele which
include: c.602C>G (p.Thr201Arg) in exon 2, c.667T>G (p.Phe223Val) and
c.744C>T (silent) in exon 5, and c.957G>A (silent) and c.1025T>C (Ile342Thr)
in exon 7. One sample (004_73) showed SNPs in exon 4 that encode for the
variant RHD*17.02 allele, which include c.505A>C (p.Met169Leu), c.509T>G
(p.Met170Arg), c.514A>T (p.Ile172Phe), c.544T>A (p.Ser182Thr), c.577G>A
(p.Glu193Lys), c.594A>T (p.Lys198Asn), and c.602C>G (p.Thr201Arg). One
donor sample (004_88) phenotyped by serology as r”r was found to be
RHD hemizygous using ddPCR. NGS data showed 399delG in exon 3
causing Val134fs which is a novel variant, listed here as novel variant 1,
that has not been reported in the literature. Figure 3.10 illustrates different
predicted amino acid changes on the RhD protein.
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Figure 3.10: Amino acid changes predicted by NGS illustrated on the RhD protein. red:
amino acid changes predicted from NGS that lead to stop codon, frame shift or splice
site change; green: amino acid changes were linked to novel RHD variants; blue: amino
acid changes predicted from NGS that link to known RHD variant; purple: amino acid
changes predicted by NGS from RHD-RHCE-RHD hybrid genes. Image courtesy of Con-
roy et al. (2005).
Of the 28 samples that were serologically phenotyped as weak D, 26 of
them were confirmed to be weak D by NGS and the RHD allele was deter-
mined. One R1r sample (004_14) and the R2Rz (004_74) sample were sero-
logically predicted to be weak D but no SNPs in the RHD gene predicting
amino acid changes in the RhD protein were detected by sequencing. For
these two samples (004_14 and 004_74), the RHAG gene was sequenced to
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test if there were any mutations in the RHAG gene that could lead to weak
D expression, (section 3.3.6).
3.3.4.2 ISBT Samples
ISBT samples (n=23) (Table 3.1) from the 1996 workshop had the RHD
gene sequenced for the presence of variant RHD alleles. Samples were
tested for RHD zygosity and genotyped using NGS. The RHD genotyp-
ing results were as follows: 2 samples (004_94 and 004_95) were geno-
typed as weak D type 1 RHD*01W.01, 1 sample (004_96) was genotyped
as partial D type DIIIa (RHD*03.01), 1 sample (004_97) was genotyped as
RHD*09.03.01, 1 sample (004_98) was genotyped as partial D type DNB
(RHD*25), 2 samples (004_99 and 004_100) were genotyped as partial DIV
type 4 (RHD*04.04). One R1r sample (004_101) was genotyped as the hy-
brid RHD gene DVI type 1 (RHD*06.01) although previously genotyped
as DVa by ISBT (1996).
Five samples (004_102- 004_106) showed exonic SNPs in exons 4 and 5 as-
sociated with RHCE4-5 insertion in the RHD gene, however, results remain
inconclusive due to the breakage of coverage in exon 6 which may indicate
deletion of that exon, which can be confirmed by exome sequencing PCR.
One sample (004_107) was genotyped as weak D type 3 RHD*01W.03, 4
samples (004_108, 004_109, 004_110, 004_111) were genotyped as partial D
type DVII RHD*07.01, and 4 samples (004_113, 004_114, 004_115, 004_116)
were genotyped as wild type RHD gene RHD*01. Sample (004_112) that
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showed hemizygous RHD gene on ddPCR presented mutations that en-
code both RHD*07.01 and RHD*17.02 which include c.329T>C (p.Leu110Pro)
in exon 2 and c.505A>C (p.Met169Leu), c.509T>G (p.Met170Arg), c.514A>T
(p.Ile172Phe), c.544T>A (p.Ser182Thr), c.577G>A (p.Glu193Lys), c.594A>T
(p.Lys198Asn), and c.602C>G (p.Thr201Arg) in exon 4, which was consid-
ered a novel RHD variant allele (novel variant 2) consisting of a hybrid of
these two alleles (Table 3.5).
3.3.4.3 Finnish Samples
35 samples (004_117- 004_151) (Table 3.1), supplied by the Finnish Red
Cross Blood Service, were from serologically considered RhD negative
pregnant females in which the genetic variation of the RHD allele could
not be determined using the SSP-PCR (Tammi, 2019). All samples were
tested for RHD zygosity using ddPCR, all samples were hemizygous for
the RHD gene except sample (004_125) which was found to be homozy-
gous (Table 3.2).
Complete sequencing of the RHD gene revealed 21 different variant RHD
alleles in 31 out of 35 samples, (Table 3.1). In total, 13 previously described
RHD variants were identified in 16 samples. These variants include 3 null
alleles, 3 DEL alleles, 3 weak D alleles, 3 partial weak D alleles, and one
allele in sample (004_151) has been reported by Karnot et al. (2016) but
no designation has been assigned by the ISBT, as found in RhesusBase
(Wagner and Flegel, 2014). The 3 null alleles were found in 3 samples
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which include: RHD*01N.61 allele in sample (004_120), RHD*01N.33 allele
in sample (004_121), and RHD*01N.35 allele in sample (004_149). The 3
DEL alleles were found in 4 samples which include: RHD*01EL.01 allele in
samples (004_117 and 004_118), RHD*01EL.08 allele in sample (004_136),
and RHD*01EL.04 allele in sample (004_126). The 3 weak D alleles were
found in 4 samples which include: RHD*01W.72 allele in sample (004_124),
RHD*01W.03 allele in sample (004_140), and RHD*01W.02 allele in sam-
ples (004_142 and 004_143). The 3 partial D alleles were found in 4 sam-
ples which include: RHD*11 allele in sample (004_122), RHD*15 in sam-
ples (004_123 and 004_146), and RHD*09.03.01 allele in sample (004_148).
Amino acid changes that encode the different RHD alleles are listed in Ta-
ble 3.5.
Eight different novel alleles identified in 15 samples, listed in Table 3.6, are
encoded by 4 novel missense mutations, 3 frame shift mutations caused by
deletions, and 1 nonsense mutation (Table 3.5). These mutations include:
one SNP c.829G>A in exon 6 that predicts amino acid change p.Gly277Arg
which was detected in 5 samples (004_127, 004_128, 004_129, 004_130,
004_139) (novel variant 10). The novel c.829G>A was confirmed using
Sanger sequencing by the Finnish research group (Tammi, 2019; Tammi
et al., 2020), since the same nucleotide change in the adjacent base, c.830G>A,
has been reported to cause the RHD*01W.12 (RHD*weak D type 12) allele.
Identification of novel SNPs showed consistent results using Sanger se-
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quencing, NGS and TGS.
In five samples (004_127, 004_128, 004_129, 004_130, 004_139), serologi-
cally phenotyped as RhD negative, one exon 6 mutation c.829G>A that
predicts amino acid change p.Gly277Arg was detected (Novel Variant 10).
This missense mutation may indicate a DEL phenotype, because missense
mutations should not cause a null phenotype. Affected amino acid in this
novel variant allele Gly277 is the same amino acid mutation that encodes
RHD*01W.12 variant allele, however, the exonic change in this weak D
type 12 allele is the adjacent base c.830G>A (p.Gly277Glu). The RHD*01W.12
allele has been associated with extremely low antigen density (Wagner
et al., 2000), which might explain the RhD negative phenotype in these
5 samples. In both exonic changes (c.829G>A and c.830G>A) a non-polar
amino acid (Glycine) is changed to, a negatively charged amino acid (Argi-
nine), for c.829G>A or (Glutamic acid) for c.830G>A. Therefore, it is ex-
pected that the novel mutation, c.829G>A (p.Gly277Arg), would have a
similar effect on the RhD protein as the c.830G>A (p.Gly277Glu) change
in RHD*01W.12. RHD DEL phenotype could be confirmed by D anti-
gen quantifying tests. Figure 3.11 shows 3D modelling of the RhD pro-






Figure 3.11: 3D model of the RhD protein showing (a) Arginine and (b) Glutamic acid in position 277. Red indicates the
position 277 in the protein structure. Protein modelling was performed using the Phyre2 software (Kelley et al., 2015).
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Two SNPs were detected in exon 3 c.421delG and c.422T>A that predict
a frame shift and amino acid change p.Val141fs and p.Val141Glu which
were detected in 3 samples (004_133, 004_134, 004_135) (novel variant 9).
A mutation in exon 5 c.782C>T that predicts amino acid change p.Pro261Leu
was detected in 2 samples (004_132, 004_141) (novel variant 8). Two mis-
sense mutations were detected in sample (004_144). The missense mu-
tation c.1154G>C was detected in exon 9. This mutation predicts amino
acid change p.Gly385Ala which encodes the RHD*01W.02 allele. However,
an additional missense mutation c.1163T>G causing amino acid change
p.Leu388Arg was detected in exon 9, for which it is considered a novel
RHD*01W.02 sub-allele (novel variant 4). Mutations c.8C>G and c.49delG
in exon 1 which predict amino acid change p.Ser3Cys and a frame shift
p.Ala17fs were found in sample (004_119) (novel variant 3). Another frame
shift SNP c.784delC in exon 5 predicts p.Gln262fs and was detected in sam-
ple (004_131) (novel variant 5), and c.519C>G in exon 4 predicts a stop
codon p.Tyr173* and was detected in sample (004_145) (novel variant 6).
A mutation in exon 7 c.1016G>C was detected in sample (004_147) and
predicts amino acid change p.Gly339Ala (novel variant 7).
Three samples (004_137, 004_138, 004_150) failed to amplify one or more
of the RHD amplicons which could be due to variations, a hybrid gene or
a deletion, in the RHD gene that compromised some of the RHD-specific
LR-PCR primers binding regions.
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Samples (004_137 and 004_138) failed to amplify RHD amplicon 6, which
includes the area between part of intron 8 to exon 10 of the RHD gene.
The Finnish research group have reported that sample 004_138 tested neg-
ative for RHD exon 10 in the SSP-PCR test, which indicates a deletion or a
hybrid sequence in that region of the RHD gene. In sample (004_137), all
exons were detected in SSP-PCR as reported by the Finnish research group
(Tammi, 2019). For both samples, the RHD gene was sequenced from the
remaining 5 amplicons but no variations that could affect RhD expression
were detected and therefore the RHD gene was considered undetermined
due to the lack of the full gene sequence.
In sample (004_150), the LR-PCR reactions of RHD amplicons 1, 2 and 3
failed, which cover the region between RHD exons 1 and 5. The LR-PCR
was repeated using primers adapted from Hyland et al. (2017) to amplify
the RHD region from exon 2 to exon 7. The results showed a complete
deletion of exon 3 (336-486del) with a partial deletion of intron 2, which
appeared as break of coverage in that region (Figure 3.12), in addition to
mutations detected in exons 4, 5, and 6 c.602C>G, c.667T>G, and c.819G>A
that predict amino acid changes p.Thr201Arg, p.Phe223Val, and a silent
mutation, respectively.
In sample (004_125) that showed two copies of the RHD gene according to
the ddPCR results (homozygous), 4 exonic mutations c.48G>C, c.602C>G,
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c.667T>G, and 819G>A were detected in exons 1, 4, 5, and 6, respectively.
These mutations predict the amino acid changes p.Trp16Cys, p.Thr201Arg,
p.Phe223Val, and a silent mutation, respectively. In the NGS data, the
frequency of the reads containing each mutation were approximately 0.5,
which indicates that the mutations are present only in one copy i.e. het-
erozygous SNPs. Probable alleles encoded by these exonic changes are ei-
ther RHD*09.03 and RHD*01.01 or RHD*09.04 and RHD*01. The latter are
the most probable alleles as it matches results acquired through SSP-PCR
as reported by the Finnish research group (Tammi, 2019).
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Table 3.6: Molecular basis of novel RHD variant alleles detected by NGS.
no. of samples Nucleotide Exon Type Amino acid Consequence Genbank accession
1 399delG 3 Del Val134fs Frame shift MN624143
1 329T>C 2 SNV Leu110Pro Missense
505A>C 4 SNV Met169Leu Missense
509T>G 4 SNV Met170Arg Missense
514A>T 4 SNV Ile172Phe Missense
544T>A 4 SNV Ser182Thr Missense
577G>A 4 SNV Glu193Lys Missense
594A>T 4 SNV Lys198Asn Missense
602C>G 4 SNV Thr201Arg Missense
1 8C>G 1 SNV Ser3Cys Missense MN366001
49delG 1 Del Ala17fs Frame shift
1 1154G>C 9 SNV Gly385Ala Missense MN365998
1163T>G 9 SNV Leu388Arg Missense
1 784delC 5 Del Gln262fs Frame shift MN365997
1 519C>G 4 SNV Tyr173* Nonsense MN365999
1 1016G>C 7 SNV Gly339Ala Missense MN366002
2 782C>T 5 SNV Pro261Leu Missense MN366000
3 421delG 3 Del Val141fs Frame shift MN365995
422T>A 3 SNV Val141Glu Missense





Figure 3.12: Complete deletion of intron 2 and exon 3 in sample 004_150 shown by the lack of coverage in that region. Sample
was amplified using Hyland et al. (2017) primers to amplify the RHD gene from exon 2 to exon 7. NGS reads aligned against




Due to RHD*DAU0 (RHD*10.00) being the reference sequence hg38, 21 ho-
mozygous SNPs were detected in all samples sequenced, (Table 3.7) which
are specific to the reference allele, i.e. RHD*DAU0 (RHD*10.00). Multiple
intronic SNPs are suspected to be haplotype specific, for example 23 SNPs,
(Table 3.8) were homozygous SNPs in all samples with the R2 haplotype.
They were detected in R2R2, R2r, and in 3 of the 6 R1R2 samples (004_35,
004_36, 004_37) which were determined by ddPCR to be hemizygous for
the RHD gene. These SNPs were also present in 6 R1R2 samples (D ho-
mozygous) (004_29, 004_30, 004_31, 004_32, 004_33, 004_34), and in the
R2Rz sample (004_74) as heterozygous SNPs.
Fifteen SNPs, (Table 3.9) were detected as homozygous in all R1R1, R1r
and in 3 out of 6 R1R2 samples (004_38, 004_39, 004_40) which were shown
by ddPCR to be hemizygous for the RHD gene. They were also detected in
all 6 R0r samples (004_63, 004_64, 004_65, 004_66, 004_67, 004_68). These
SNPs were also found as heterozygous SNPs in 6 R1R2 samples (D ho-
mozygous) (004_29, 004_30, 004_31, 004_32, 004_33, 004_34), and in the
R2Rz sample (004_74).
Table 3.10 shows the different intronic SNPs detected and their correspon-
dence in R2 and R1, R0, Rz RHD alleles in comparison to the reference se-
quence. From the 519 intronic SNPs detected most were not conserved
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across each haplotype (data not shown). Most of the SNPs in Table 3.10
have been reported and show corresponding reference numbers in the
database of SNPs (Sherry et al., 2001). All Rh haplotype specific intronic
SNPs were mapped to the RHD gene (Figure 3.13).
Intronic SNPs were assessed for the RHD variant alleles for the ISBT sam-
ples (n=23). Samples genotyped as RHD*01W.01 (004_94 , 004_95), RHD*04.04
(004_99 and 004_100), RHD*01W.03 (004_107), RHD*07.01 (004_108, 004_109,
004_110), and RHD*17.01 (004_111) showed R1, R0, Rz specific SNPs. The
sample genotyped as partial D RHD*25 (004_98) showed R2 specific SNPs.
Intronic SNPs pattern for 6 ISBT samples (004_101-004_106), where a hy-
brid RHD allele is expected, and 2 samples genotyped as RHD*03.01 (004_96,
004_97) was challenging to determine. The RHD*06.01 and RHD*03.01 al-
leles showed some of the R1, R0, Rz SNPs and some of the R2 SNPs. In the
6 ISBT samples, showed exonic SNPs associated with RHCE4-5 insertion
in the RHD gene, intronic SNPs located between intron 3 and 6 were not
consistent. This variation in intronic SNP patterns is due to RHCE inser-
tion in the RHD gene. Intronic SNPs located in other introns were con-
sistent and matched with patterns observed previously. Although some
ISBT samples were lacking Rh phenotyping results, we attempted to pre-
dict the probable correct Rh haplotype using the RHD zygosity results,




Intronic changes were also studied for the Finnish samples (n=35) to de-
termine intronic SNP patterns, and whether R1, R0, Rz SNPs or R2 SNPs
were present. We found that samples showed a clear cut pattern for in-
tronic SNPs, including novel variant alleles. Samples that were found to be
hemizygous for the RHD gene using ddPCR and were phenotyped as r’r,
r’r’, rr showed homozygous R1, R0, Rz intronic SNPs. Sample (004_125)
phenotyped as r’r and showed hemizygous RHD gene on ddPCR also pre-
sented homozygous R1, R0, Rz intronic SNPs. Other hemizygous samples
phenotyped as r’r” and r”r showed homozygous R2 SNPs.
In 3 samples (004_69, 004_97, 004_148) genotyped as RHD*09.03.01 (DAR3.1),
33 intronic SNPs were detected as homozygous SNPs, (Table 3.11), which
could be specific to this allele. Eleven intronic SNPs were detected as ho-
mozygous SNPs (Table 3.12) in the 3 samples genotyped as RHD*09.03.01
(DAR3.1), 1 sample genotyped as RHD*09.01.02 (004_70), and in 1 sample
genotyped as RHD*03.01 (004_96), and as heterozygous SNPs in sample
(004_125) that predicted to have two variant RHD genes in which one is
expected to be RHD*09.04.
In Table 3.13 the most probable Rh haplotype was assigned for samples
that were incorrectly assigned Rh haplotype or phenotyped as D negative
and tested as RHD positive using ddPCR. For these samples, intronic SNP
pattern, Rh serology results, RHD allele as identified by NGS, and linked
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Table 3.7: Position of intronic variations and their reference SNP number detected in all
samples sequenced. As the reference sequence is RHD*DAU0 (RHD*10.00), these nu-
cleotide changes are predicted to be RHD*DAU0 (RHD*10.00) specific.
Position hg38 All samples Intron rs no. α
25,277,761 A G 1 rs28661958
25,286,520 T C 2 rs183024534
25,286,601 T A 2 -
25,286,605 A T 2 -
25,286,674 C T 2 -
25,286,732 A G 2 -
25,290,908 T C 3 rs28521909
25,290,915 G A 3 rs28562109
25,295,850 A G 3 rs28451966
25,297,140 G A 3 rs28786680
25,305,164 G T 6 rs28703207
25,308,306 T C 7 rs28374144
25,308,317 T C 7 rs28719684
25,308,325 G A 7 rs71493569
25,308,326 C T 7 rs71493569
25,308,403 C T 7 rs1801096
25,316,058 A G 7 rs28453868
25,319,292 T C 8 rs28397158
25,322,588 A G 9 rs28435180
25,327,036 G A 9 rs61777612
25,329,789 A G 10 rs28654325
αFrom the database of SNPs (Sherry et al., 2001).
(-) Not found in the database of SNPs.
Grey indicates SNPs that were not detected by MinION™ sequencing.
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Table 3.8: Intronic SNPs present in all
samples with R2 haplotype.
Position SNP Intron rs no. α
25,282,654 A>G 1 rs3866916
25,285,089* G>A 2 rs675072
25,287,909* C>G 2 rs28718098
25,295,072 G>A 3 rs372986392
25,295,354 C>T 3 rs2904840
25,295,489* C>T 3 rs190056379
25,295,708 G>A 3 rs182346769
25,295,731 A>G 3 rs201512625
25,295,739 G>A 3 rs200682399
25,295,753 A>G 3 rs143670081
25,298,980* T>C 3 rs2904843
25,300,575* C>G 3 rs2986167
25,305,898 A>G 6 rs12126031
25,307,714 G>A 7 rs2257611
25,308,845 G>C 7 rs2478025
25,311,722 T>A 7 rs796579065
25,316,269 A>G 7 rs2427767
25,320,442* T>G 8 rs3927482
25,321,858* T>C 8 rs28669938
25,323,393 C>T 9 rs77160738
25,323,618 G>C 9 rs201304363
25,323,713 G>C 9 rs202154122
25,327,668 A>G 9 -
αFrom the database of SNPs (Sherry et al., 2001).
(-) Not found in the database of SNPs.
* SNPs were investigated previously using Sanger
sequencing.
Intronic SNPs were homozygous in all R2r
samples, R2R2 samples and in 3 out of the 6 R1R2
samples that tested as hemizygous for the RHD
gene by ddPCR, and as heterozygous in R1R2
samples, and the R2Rz sample.
Table 3.9: Intronic SNPs present in all
samples with R1, R0, and RZ haplotypes.
Position SNP Intron rs no. α
25,284,544 G>C 1 rs2301153
25,292,953 G>A 3 rs28645510
25,295,317 G>A 3 rs2986157
25,295,797 T>A 3 rs2986163
25,295,800 G>A 3 rs2986164
25,296,764 A>C 3 rs599792
25,297,476 A>G 3 rs1830962
25,298,410 G>C 3 rs1293267
25,301,905 T>G 5 rs28510210
25,304,945 A>T 6 rs28685153
25,307,040 G>C 7 rs3118453
25,311,520 G>A 7 rs2478028
25,311,722 T>G 7 rs796579065
25,320,257 A>C 8 rs28628791
25,329,839 A>T 10 rs28668998
αFrom the database of SNPs (Sherry et al., 2001).
SNPs were present as homozygous in all R1R1
samples, R1r samples, and R0r samples, and in 3
out of the 6 R1R2 samples that tested as
hemizygous for the RHD gene by ddPCR. SNPs
were heterozygous in the 6 homozygous R1R2





Table 3.10: Position of intronic variations determined by NGS and their corresponding nucleotide in R2 and R1, R0, Rz RHD
alleles in comparison to the reference sequence (hg38).
Position rs no. α Intron hg38 R1,R0,Rz R2
25,277,761 rs28661958 1 A G G
25,282,654 rs3866916 1 A A G
25,284,544 rs2301153 1 G C G
25,285,089 rs675072 2 G G A
25,286,520 rs183024534 2 T C C
25,286,601 - 2 T A A
25,286,605 - 2 A T T
25,286,674 - 2 C T T
25,286,732 - 2 A G G
25,287,909 rs28718098 2 C C G
25,290,908 rs28521909 3 T C C
25,290,915 rs28562109 3 G A A
25,292,953 rs28645510 3 G A G
25,295,072 rs372986392 3 G G A
25,295,317 rs2986157 3 G A G
25,295,354 rs2904840 3 C C T
25,295,489 rs190056379 3 C C T
25,295,708 rs182346769 3 G G A
25,295,731 rs201512625 3 A A G
25,295,739 rs200682399 3 G G A
25,295,753 rs143670081 3 A A G
25,295,797 rs2986163 3 T A T
25,295,800 rs2986164 3 G A G
25,295,850 rs28451966 3 A G G
25,296,764 rs599792 3 A C A
25,297,140 rs28786680 3 G A A
25,297,476 rs1830962 3 A G A
25,298,410 rs1293267 3 G C G
25,298,980 rs2904843 3 T T C
Position rs no. α Intron hg38 R1,R0,Rz R2
25,300,575 rs2986167 3 C C G
25,301,905 rs28510210 *5 T G T
25,304,945 rs28685153 *6 A T A
25,305,164 rs28703207 *6 G T T
25,305,898 rs12126031 *6 A A G
25,307,040 rs3118453 7 G C G
25,307,714 rs2257611 7 G G A
25,308,306 rs28374144 7 T C C
25,308,317 rs28719684 7 T C C
25,308,325 rs71493569 7 G A A
25,308,326 rs71493569 7 C T T
25,308,403 rs1801096 7 C T T
25,308,845 rs2478025 7 G G C
25,311,520 rs2478028 7 G A G
25,311,722 x rs796579065 7 T G A
25,316,058 rs28453868 7 A G G
25,316,269 rs2427767 7 A A G
25,319,292 rs28397158 8 T C C
25,320,257 rs28628791 8 A C A
25,320,442 rs3927482 8 T T G
25,321,858 rs28669938 8 T T C
25,322,588 rs28435180 9 A G G
25,323,393 rs77160738 9 C C T
25,323,618 rs201304363 9 G G C
25,323,713 rs202154122 9 G G C
25,327,036 rs61777612 9 G A A
25,327,668 - 9 A A G
25,329,789 rs28654325 10 A G G
25,329,839 rs28668998 10 A T A
α From the database of SNPs (Sherry et al., 2001).
(-) Not found in the database of SNPs.
x SNP position shows three different nucleotides, T for reference (hg38), G for R1, R0, Rz haplotypes, and A for R2 haplotype.
*Slight variation was detected in introns 4, 5, and 6 which could be due to their small sizes (427bp, 1635bp, 3137bp), respectively.
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Table 3.11: Intronic SNPs and their ref-
erence SNP number present in 3 samples
genotyped as RHD*09.03.01 (DAR3.1).
Position SNP Intron rs no. α
25,294,998 T>C 3 rs565983375
25,295,395 A>G 3 rs113859891
25,295,403 G>A 3 rs112427260
25,302,318 G>del- 5 rs568375574
25,303,820 A>C 6 rs595776
25,306,247 A>G 6 rs148021941
25,307,491 A>G 7 rs149085087
25,308,882 G>C 7 rs369127976
25,308,889 T>C 7 rs2986170
25,308,929 A>T 7 rs377167394
25,308,964 C>T 7 rs374258180
25,309,005 C>A 7 rs182746791
25,309,011 A>G 7 rs371128974
25,309,052 C>T 7 rs368386643
25,309,064 A>G 7 rs375347442
25,309,178 T>C 7 rs150952004
25,309,201 A>G 7 rs1342381686
25,309,243 A>G 7 rs1443666726
25,309,268 C>T 7 rs1424093742
25,309,320 G>A 7 rs1317071825
25,309,349 C>G 7 rs537011312
25,309,511 T>A 7 rs1233220393
25,309,531 A>T 7 rs1282313512
25,309,592 T>G 7 rs1472960480
25,309,699 C>T 7 rs2986171
25,309,702 G>T 7 rs1375423938
25,309,706 A>G 7 rs592372
25,309,775 C>T 7 rs592784
25,309,828 C>G 7 rs116689941
25,309,830 C>T 7 rs750012340
25,317,824 A>T 8 rs528996192
25,318,601 A>-del 8 rs200414156
25,318,602 A>-del 8 rs200414156
25,326,666 A>C 9 -
αFrom the database of SNPs (Sherry et al., 2001)
(-) Not found in the database of SNPs.
Table 3.12: Intronic SNPs and their
reference SNP number present in
samples genotyped as RHD*09.03.01,
RHD*09.01.02, RHD*03.01, and
RHD*09.03.
Position SNP Intron rs no. α
25,297,129 A>G 3 rs565454189
25,297,131 C>T 3 rs192974801
25,298,827 G>A 3 rs111968158
25,302,081 G>A 5 rs145236797
25,304,459 A>G 6 rs28534644
25,308,085 T>C 7 rs376112497
25,310,078 C>T 7 rs187468762
25,313,241 A>T 7 rs111844516
25,316,554 G>A 7 rs536830264
25,320,143 C>A 8 rs151132067
25,320,272 A>G 8 rs115135456
αFrom the database of SNPs (Sherry et al., 2001).
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Table 3.13: Rh haplotype corrected for samples where serologically predicted genotypes do not agree with NGS RHD geno-
typing results.
Lab no. Rh serologyγ RhCcEe phenotypeγ RHD zygosity RHD allele Linked haplotype ∇ Intronic SNPs pattern Most probable haplotype †
004_07 R1R1 Ce Discrepancy RHD*01W.01 R1 (DCe) R1, R0, Rz R1R1 (DCe/DCe)
004_14 R1r Ce Homozygous RHD*01 NA R1, R0, Rz R1R1 (DCe/DCe)
004_35 R1R2 CcEe Hemizygous RHD*01W.02 R2 (DcE) R2 R2r′ (DcE/dCe)
004_36 R1R2 CcEe Hemizygous RHD*01 NA R2 R2r′ (DcE/dCe)
004_37 R1R2 CcEe Hemizygous RHD*01 NA R2 R2r′ (DcE/dCe)
004_38 R1R2 CcEe Hemizygous RHD*01 NA R1, R0, Rz R1r′′ (DCe/dcE)
004_39 R1R2 CcEe Hemizygous RHD*01 NA R1, R0, Rz R1r′′ (DCe/dcE)
004_40 R1R2 CcEe Hemizygous RHD*01 NA R1, R0, Rz R1r′′ (DCe/dcE)
004_42 R2R2 cE Hemizygous RHD*01W.02 R2 (DcE) R2 R2r′′ (DcE/dcE)
004_88 r”r cEe Hemizygous Novel variant 1 NA R2 R2r (DcE/dce)
004_94 No data No data Hemizygous RHD*01W.01 R1 (DCe) R1, R0, Rz R1 (DCe/-)
004_95 No data No data Hemizygous RHD*01W.01 R1 (DCe) R1, R0, Rz R1 (DCe/-)
004_96 R1r Cce Hemizygous RHD*03.01 R0 (Dce) R1, R0, Rz R1r (DCe/dce) double check
004_97 No data No data Hemizygous RHD*09.03.01 R0 (Dce) R1, R0, Rz R0 (Dce/-)
004_98 No data No data Hemizygous RHD*25 R1 (DCe) R1, R0, Rz R1 (DCe/-)
004_99 No data No data Hemizygous RHD*04.04 R1 (DCe) R1, R0, Rz R1 (DCe/-)
004_100 No data No data Hemizygous RHD*04.04 R1 (DCe) R1, R0, Rz R1 (DCe/-)
004_101 R1r Cce Hemizygous RHD*06.01 R2 (DcE) R1 R1r (DCe/dce)
004_102 R1r Cce Hemizygous Undetermined NA R1, R0, Rz R1r (DCe/dce)
004_103 R1r Cce Hemizygous Undetermined NA R1, R0, Rz R2 (DcE/dce)
004_104 R2r cEe Hemizygous Undetermined NA R2 R2 (DcE/dce)
004_105 R2r cEe Hemizygous Undetermined NA R2 R2r (DcE/dce)
004_106 No data No data Hemizygous Undetermined NA R2 R2 (DcE/-)
004_107 No data No data Hemizygous RHD*01W.03 R1 (DCe) R1, R0, Rz R1 (DCe/-)
004_108 R1r Cce Hemizygous RHD*07.01 R1 (DCe) R1, R0, Rz R1r (DCe/dce)
004_109 R1r Cce Hemizygous RHD*07.01 R1 (DCe) R1, R0, Rz R1r (DCe/dce)
004_110 R1r Cce Hemizygous RHD*07.01 R1 (DCe) R1, R0, Rz R1r (DCe/dce)
004_111 R1r Cce Hemizygous RHD*17.01 multiple R1, R0, Rz R1r
004_112 No data No data Hemizygous Novel variant 2 NA R1, R0, Rz -
004_113 No data No data Hemizygous RHD*01 Not reported R1, R0, Rz -
004_114 No data No data Homozygous RHD*01 Not reported R1, R0, Rz -
continued . . .
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004_115 No data No data Hemizygous RHD*01 Not reported R1, R0, Rz -
004_116 No data No data Homozygous RHD*01 Not reported R1, R0, Rz -
004_117 D- Cce Hemizygous RHD*01EL.01 R1 (DCe) R1, R0, Rz R1r (DCe/dce)
004_118 D- Cce Hemizygous RHD*01EL.01 R1 (DCe) R1, R0, Rz R1r (DCe/dce)
004_119 D- Cce Hemizygous Novel variant 3 NA R1, R0, Rz R1r (DCe/dce)
004_120 D- Cce Hemizygous RHD*01N.61 R1 (DCe) R1, R0, Rz R1r (DCe/dce)
004_121 D- Cce Hemizygous RHD*01N.33 R1 (DCe) R1, R0, Rz R1r (DCe/dce)
004_122 D- Cce Hemizygous RHD*11 R0 (Dce) R1, R0, Rz R0r′ (Dce/dCe)
004_123 D- Cce Hemizygous RHD*15 R2 (DcE) R1, R0, Rz R1r (DCe/dce)
004_124 Weak D+ Cce Hemizygous RHD*01W.72 Not reported R1, R0, Rz R1r (DCe/dce)
004_125 Weak D+ Cce Homozygous Undetermined NA R1, R0, Rz R1R0 (DCe/Dce)
004_126 D- Cce Hemizygous RHD*01EL.04 R1 (DCe) R1, R0, Rz R1r (DCe/dce)
004_127 D- Cce Hemizygous Novel variant 10 NA R1, R0, Rz R1r (DCe/dce)
004_128 D- Cce Hemizygous Novel variant 10 NA R1, R0, Rz R1r (DCe/dce)
004_129 D- Cce Hemizygous Novel variant 10 NA R1, R0, Rz R1r (DCe/dce)
004_130 D- Cce Hemizygous Novel variant 10 NA R1, R0, Rz R1r (DCe/dce)
004_131 D- Cce Hemizygous Novel variant 5 NA R1, R0, Rz R1r (DCe/dce)
004_132 Weak D+ Cce Hemizygous Novel variant 8 NA R1, R0, Rz R1r (DCe/dce)
004_133 D- Cce Hemizygous Novel variant 9 NA R1, R0, Rz R1r (DCe/dce)
004_134 D- Cce Hemizygous Novel variant 9 NA R1, R0, Rz R1r (DCe/dce)
004_135 D- Cce Hemizygous Novel variant 9 NA R1, R0, Rz R1r (DCe/dce)
004_136 D- Cce Hemizygous RHD*01EL.08 R1 (DCe) R1, R0, Rz R1r (DCe/dce)
004_137 D- Cce Hemizygous Undetermined NA R1, R0, Rz R1r (DCe/dce)
004_138 D- Cce Hemizygous Undetermined NA R1, R0, Rz R1r (DCe/dce)
004_139 D- Ce Hemizygous Novel variant 10 NA R1, R0, Rz R1r (DCe/dCe)
004_140 Weak D+ Ce Hemizygous RHD*01W.03 Not reported R1, R0, Rz R1r′ (DCe/dCe)
004_141 Weak D+ Ce Hemizygous Novel variant 8 NA R1, R0, Rz R1r′ (DCe/dCe)
004_142 D- CcEe Hemizygous RHD*01W.02 R2 (DcE) R2 R2r′ (DcE/dCe)
004_143 D- CcEe Hemizygous RHD*01W.02 R2 (DcE) R2 R2r′ (DcE/dCe)
004_144 D- cEe Hemizygous Novel variant 4 NA R2 R2r (DcE/dce)
004_145 D- cEe Hemizygous Novel variant 6 NA R2 R2r (DcE/dce)
004_146 D- cEe Hemizygous RHD*15 R2 (DcE) R2 R2r′ (DcE/dCe)
004_147 Weak D+ cEe Hemizygous Novel variant 7 NA R2 R2r (DcE/dce)
004_148 D+ ce Hemizygous RHD*09.03.01 R0 (Dce) R1, R0, Rz R0r (Dce/dce)
continued . . .
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004_149 D- ce Hemizygous RHD*01N.35 Not reported R1, R0, Rz R0r (Dce/dce)
004_150 D- ce Hemizygous Undetermined NA R1, R0, Rz R0r (Dce/dce)
004_151 D- ce Hemizygous No designation assigned* Not reported R1, R0, Rz R0r (Dce/dce)
Blue indicates samples were serologically phenotyped as RhD negative.
NA= Not applicable.
γ As supplied by the NHSBT, Bristol, United Kingdom, and the Finnish Red Cross Blood Service, Helsinki, Finland.
- Rh probable haplotype was not determined due to the lack of Rh serological results.
∇ Rh haplotypes linked to the variant RHD allele (Wagner and Flegel, 2014).
† Probable Rh haplotypes are predicted by the results of Rh serology phenotype, RHD zygosity by ddPCR, RHD intronic SNPs pattern, and linked
haplotype to the variant allele in literature if applicable.
*As found on RhesusBase (Wagner and Flegel, 2014).
**Allele linked to DcE but sample phenotyped as Cce and present intronic R1, R0, Rz SNPs pattern, therefore most probable haplotypes are DCe or Dce.
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The RHAG gene was sequenced for two samples (004_14 and 004_74),
that were serologically phenotyped as weak D but no RHD mutations
were detected by NGS that would explain the weak D reactivity. In sam-
ple (004_14), two heterozygous exon 6 mutations were detected includ-
ing c.808G>A (p.Val270Ile) which encodes for the RHAG*04 allele (Fig-
ure 3.14), and c.861G>A (silent). Sample (004_74) showed a wild type
RHAG*01 allele predicting no amino acid changes.
Figure 3.14: RhAG intracellular domains with amino acids illustrated in circles. Amino
acid change Val270Ile indicated with an arrow was detected in one R1r sample, serolog-
ically typed as weak D, with no amino acid changes predicted from the RHD NGS data.
Image courtesy of Conroy et al. (2005).
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3.3.7 RHD Sequencing Using MinION™
3.3.7.1 MinION™ Sequence Quality
Thirteen samples were genotyped for the RHD gene using MinION™,
utilising the same LR-PCR amplicons used in the Ion PGM™ sequencing.
Sequencing library was prepared and data was analysed as described in
sections 2.12 and 2.14.2, respectively. Fast5 files generated from the raw
files were subjected to sequence quality analysis using EPI2ME software
(Oxford Nanopore Technologies, United Kingdom). Figure 3.15 shows an
average quality PHRED-score of 11, and reads length mode of 10,450 bp.




Figure 3.15: Sequence quality analysis performed on MinION™ data using EPI2ME soft-
ware. A. Quality score (x axis) and number of reads detected at that quality (y axis). Av-
erage PHRED score of about 11 was observed. B. Distribution of reads sequence lengths
in bp (x axis) and number of reads of a specific length (y axis).
3.3.7.2 RHD Genotyping Using MinION™
gDNA samples (n=13) (Table 3.14) in which 12 samples (004_122, 004_123,
004_125, 004_130, 004_131, 004_133, 004_134, 004_143, 004_144, 004_145,
004_146, 004_147) were either serologically phenotyped as RhD negative
or weak D (Finnish samples), and 1 R2Rz sample (004_74) (blood donor
sample) phenotyped by serology as weak D. Samples were sequenced us-
ing the MinION™ for the RHD gene. Data was analysed as described in
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section 2.14.2, and mapped to the RHD hg38 reference sequence. Mapped
data to the hg38 reference sequence were visualised using IGV software,
(Figure 3.16). As noted previously, the RHD human reference sequence in
the hg38 encodes a variant RHD allele RHD*DAU0 encoded by c.1136C>T
(p.Thr379Met) in exon 9. Therefore, all 13 samples showed a homozygous
SNP in exon 9 c.1136T>C (Met379Thr), (Figure 3.9).
Variants calling was performed on the 13 samples sequenced and a vari-
ant track was generated for each sample, which was then compared to
the variant track generated from the Ion PGM™ sequencing data for the
same samples. Figure 3.17 shows mapped reads from Ion PGM™ and
MinION™ aligned against each other. All exonic SNPs detected in the 13
samples agreed with the ones detected from data generated by Ion PGM™
which are listed in Table 3.14. Intronic changes detected were also com-
pared and agreed to the SNPs detected by Ion PGM™ and all Rh haplo-
type specific SNPs listed in Tables 3.7, 3.8, 3.9 except for 6 SNPs. These 6
intronic SNPs were expected to be specific to the RHD reference sequence





Figure 3.16: MinION™ reads, from a single representative sample, mapped to the hg38 reference sequence visualised using





Figure 3.17: Ion PGM™ reads compared to the MinION™ reads using CLC Workbench 10. Ion PGM™ reads (A) and Min-
ION™ reads (B) of the same sample (004_144) mapped to the hg38 reference sequence in an alignment. Two exonic changes




Table 3.14: Samples sequenced using MinION™
Lab no. RhD phenotype RHD zygosity Exonic SNPs* RHD allele
004_74 weak D+ Homozygous - RHD*01
004_122 Negative Hemizygous 885G>T RHD*11
004_123 Negative Hemizygous 845G>A RHD*15
004_125 weak D+ Homozygous 48G>C, 602C>G, 667T>G Undetermined
004_130 Negative Hemizygous 829G>A Novel variant 10
004_131 Negative Hemizygous 784delC Novel variant 5
004_133 Negative Hemizygous 421delG, 422T>A Novel variant 9
004_134 Negative Hemizygous 421delG, 422T>A Novel variant 9
004_143 Negative Hemizygous 1154G>C RHD*01W.02
004_144 Negative Hemizygous 1154G>C, 1163T>G Novel variant 4
004_145 Negative Hemizygous 519C>G Novel variant 6
004_146 Negative Hemizygous 845G>A RHD*15
004_147 weak D+ Hemizygous 1016G>C Novel variant 7




3.4.1 ddPCR Discrepant Results Characterised by RHD NGS
ddPCR was used to test for two targets in the RHD gene against the ref-
erence gene AGO1 on chromosome 1. ddPCR has demonstrated high sen-
sitivity when used as a detection method for RHD genotyping (Sillence
et al., 2015, 2017). All samples included in the sequencing run demon-
strated compatible zygosity results with serologically predicted genotype
except for samples listed in Table 3.2. Eight samples showed incompatible
results with predicted genotype by serological testing which include: one
R1r sample (004_14) which showed the presence of a homozygous RHD
gene, six R1R2 samples (004_35, 004_36, 004_37, 004_38, 004_39, 004_40)
which showed the presence of a hemizygous RHD gene, and one R2R2
sample (004_42) showed as hemizygous for the RHD gene.
One R1R1 sample (004_07) showed discrepancy between the RHD5/AGO1
ratio (0.57) and RHD7/AGO1 ratio (1.0). This discrepancy between hem-
izygous RHD5 and homozygous RHD7 indicating that one of the RHD
alleles has a deletion in exon 5. This gene deletion could not be detected
through NGS due to the presence of a wild type copy of the other RHD
allele.
The six R1R2 (DCe/DcE) samples which showed only one copy of the
RHD gene (hemizygous), implied that the samples had incorrect serolog-
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ically predicted genotypes by serology findings based on the probability
of the gene in the population, in these cases the genotypes are in fact less
frequent or occurring with a lower probability.





(DcE/dCe), or R0ry (Dce/dCE) based on their RHD zygosity results.
All these Rh genotypes could be inappropriately assigned by serology as
R1R2 (DCe/DcE) due to gene frequencies in the population. Three of the
R1R2 (004_35, 004_36, 004_37) samples have the intronic SNPs suspected
to be linked to the R2 haplotype and are missing all the other intronic SNPs
that are linked to the R1, R0, Rz haplotypes. Sample 004_35 was geno-
typed as weak D type 2, and due to the link between the R2 haplotype and
weak D type 2, this sample could only be R2r
′
(DcE/dCe). The other two
samples could also be genotyped as R2r
′
(DcE/dCe) as inferred by their
intronic SNPs pattern. The correct genotype of the other three hemizy-
gous R1R2 samples (004_38, 004_39, 004_40) missing the R2 specific SNPs
could be either R1r
′ ′
(DCe/dcE), Rzr (DCE/dce), or R0ry (Dce/dCE). Con-
sidering the frequency of these alleles (Daniels, 2013c) in the population,
in which R1r
′ ′
is 1%, Rzr is 0.19%, and R0ry is less than 0.01%, it is very
likely for these samples to be R1r
′ ′
(DCe/dcE). Based on our zygosity re-
sults, the frequency of R1r
′ ′
seems to be higher than anticipated (Daniels,
2013c) in the population. Definitive genotypes for these samples could be
confirmed by sequencing the RHCE gene, Chapter 4.
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The R1r (004_14) sample that was homozygous RHD by ddPCR showed
R1/R0/Rz related SNPs and was missing all R2 related SNPs which sug-
gests that correct genotype could be R1R0 (DCe/Dce). The hemizygous
R2R2 sample (004_42) was genotyped as weak D type 2 and showed R2
specific SNPs, therefore, its correct genotype could only be R2r
′′
(DcE/dcE).
Samples genotyped as weak D type 2 (004_142 and 004_143) showed in-
tronic SNPs specific to R2 haplotype and were originally assigned their
haplotype by serology as r”r. Weak D type 2 is linked to R2 (DcE) (Wagner
et al., 1999) which means the only correct haplotype for these two sam-
ples is R2r′. Sample (004_124) genotyped as RHD*01W.72 was originally
assigned by serology Rh haplotype as r’r. This sample showed intronic
SNPs specific for R1, R0, Rz haplotypes which suggest its correct haplo-
type to be either R1r or R0r′. Sample (004_140) genotyped as RHD*01W.03
was serologically assigned Rh haplotype as r’r’. The RHD*01W.03 allele
is linked to the R1 (DCe) haplotype (Wagner et al., 1999) which indicates
that the only probable correct haplotype for this sample is R1r′. Corrected
Rh haplotype for all discrepant samples are listed in Table 3.13.
3.4.2 RHD Reference Sequences
We have established a methodology to fully sequence the RHD gene in-
cluding introns and all exons which can be used to study the different
RHD alleles in the population to establish reference RHD allele sequences
176
DISCUSSION
and identify novel variants. We sequenced the RHD gene in samples that
were confirmed to be hemizygous (one copy) RHD samples by ddPCR,
and compared those sequences with homozygous (two copy) RHD genes
in samples confirmed to be as such by ddPCR.
Through analysing intronic SNPs, two different haplotype specific pat-
terns were identified in which one is specific for R1, R0, Rz haplotypes and
the other is R2 haplotype specific. Based on that, two reference sequences
were established and submitted to Genbank and registered with accession
numbers MG944308 and MG944309 for the R1, R0, Rz haplotypes and the
R2 haplotype, respectively.
3.4.3 RHD Genotyping
Data analysis of the (n= 133) samples showed that 48 samples carried the
RHD wild type allele RHD*01. Other samples (n= 85) showed RHD vari-
ant alleles, in which 59 samples linked to known RHD variant alleles, and
17 samples showed novel RHD variant alleles. In 9 samples the RHD geno-
typing results were inconclusive.
3.4.3.1 RHD Known Variants
Known variants found in 59 samples included weak, partial, DEL and null
RHD alleles. Four different weak D alleles were detected in 24 samples
in which: 16 samples were genotyped as RHD*01W.01, 14 samples were
genotyped as RHD*01W.02, 3 samples were genotyped as RHD*01W.03,
and 1 sample genotyped as RHD*01W.72. These results agree with the
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common weak D alleles in Caucasian (weak D types 1 and 2) (Daniels,
2013b) that are associated with the most common Rh haplotypes R1 (DCe)
and R2 (DcE) respectively (Wagner et al., 1999; Flegel, 2007a).
Eleven partial weak D alleles were found in 17 samples in which 1 sam-
ple was genotyped as RHD*06.01 (DVI). DVI is the most common partial
D phenotype which results from a hybrid RHD-RHCE-RHD gene leading
to the loss of multiple D antigen epitopes including epD 1-4, 7-22, 26-29
on the 30-epitope model (Avent et al., 1997). The hybrid allele has origi-
nated from a conversion event where RHD exons 4 and 5 are replaced by
RHCE exons 4 and 5. Individuals with a DVI allele could be phenotyped
by serology (using polyclonal antisera) as RhD positive which places them
at risk of developing RhD antibodies to missing D epitopes when exposed
to normal RhD antigen. Pregnant females phenotyped as DVI, with an
RhD positive fetus, need to receive prophylactic anti-D to prevent the de-
velopment of Rh antibodies which are clinically significant and can lead
to HTRs and HDFN (Avent et al., 1997), discussed in sections 1.8.1 and
1.8.2. Three samples were genotyped as RHD*07.01 encoded by c.329C>T
in exon 2 predicting amino acid Proline substituting Leucine at position
110 which results in the loss of RhD antigen epitope epD8 (Rouillac et al.,
1995).
In three samples, the RHD allele was identified as weak partial RHD allele
in which sample was genotyped as RHD*11 and two samples were geno-
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typed as RHD*15. Two samples genotyped as weak D type 15 (RHD*15)
express a very weak level of antigen D with qualitative changes to its epi-
topes which mostly fails to react with RhD antisera which explains the D
negative serology results (Körmöczi et al., 2005). Partial weak D could be
mis-phenotyped by serology as RhD negative due to the fact that some
of the RhD epitopes are either altered or completely absent which might
affect antigen-antibody binding sites leading to false negative phenotyp-
ing results. Incorrectly phenotyped RhD negative donors impose a seri-
ous risk of immunisation on RhD negative patients (Avent et al., 1997).
Cases of RhD alloantibodies in individuals with weak D type 15 pheno-
type have been reported (Wagner et al., 2000). Therefore, patients geno-
typed as RHD*15 should be transfused with RhD negative blood to pre-
vent possible sensitisation.
One sample was genotyped as partial RHD*25 allele (DNB) which is the
most common partial D allele in whites in Central Europe (Wagner et al.,
2002). The DNB allele present a normal positive D in serological pheno-
typing, however, cases of immunisation (allo-anti-D) in DNB individuals
have been reported after immunisation events. DNB is the underlying al-
lele in which the majority of partial D immunisation occur in whites (Wag-
ner et al., 2002).
Two samples were genotyped as RHD*04.04 (DIV.4) which results from a
gene conversion event where part of the RHD exon 7 is substituted by the
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equivalent region from the RHCE gene (Körmöczi et al., 2005; von Zabern
et al., 2013). One sample was genotyped as RHD*17.01 (DFR-1), and one
as RHD*17.02 (DFR-2), which both results from a hybrid RHD-RHCE-RHD
gene in exon 4 (Rouillac et al., 1995; von Zabern and Flegel, 2007). Substi-
tution in the RHD gene results in the loss of some the RhD epitopes leading
to partial expression of the D antigen.
Three DEL alleles were detected in 4 samples in which 2 samples were
genotyped as RHD*01EL.01, 1 sample was genotyped as RHD*01EL.04,
and 1 sample was genotyped as RHD*01EL.08, identified firstly in German
blood donors (Wagner et al., 2001). DEL phenotype expresses very weak D
antigen that could only be detected by adsorption, elution techniques, and
molecular genotyping (Kwon et al., 2017), hence, samples are phenotyped
by serology as Rh D-negative. Flegel et al. (2009) recommends that blood
units genotyped as DEL should be stored with RhD positive blood units
and only transfused to RhD positive patients.
It was believed that very weak expression of antigen D most likely will
not elicit an immune response, but cases of antigen D allo-sensitisation
caused by DEL RBCs transfusion to Rh D-negative patients have been re-
ported (Wagner et al., 2005; Yasuda et al., 2005; Shao et al., 2012; Yang et al.,
2015). Shao et al. (2012) recommended that Rh D-negative patients should
be transfused with only Rh D-negative RBCs and emphasises the impor-
tance of correctly genotyping apparently Rh D-negative donors to prevent
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anti-D development in Rh D-negative patients.
Three negative RHD alleles were detected in 3 samples, in which 1 sample
was genotyped as RHD*01N.35, 1 sample was genotyped as RHD*01N.61,
and 1 sample was genotyped as RHD*01N.33. The RHD*01N.35 was first
described by Maréchal et al. (2007) in the French population. The other
two null alleles RHD*01N.35 and RHD*01N.61 were first identified in Ger-
mans (Flegel et al., 2009), in which mutations in these alleles lead to pre-
mature stop codon with truncated non-functional protein. Individuals car-
rying null alleles should be considered RhD negative and only transfused
with RhD negative blood to prevent immunisation (Maréchal et al., 2007).
In sample (004_41), mutation c.1154G>C in exon 9 was detected which
encodes RHD*01W.02 that predicts amino acid change p.Gly385Ala. The
frequency of the reads containing each mutation were approximately 0.5
(i.e. heterozygous SNP), which indicates that one allele is a variant allele
RHD*01W.02 and the other is a wild type RHD allele. Wild type RHD al-
lele produce a complete RhD protein that will mask the presence of a weak
RHD allele, which makes it impossible to detect the weak D in this sample
by serology as it would be masked by the normal RhD protein.
In samples genotyped as weak D, four samples were serologically phe-
notyped as either D negative or very weak D. These samples included:
sample (004_124) genotyped as RHD*01W.72, sample (004_140) genotyped
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as RHD*01W.03, and two samples (004_142 and 004_143) genotyped as
RHD*01W.02. Weak D phenotype should express D antigen at a detectable
level by serology (Sandler et al., 2017). It has been reported that the pres-
ence of the RHCE*C expression has a suppressive effect on the RhD anti-
gen (Szymanski, 1987; Araszkiewicz and Szymanski, 1989; Daniels, 2013c).
All four samples were phenotyped by serology as Rh C-positive. In these
samples, the D antigen expression was weakened by the exonic SNPs in
the RHD gene and the RhC suppressive effect on the D antigen. The C
suppressive effect on antigen D can cause reduction of the D antigen den-
sity and lead to a DEL phenotype (Szymanski, 1987; Daniels, 2013c), which
makes it challenging to detect the D antigen by routine serology. Probable
correct Rh haplotypes were hypothesised for these samples based on their
Rh serological phenotype, RHD zygosity results, RHD allele identified by
NGS and intronic SNP patterns detected (Table 3.13).
To compare the C suppressive effect on antigen D expression in differ-
ent samples, four Finnish samples (004_124, 004_140, 004_142, 004_143)
were compared to other blood donor samples of the same RHD allele.
The C suppressive effect on D antigen expression, known as Ceppellini
effect, was first explained in an extensive family phenotyping analysis
that showed weak D reactivity may occur without genetic mutations (Cep-
pellini et al., 1955). Ceppellini et al. (1955) noted that DCe/dce genotype
produces normal D expression when c is in trans (i.e on the opposite hap-
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lotype), and DCe/dCe produces weak D expression when C in in trans.
Different studies confirmed that the expression of C antigen reduces the
D expression, although mechanism is not very clear (McGann et al., 2012).
McGann et al. (2012) suggest that the RHCE gene may directly suppress
the RHD gene transcription, or may influence post-translational modifica-
tions. It is also possible that the presence of both C and D antigens lead to
steric hindrance on the cell membrane leading to reduction of D antigen
expression (McGann et al., 2012).
Samples (004_140 and 004_28) were genotyped as RHD*01W.03 and were
both serologically phenotyped as RhC-positive; however, sample (004_140)
shows two copies of RHCE*C (RHCE*Ce) in cis and trans; on the contrary,
the blood donor sample shows only one copy of the RHCE*C with sero-
logically predicted haplotype R1r (DCe/dce) (c in trans). The blood donor
sample may not be affected by Ceppellini effect as C is in trans (i.e on
the same haplotype). However, Araszkiewicz and Szymanski (1989) in
a D antigen quantitative study found that the lowest number of D anti-
gens (285 per cell) was expressed in people with C in cis and trans (C ho-
mozygous) which may be the reason of very weak D reactivity in sample
(004_140). This may indicate that RHCE*C presence in cis and trans (2
copies of C) could severely lower the RhD density on the RBCs making




Four samples were phenotyped by serology as D negative but genotyped
as weak partial D allele. Variants include: 1 sample genotyped as RHD*11
(RHD*weak partial 11), 2 samples genotyped RHD*15 (RHD*DNB), 1 sam-
ple genotyped as RHD*09.03.01 (RHD*DAR3.01), 1 sample genotyped as
RHD*09.01.02, and 1 sample genotyped as RHD*03.01. Weak and partial D
occurs due to multiple changes in the RhD protein that have both quanti-
tative and qualitative effects on the protein expression (Wagner et al., 1999,
2000; Rizzo et al., 2012). These changes could make it challenging to cor-
rectly phenotype the D antigen as they alter the D antigen epitopes and
subsequently the antibody binding ability to bind epitopes. According to
Rizzo et al. (2012) and Flegel (2007a), patients with partial D phenotype
should be considered RhD negative and transfused with RhD negative
blood due to the risk of antibody production to missing or altered epi-
topes.
One ISBT sample (004_101) was serologically phenotyped as R1r and geno-
typed previously as DVa where RHCE exon 4 insertion is observed. How-
ever, variants detected from NGS data showed exonic SNPs that indicate
the RHD exon 4 and 5 were replaced with the RHCE ones, which encode
the RHD*06.01 allele. This variant allele is linked to the R2 haplotype
Avent et al. (1997) but this sample shows that the hybrid allele also ex-
pressed in R1 haplotype. This allele when expressed in R1 (DCe) haplo-
type lacks exon 5 SNP c.676G>C (p.Ala226Pro) that encodes the RhE anti-
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gen in the RHCE gene. This support the finding that RHD*06.01 variant
allele occurs in R1 and R2 haplotypes.
Five ISBT samples (004_102- 004_106), genotyped previously by ISBT (1996))
as DVI type I, very weakly amplified RHD amplicon 4 that covers the re-
gion from intron 4 to intron 7. These samples, when tested for RHD gene
zygosity using ddPCR, showed ratios of ≈ 0.5 and ≈ 0 for RHD7/ AGO1
and RHD5/ AGO1 assays respectively, which indicate the presence of a
hemizygous RHD gene with a deletion of exon 5. The DVI type I allele is
a hybrid RHD gene, expresses partial RhD protein, where exons 4 and 5
are replaced with the RHCE gene correlated exons, RHD-RHCE(4-5)-RHD,
hence the negative results for RHD exon 5 assay. However, NGS data
for these samples showed SNPs associated with RHCE(4-5) insertion in
the RHD gene and breakage of coverage in exon 6 indicating a deletion.
Deletion could be confirmed using alternative methods such as exome se-
quencing. It is not clear how these samples were mis-genotyped previ-
ously as DVI type I, but it is clear that the deletion of exon 6 has occurred
on DVI type I allele backbone. All 5 samples were phenotyped by serology
as RhD positive, therefore, it is expected that the deletion of exon 6 did not
completely disturb the RhD protein and a partial expression is expected.
One blood donor (004_88) sample and 28 Finnish samples were serologi-
cally phenotyped as D negative (Table 3.13) but tested RHD hemizygous
using dPCR. In 3 samples out of the 28 Finnish samples, RHD genotyping
185
DISCUSSION
results were inconclusive, discussed in more detail in section 3.4.4. Out
of the remaining 26 samples, 13 RhD negative samples carried novel RHD
alleles encoded by novel mutations discussed in section 3.4.3.2.
In one sample (004_151) mutation c.395_396dupGG was detected in exon
3 that predicts p.Lys133fs frame shift. This has been reported in the litera-
ture by Karnot et al. (2016) but no designation was assigned by the ISBT as
found in RhesusBase (Wagner and Flegel, 2014). The insertion most likely
causes a frame shift and a truncated non-functional protein that causes a
null phenotype. This is consistent with the negative serology results of
this sample.
3.4.3.2 RHD Novel Alleles
In 18 samples, detected mutations did not link to known RHD alleles and
these were considered novel RHD variants.The 18 samples included 16
serologically D negative Finnish pregnant female samples with undeter-
mined variant RHD allele, 1 serologically D negative blood donor sample,
and 1 ISBT sample with unknown Rh serology results. All 18 samples
tested as hemizygous RHD gene on dPCR. Five variants, were considered
Rh D-negative alleles in which exonic missense mutations led to a frame
shift or a stop codon.
Sample (004_119), presented exon 1 deletion c.49delG predicting frame
shift change at p.Ala17fs on RHD*01W.03 backbone that is encoded by
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exon 1 c.8C>G (p.Ser3Cys). Frame shift prevents translation and pro-
tein synthesis, which would explain the D-negative phenotype by serol-
ogy. In three samples two exon 3 mutations were detected c.421delG and
c.422T>A that predict amino acid changes p.Val141fs and p.Val141Glu, re-
spectively (Novel variant 9). The novel mutations c.421delG, c.784delC,
c.519C>G, and c.399delG are expected to cause null phenotypes, which
would be consistent with the observed D-negative results in the RhD phe-
notyping of the samples.
One hemizygous RHD ISBT sample (004_112) showed mutations associ-
ated with RHD*07.01 and RHD*17.02 variant alleles which include c.329T>C
(p.Leu110Pro) in exon 2 and c.505A>C (p.Met169Leu), c.509T>G (p.Met170Arg),
c.514A>T (p.Ile172Phe), c.544T>A (p.Ser182Thr), c.577G>A (p.Glu193Lys),
c.594A>T (p.Lys198Asn), and c.602C>G (p.Thr201Arg) in exon 4. This
sample encodes a novel hybrid RHD allele of the two variants RHD*07.01
and RHD*17.02 alleles, (Novel variant 2).
In sample (004_144), a novel mutation was identified on a backbone of
RHD*01W.2. Sample (004_144) showed mutation in exon 9 c.1154G>C
predicting amino acid change p.Gly385Ala that encodes RHD*01W.02, in
addition to another exon 9 mutation c.1163T>G predicting amino acid
change p.Leu388Arg (Novel Variant 4), which is located in the transmem-
brane region of the RhD protein. Whether the phenotype in the sample is
DEL, could only be confirmed with antigen quantifying tests.
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Novel mutations that present on the backbone of a known variant can alter
and reduce the D antigen and can be easily mis-genotyped as in samples
(004_119, 004_144). For example, if sample (004_119) was genotyped us-
ing single SNP genotyping assays designed to detect weak D mutations, it
could be mis-genotyped as a RHD*01W.03 rather than a D negative sam-
ple.
Novel mutations are a concern and need to be included in current geno-
typing platforms to allow detection of a wider range of blood group vari-
ants. It is mostly important to identify apparent RhD negative or weak
D donors if they were incorrectly phenotyped as RhD negative, as they
pose the risk of immunisation on RhD negative patients. Weak D type 1, 2
and 3 individuals can be safely transfused with D positive blood without
being at risk of immunisation (Sandler et al., 2015). However, transfus-
ing RhD negative patient as in sample (004_119) with RhD positive RBCs
carries a high risk of sensitisation. Sandler et al. (2017) advise that when
serological weak D phenotypes are detected, transfusion facilities ought to
determine the RHD genotype through further testing, which would mean
individuals with a serological weak D phenotype would then be managed
as RhD-positive or RhD-negative, according to their RHD genotype.
The case of such samples highlights the power of BGG using NGS in
detecting novel mutations and not solely dependent on genotyping for
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known variants through available genotyping methods such as SSP-PCR.
NGS can therefore improve the safety of blood transfusion practices.
3.4.4 Inconclusive Genotyping Results
Four samples failed to amplify one or more of the RHD amplicons, which
could be due to variations in the RHD gene that compromised some of the
primer binding regions, discussed in more detail in section 3.4.11.
Two samples (004_137 and 004_138) failed to amplify amplicon 6. The
Finnish research group reported that sample (004_138) showed a nega-
tive result for exon 10 in the SSP-PCR (Tammi, 2019), indicating that there
probably is a deletion or a hybrid gene around exon 10 of the RHD gene.
Complete or partial deletion of exons 9 and 10 are often associated with
DEL phenotype (Fichou et al., 2012; Srivastava et al., 2018; Lopez et al.,
2018). Srivastava et al. (2018) identified a 7640bp deletion in the RHD gene
which includes part of intron 9 and exon 10. This deletion was confirmed
(using adsorption and elution techniques) to encode RhD negative allele
Srivastava et al. (2018).
The effect of lacking the 8 amino acids encoded by exon 10 is not clear
as aromatic and hydrophobic C-terminal amino acids crucial for RhD ex-
pression which include valine, phenylalanine, and tryptophan at positions
406, 407, and 408, respectively are present (exon 9) (Srivastava et al., 2018).
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Further testing, using a more accurate phenotyping techniques such as
elution or flow cytometry, is necessary to determine the effect of exon 10
deletion and the status of the RhD protein.
The RHD gene was sequenced for both samples for 5 out 6 amplicons and
no variations that could affect RhD expression were detected; therefore,
the RHD gene was considered undetermined due to the lack of the full
gene sequence.
RHD amplicons 1, 2 and 3 failed to amplify in sample (004_150), which
cover the region between RHD exons 1 and 5. The LR-PCR was repeated
using primers adapted from Hyland et al. (2017) to amplify the RHD re-
gion from exon 2 to exon 7. Data analysis showed 3 exonic mutations de-
tected in exons 4, 5, and a complete deletion of exon 3 (336-486del). This
large deletion of exon 3 explains the D negative phenotype in this sample,
as the 3 exonic mutations do not encode for a null allele but in fact en-
code for the RHD*09.03.01 variant allele. Exon 3 deletion most probably
occurred on RHD*09.03.01 allele. The complete deletion of exon 3 has pre-
vented a successful translation which leads to RhD negative status.
In sample (004_125) that was found to be homozygous for the RHD gene
on ddPCR, exonic mutations detected included c.48G>C in exon 1, c.602C>G
in exon 4, c.667T>G in exons 5, and c.819G>A in exon 6 that predict amino
acid changes p.Trp16Cys, p.Thr201Arg, p.Phe223Val, and silent mutation,
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respectively. All SNPs detected were heterozygous which indicates pres-
ence of two variant RHD alleles (compound heterozygote). Possible alleles
encoded by these exonic changes are either RHD*09.03 and RHD*01.01 or
RHD*09.04 and RHD*01. The SSP-PCR CDE kit results reported by Tammi
(2019) indicated a presence of weak D 4.0/4.1 allele, which supports NGS
results. However, presence of a wild type RHD allele that produces a nor-
mal RhD protein does not agree with the weak D reactivity in serology.
In serology testing, normal D would mask the weak D reactivity and re-
sult would be RhD positive instead of weak D. Therefore, presence of an
intact copy of either RHD*01.01 or RHD*01 allele is unlikely. No other mu-
tations predicting amino acid changes or splice site disruptions were de-
tected. The most possible explanation for this sample is that the wild type
RHD allele (RHD*01) is possibly a variant allele that harbours a deletion
or a conversion, masked by the presence of an intact copy of the RHD gene
(RHD*09.04). The possible deletion will lead to a null phenotype. There-
fore, only one copy of the RHD gene will produce RhD protein which for
this sample is the RHD*09.04 allele which encodes a weak D. Genotyping
results for this sample remains inconclusive.
Sample (004_73) failed to amplify RHD amplicon 4 that covers the region
from intron 4 to intron 7. Different SNPs were detected in exon 4 that
indicate a hybrid RHD-RHCE(4)-RHD gene where exon 4 of the RHD is
replaced by RHCE exon 4. These changes included c.505A>C; c.509T>G;
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c.514A>T; c.544T>A; c.577G>A; c.594A>T; c.602 C>G and predict amino
acid changes p.Met169Leu, p.Met170Arg, p.Ile172Phe, p.Ser182Thr, p.Glu193Lys,
p.Lys198Asn, p.Thr201Arg which encode the RHD*17.02 allele. This vari-
ant RHD allele is linked typically to the R1 (DCe) haplotype (Faas et al.,
1997; Wagner and Flegel, 2014), however, this sample was assigned by
serology as R0r (Dce/dce). This means that RHD*17.02 variant allele could
also be found in the R0 (Dce) haplotype. Genotyping results for sample
(004_73) remain inconclusive due to the lack of the complete RHD se-
quence.
3.4.5 Rh Haplotype Specific Intronic SNPs
Analysing intronic SNPs, revealed 21 homozygous SNPs present in all
samples sequenced.These represent SNP variants of the RHD*DAU0 (RHD*10.00)
allele, which the hg38 reference sequence encodes. Some intronic SNPs
were found to be present in a specific haplotype (R2), 23 SNPs were ho-
mozygous in all R2r, R2R2 and in 3 of the 6 R1R2 samples that tested as
hemizygous by ddPCR. They were also detected as heterozygous SNPs in
all R1R2 samples tested as homozygous by ddPCR and in the R2Rz sam-
ple. Homozygous intronic mutations were detected in all R1R1, R1r, and
in the other 3 of the 6 R1R2 samples tested as hemizygous in ddPCR.These
SNPs were also present in six R0r samples and detected as heterozygous
SNPs in six R1R2 samples tested as homozygous by ddPCR and in the
R2Rz sample. The similarities of intronic SNPs pattern between differ-
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ent haplotypes (R1, R0, and Rz) suggest that these haplotypes might have
arisen from the same ancestral gene. There were no intronic SNPs specific
to each of the R1, R0, or Rz alleles, (Figure 3.13).
These intronic SNP patterns were found to be inconsistent in samples
where hybrid RHD allele is expected. This is due to the RHCE insertion,
as found in the ISBT samples (004_101-004_106) where exonic SNPs de-
tected indicate hybrid RHD-RHCE(4-5)-RHD allele. Intronic SNPs located
in introns 3-6 were inconsistent with Rh haplotype assigned by serology,
however, other intronic SNPs were consistent with previous patterns iden-
tified.
Intronic SNPs related to R2 haplotype were compared to the previous
SNPs that were investigated at the beginning of this research detected
by Halawani (2015). Because previous work used the reference sequence
hg19, SNPs were correlated to the new accession system used in the refer-
ence sequence hg38, (Table 3.3).
3.4.6 RHD Allele Specific Intronic SNPs
Three samples (004_69, 004_97, 004_148) genotyped as RHD*09.03.01, 1
sample genotyped as RHD*09.01.02 (004_70), 1 sample (004_96) genotyped
as RHD*03.01, and 1 sample (004_125) that possibly carries the RHD*09.03
allele showed 11 intronic SNPs that could be specific to their originating al-
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lele. Amino acid sequences of different RHD alleles detected in this study
were compared and a phylogenetic tree was created using www.phylogeny.fr
(Dereeper et al., 2008), to determine if theses variant alleles were orig-
inating from the ancestral gene. Figure 3.18 shows that RHD*09.03.01,
RHD*09.01.02, and RHD*09.03 alleles appear to be originated from the
same ancestral gene. Samples (004_69, 004_97, 004_148) genotyped as
RHD*09.03.01 (DAR3.1), 33 intronic SNPs were detected as homozygous
SNPs in these samples, which were specific to the DAR3.1 allele.
3.4.7 Rh Haplotype Determination
We attempted to determine the probable correct Rh haplotype for sam-
ples where Rh serology results did not agree with the RHD genotyping
results. To assign the most probable correct haplotype for these samples,
we studied the literature to identify if the RHD variant allele was linked
to a specific haplotype (Wagner et al., 1999; Wagner and Flegel, 2014). We
also considered the RhCcEe serology phenotyping results, RHD zygosity
testing results, and the intronic SNP patterns detected in the sequence.
In samples in which a previously reported variant was identified (Wagner
and Flegel, 2014), for example, weak D type 1 RHD*01W.01 was detected
in R1 (DCe) haplotype samples, weak D type 2 RHD*01W.02 was found in
R2 (DcE) haplotype samples, and weak D type 3 RHD*01W.03 was iden-
tified in R1 (DCe) haplotype sample (Wagner et al., 1999), the probable
variant haplotypes were consistent with the reported variant haplotypes
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in all but two samples (004_73 and 004_123).
The RHD*15 allele, found in two samples (004_123 and 004_146), is usu-
ally associated with antigen E and observed in the R2 (DcE) haplotype
(Wagner and Flegel, 2014) which is the most probable haplotype for sam-
ple (004_146), which is supported by the R2 intronic SNP pattern found in
the sequence. However, Ye et al. (2014) observed 2/64 samples identified
as RHD*15 in the ee (Cce) phenotype. In sample (004_123), which showed
the R1, R0.Rz intronic SNP pattern, the most likely variant haplotype is R1
(DCe), which supports the observation of RHD*15 associated also with e.
Sample (004_73) genotyped by NGS as RHD*17.02, which is associated
with R1 (DCe) haplotype (Wagner and Flegel, 2014). However, sample
was assigned by serology as R0r (Dce/dce). This means that the RHD*17.02
allele is also associated with R0 (Dce) haplotype as well as R1 (DCe).
3.4.8 Evolution of RHD Variant Alleles
The evolution of the RHD gene, discussed in section 1.4, is thought to be
through a duplication event in the RHCe*ce allele where the RHD gene ori-
entation was altered (Carritt et al., 1997; Okuda and Kajii, 2002). Intronic
polymorphism in the RHCE intron 2 is a reminder of that genomic event.
Different studies have established that the Rh original haplotype was R0
(Dce) through studying different intronic variations in the RHD and RHCE
genes (Carritt et al., 1997; Okuda and Kajii, 2002).
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In this study, RHD intronic variation patterns could be linked to the evo-
lution of theses alleles from the same ancestral gene. Figure 3.18 shows
a phylogenetic tree of the RHD different alleles that were detected in this
study. Most of the RHD alleles are caused by single nucleotide variations
on the backbone of the RHD wild type allele, while others occur on the
backbone of a variant RHD allele.
196
DISCUSSION




Two samples (004_14 and 004_74) were serologically phenotyped as weak
D; however, no amino acid changes were predicted from sequencing of the
RHD gene. Different mutations in the RHAG gene have been reported that
disturb the expression of the Rh proteins (Polin et al., 2016; Mu et al., 2019;
Wen et al., 2019). Therefore, we sequenced the RHAG gene for these sam-
ples (004_14 and 004_74) that showed weak D reactivity without finding
any alterations in the RHD gene. Sample (004_14) showed a heterozygous
SNP 808G>A in exon 6 of the RHAG gene leading to Val270Ile that en-
codes the RHAG*04 allele (Figure 3.14), in addition to a silent SNP in exon
6 861G>A. Although this SNPs is a heterozygous, it could be the main
cause of the weak D reactivity, hence no changes were detected from the
sequencing of the RHD gene in this sample to explain the weak D reac-
tivity. Protein interaction model of the RhD and RhAG proteins was vi-
sualised on the CLC workbench 10 to locate the Val270Ils. The Val270Ile
is not located on the interaction face of the RhAG protein. Further inves-
tigation of this allele and how it may affect the RhD protein is needed to
understand the effect of such mutations on the expression on the Rh pro-
teins. Wen et al. (2019) has reported other mutations in the RHAG gene




MinION™ sequencer was utilised to sequence the complete RHD gene
from 13 samples in 6 overlapping amplicons, which were also sequenced
on the Ion PGM™. Quality assessment for reads was preformed and an
average quality PHRED-score of 11 was detected (Figure 3.15), which in-
dicates accuracy of about 90%. According to Laver et al. (2015) MinION™
error rate per base with a certain quality number does not correspond
to error rate per base expected for PHRED value of the same quality re-
sults, which means that MinION™ sequencing quality score does not cor-
respond with PHRED-score as NGS technologies. Using R6 MinION™
chemistry, they found that MinION™ has about 40% error on single read
sequencing (Laver et al., 2015); however, in current work 1D flow cells R9
version was used for sequencing which shows lower error rate (Tyler et al.,
2018).
SMS allows real time sequencing and data analysis while reducing prepa-
ration and sequencing time (Schadt et al., 2010; Lu et al., 2016). Error in the
MinION™ sequencing occurs in specific sequences with 11% estimated
error rate (Magi et al., 2016). However, with 40x depth of coverage Min-
ION™ may cause a false substitution and insertion every 10–50 kb and
a false deletion every 1000 bp, which may cause an issue in detection of
variations (Magi et al., 2016). However, in this work we did not encounter
an issue in that matter as high coverage across the gene was achieved with
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up to 500x in some regions. Variation in coverage is expected due to the
fact that LR-PCR amplicons are sequenced. In BGG using MinION™, we
were able to detect exonic and intronic SNPs and identify alleles which
agree with ones found using Ion PGM™
MinION™ library preparation and sequencing time was reduced to a day
from 4-5 days in NGS, after PCR amplification and purification which
takes 3 days for 20 samples. SMS was successful in BGG and provided suf-
ficient data to call variants and determine alleles. However, data handling,
storage and analysis in MinION™ are challenging. The evolving nature of
this sequencing technology makes it difficult to establish a user friendly
software that would enable fast and accurate data analysis to make it suit-
able for clinical use.
3.4.11 LR-PCR Limitations
The RHD gene was fully sequenced on the Ion PGM™ and MinION™
through LR-PCR amplification. Although LR-PCR is an efficient tech-
nique in amplifying the gene for sequencing, the LR-PCR approach is
limited. Hybrid RHD-RHCE alleles or partial D alleles may not amplify
if a primer position is compromised by deletion or mutations. The RHD-
specific primers in this study were tested with different weak and partial D
samples including; RHD*DVI.01, RHD*DNB, RHD*DIV.04, RHD*DVII.01,
DFR1, DFR2, and RHD*DIIIa. Amplification for all 6 PCR amplicons was
achieved in all samples except for samples with the RHD*DVI.01 allele,
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in which amplicon 4 amplified very weakly, which affected the coverage
around exon 5.
The RHD primers designed in this study also failed to amplify 3 Finnish
samples (004_137, 004_138, 004_150). Two samples (004_137, 004_138)
failed to amplify the RHD amplicon 6, while sample (004_150) failed to
amplify RHD amplicons 1, 2, and 3. Hyland et al. (2017) LR-PCR primers
were used to amplify the RHD gene from exon 2 to exon 7 for sample
(004_150), which was successful. Data analysis revealed a complete dele-
tion of intron 2 and exon 3, which explains the failure of amplification of
the RHD amplicons 1, 2, and 3 that cover the RHD gene from exon 1 to
intron 4.
Amplification issues could be resolved in the future by using a hybrid
primer approach; for example, an RHD specific forward primer and an
RHCE specific reverse primer or removing PCR amplification by utilising
SMS technology. SMS allow real time sequencing and data analysis while
reducing preparation and sequencing time (Schadt et al., 2010; Lu et al.,
2016), which was explored in section 3.3.7.2. SMS was successful and pro-
vided sufficient data to call variants and determine alleles and reduced




We sequenced the complete RHD gene in samples (n=133) using NGS to
study RHD mutations, assess variations present in the population, identify
novel variants and establish reference RHD allele sequences. Ten novel al-
leles were identified in 18 samples. Reference sequences for these novel
alleles were submitted to Genbank and assigned accession numbers. The
use of NGS in BGG to overcome limitations in other genotyping platforms
has been promising.
NGS of the complete RHD gene was effective in identifying exonic and
intronic changes encoding known and novel variants of RHD gene. How-
ever, in samples where a hybrid RHD gene or a large deletion exists, LR-
PCR amplification was not successful as one or more of the primers’ bind-
ing regions have been affected, thus preventing annealing.
NGS also enabled exploring the intronic SNPs and their relation to a spe-
cific Rh haplotype. Twenty-one intronic SNPs were identified in all sam-
ples sequenced (n=133) indicating their specificity to the RHD*DAU0 (RHD*10.00)
haplotype which the hg38 reference sequence encodes. Twenty-three in-
tronic SNPs were found to be R2 specific, and 15 were related to R1, R0 and
Rz haplotypes. Intronic SNPs may represent a novel diagnostic approach
to investigate known and novel variants of the RHD and RHCE genes.
NGS allows the study of intronic and exonic changes in blood group genes
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enabling the detection of known and novel mutations, which ultimately




4. RHCE Genotyping Using NGS
4.1 Introduction
The Rh blood group antigens are encoded by two closely related genes,
the RHD and the RHCE genes located on chromosome 1, which encode the
RhD protein and RhCcEe protein, respectively (Colin et al., 1991; Wagner
and Flegel, 2000). The two closely related genes encode 55 different anti-
gens in the Rh system; five of them are considered the leading antigens,
which include RhD, RhC, Rhc, RhE, and Rhe. Although RhD is the most
immunogenic and clinically significant antigen in the Rh blood group sys-
tem, other antigens are immunogenic and antigen incompatibility could
lead to HTRs and HDFN, discussed in sections 1.8.1 and 1.8.2, including C,
c, E, e antigens (Le van Kim et al., 1992; Ranasinghe et al., 2003; Kumawat
et al., 2012; Sheeladevi et al., 2013; Avent, 2018). Single nucleotide varia-
tion is the main reason for the RHCE gene polymorphism, which gives rise
to different antigens.
Six exonic variations in the RHCE gene (c.48C>G, c.150C>T, c.178C>A,
c.201A>G, c.203A>G, c.307C>T) lead to amino acid alterations (p.Cys16Trp,
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p.Leu60Ile, p.Asn68Ser, p.Pro103Ser) that have been linked to the Rhc>RhC
change, however, the c.307C>T (p.Pro103Ser) mutation is the key muta-
tion (Mouro et al., 1993; Simsek et al., 1994). Mutation c.676G>C in exon
5 (p.Ala226Pro) is the key mutation for the Rhe>RhE polymorphism. Mu-
tations in the RHCE gene lead to different variations of the Rh antigens
including weakened and partial expression, for example, Cw, Ew and VS
antigen.
Serological tests used for Rh phenotyping cannot differentiate between
normal or altered epitopes, especially in partial expression (Moulds et al.,
2014). For example, serological tests cannot differentiate between par-
tial RhC and normal expression as long antibody binding sites are not
affected. Incorrectly phenotyping patients for Rh antigens could lead to
allo-antibody production and therefore make finding compatible blood for
transfusion a rigorous mission.
WES has previously been used to sequence the coding regions of the RHCE
gene to determine the RHCE alleles (Chou et al., 2017; Schoeman et al.,
2018). However, in the work presented here the whole RHCE gene has
been sequenced including coding and non-coding regions. To sequence
the RHCE gene, we used the same approach used for the RHD sequenc-
ing. Eight overlapping LR-PCR amplicons were used to amplify the RHCE
gene for sequencing. All samples sequenced for the RHCE gene were also
sequenced for the RHD gene, except for RhD negative samples that were
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confirmed to be RHD negative by RHD zygosity testing using ddPCR.
4.2 Aim and Objectives
We aimed to develop a methodology to fully sequence the RHCE gene,
from samples that had been sequenced for the RHD gene, to establish
RHCE allele reference sequences by studying intronic SNP patterns in dif-
ferent RHCE alleles.To achieve our aim, objectives were as follow:
1. Design LR-PCR RHCE specific primers that would allow specific am-
plification from the target gene.
2. Sequence the RHCE gene using Ion PGM™ and analyse data using
hg38 as the reference sequence.
3. Call variants and study intronic SNP patterns present in different
RHCE alleles.
4. Utilise detected intronic SNPs to establish RHCE allele specific refer-
ence sequences.
5. Compare intronic SNP patterns found in the RHD gene with ones





4.3.1 RHCE NGS Data Quality & Coverage
The RHCE gene was sequenced with the same approach used for the RHD
gene sequencing, in which the RHCE gene was amplified in 8 overlapping
LR-PCR amplicons, (Figure 2.2). Samples included in the RHCE genotyp-
ing were also genotyped for the RHD gene except for samples that tested
negative for the RHD gene on ddPCR (n=18). In these samples, RHD zy-
gosity testing showed a ratio ≈ 0 for RHD5 and RHD7 assays against the
reference gene AGO1, indicating a deletion of the RHD gene.
Three sequencing libraries were prepared and sequenced on the Ion PGM™
as described in section 2.9, in which each sequencing run contained 34,
35, and 47 samples (Table 4.1). ISPs loading density, number of reads af-
ter polyclonal filter, and distribution of reads length was reported after
each sequencing run from the Ion PGM™. ISPs loading density refers to
the percentage of chip wells that contain ISP, in which red colour indi-
cates adequate loading density, yellow indicates less-than adequate load-
ing density, and blue indicates inadequate loading density or absence of
beads. Figure 4.1 shows a sequencing run summary in which the sequenc-
ing library contained 47 samples. Low ISPs loading density (59%) was no-
ticed in this RHCE sequence run. High polyclonal percentage (35%) was
also noticed which might be due to high number of reads in the sequence
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Table 4.1: Ion PGM™ sequencing run summary report details for RHCE sequencing runs
Library No. of ISP loading Polyclonal Usable reads Total usable Average reads
no. samples (%) (%) (%) reads /sample
1 34 79 31 63 3,146,839 92,554
2 35 65 47 40 1,616,947 46,198
3 47 59 35 47 3,051,892 63,581
run. Low ISPs density and high polyclonal percentage in this sequence
run decreased the number of usable reads to 47% (about 3 million reads),
which lead to the loss of reads in some samples (004_99, 004_102, 004_111,
004_113).
Figure 4.1: Ion PGM™ sequencing run summary for the RHCE gene from a single repre-
sentative run. (a) The loading density in 316™ Chip was 59% of the chip capacity, giving
a final throughput of 481 Mb. (b) Over 3 million reads were recovered after enrichment
and polyclonal filters. (c) A histogram shows the distribution of the reads length mean
around 158 bp, in which the y-axis and x-axis represent the read count and the read length
in bp, respectively.
NGS data, obtained in FASTQ files, was assessed for sequence quality.
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CLC workbench 10 software was utilised to generate a sequence sum-
mary report similar to the ones generated for RHD gene sequencing. High
PHRED sequence quality score was noticed across all the samples sequenced.
PHRED score represents the quality score of each base, which estimates
the probability of an error in the sequence. Figure 4.2 shows a PHRED
score of over 30 for a representative sample that was sequenced indicating
>99% accuracy. Full coverage across the gene was achieved except for a re-
gion in intron 7 (25,378,316- 25,381,617) and in some samples breakage of
coverage in intron 2 was noticed which could be due to poor PCR ampli-
fication of amplicon RHCE-2. Depth of coverage across the RHCE coding
regions was adequate (Figure 4.3) and sufficient for calling variants, ex-
cept for a region in intron 7 where breakage of coverage was noticed from




Figure 4.2: RHCE gene sequence quality summary report generated by the CLC work-
bench 10 software from a single representative sample. A. Distribution of reads sequence
lengths from a single representative sample; x axis: sequence length in base-pairs, y axis:
number of reads showing a specific length normalized to the total number of sequences.
B. PHRED score for RHCE gene sequence from a single representative sample. x axis:
PHRED-score; y axis: percentage of sequences, normalized to the total number of reads,
noted at that quality. C. The number of sequences that cover the individual base positions
from a single representative sample, x axis: base position; y axis: number of sequences
covering individual base positions normalized to the total number of sequences.
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FASTQ reads mapped to the RHCE gene in the hg38 reference sequence.
Genes in the chromosomal assembly including the homologous RHD gene
were masked in the mapping process to prevent reads from scattering. De-
tailed mapping report was generated using the CLC workbench 10 sim-
ilarly to the ones generated in the RHD genotyping analysis, which in-
cluded coverage analysis, mismatches analysis, read length distribution,
insertion and deletion level, and quality for match and mismatch distribu-
tion.
Variant detection was performed on a minimum coverage of 30 (i.e the
numbers of overlapping reads over a single base) and variants detected
were analysed on a single base basis considering different parameters in-
cluding number and percentage of reads and nucleotide count (Nielsen
et al., 2011). Breakage of coverage was noticed in intron 7 and intron 2
in some samples, but a full coverage across all 10 exons was achieved and
depth of sequencing coverage was adequate and sufficient for calling vari-
ants in most samples, (Figures 4.3 & 4.4). In 4 samples (004_99, 004_102,
004_111, 004_113), with low number of reads, adequate coverage over ex-
ons was not achieved which made allele determination impossible.
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Figure 4.3: Level of coverage across the RHCE gene from a single representative sample.
Level of coverage (x axis) and number of bases observed at that level (y axis). A total
of 54,653 positions (RHCE gene) have coverage between 1 and 710. Positions of zero





Figure 4.4: Depth of coverage of the RHCE gene sequence from a single representative sample. (top) Eight RHCE amplicons
mapped to the RHCE gene (refer to Figure 2.2). ↓ Breakage of coverage noticed in RHCE intron 7.
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4.3.2 RHCE NGS Genotyping
Samples (n=100) were genotyped for the RHCE gene using NGS in which
(n=87) were blood donor samples and (n=13) were samples from the ISBT
workshop ISBT (1996). Blood donor samples included 7 R1R1, 20 R1r, 9
R1R2, 6 R2R2, 14 R2r, 11 R0r, 1 R2Rz, 6 rr, 7 r’r, and 6 r"r samples. The
ISBT workshop samples did not have Rh serological results available. The
RHCE sequencing data was analysed to determine the RHCE alleles for
each sample (Table 4.2). Different alleles were compared to determine
which SNPs belonged to which allele, especially in heterozygous samples,
in an attempt to phase the RHCE alleles. The RHCE reference sequence
in hg38 shows c.307C (p.Pro103) in exon 2, c.676G (p.Ala226) in exon 5,
and c.48C (p.Cys16) in exon 1 that encode weak ce allele RHCE*01.01. The
reference sequence hg38 shows nucleotides associated with Rhc in exon
2 which include: c.150C (silent). c.178C (p.Leu60), c.201A (silent), c.203A
(p.Asn68), c.307C (p.Pro103) .
It is important to keep in mind that the hg38 reference sequence is a variant
RHCE allele RHCE*01.01 that presents c.48C (p.16Cys) in exon 1. Therefore
when sequence data is analysed against the hg38 reference sequence, sam-
ples phenotyped by serology as normal e showed a SNP in exon 1 c.48C>G
(p.Cys16Trp), (Figure 4.5). On the other hand, other alleles associated with
the c.48G>C SNP, for example RHCE*02 allele, the SNP was not detected
as it matches the reference sequence. SNP c.48C>G (p.Cys16Trp) in exon
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1 encodes the RHCE*01 allele. Table 4.3 lists the different RHCE alleles
detected in samples sequenced by NGS.
Figure 4.5: A. RHCE hg38 reference sequence is a variant allele that shows c.48C (p.Cys16)
in exon 1 that encodes RHCE*01.01. B. Samples sequenced with normal Rhce expression
show c.48C>G (p.Cys16Trp) when aligned to the reference sequence.
4.3.2.1 NHSBT Blood Donor Samples
NGS data was analysed, variants called and the allele they encode are
listed in Table 4.2. In seven R1R1 (DCe/DCe) samples (004_01- 004_07),
5 homozygous exonic changes were detected in exon 2 including c.150C>T
(p.silent), c.178C>A (p.Leu60Ile), c.201A>G (p.silent), c.203A>G (p.Asn68Ser),
c.307C>T (p.Pro103Ser) which encode for homozygous RHCE*02 (RHCE*Ce)
allele.
Twenty R1r (DCe/dce) samples (004_08- 004_023 and 004_25-004_28) and
5 r’r (dCe/dce) samples (004_81- 004_85) showed 6 heterozygous exonic
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changes, c.48C>G in exon 1 predicting amino acid change p.Cys16Trp which
encode for RHCE*01 (RHCE*ce). Five changes were detected in exon 2
including c.150C>T (p.silent), c.178C>A (p.Leu60Ile), c.201A>G (p.silent),
c.203A>G (p.Asn68Ser), c.307C>T (p.Pro103Ser) which encode RHCE*02
(RHCE*Ce) allele. These samples encode heterozygous RHCE*02; RHCE*01
(RHCE*Ce; RHCE*ce) alleles.
Nine samples assigned their genotype by serology as R1R2 (DCe/DcE)
(004_29, 004_30, 004_31, 004_33, 004_34, 004_35, 004_37, 004_39, 004_40)
showed 7 heterozygous exonic changes in exons 1, 2, and 5. Heterozy-
gous SNPs in exons 1 c.48C>G and 5 c.676G>C predicting amino acid
changes p.Cys16Trp and p.Ala226Pro, respectively, encode the RHCE*03
(RHCE*cE) allele. SNPs in exon 2 c.150C>T (p.silent), c.178C>A (p.Leu60Ile),
c.201A>G (p.silent), c.203A>G (p.Asn68Ser), c.307C>T (p.Pro103Ser) en-
code RHCE*02 (RHCE*Ce) allele. These samples encode heterozygous RHCE*02;
RHCE*03 (RHCE*Ce; RHCE*cE) alleles.
Six R2R2 (DcE/DcE) samples (004_41, 004_42, 004_43, 004_45, 004_46,
004_47) showed 2 homozygous SNPs in exon 1 c.48C>G and exon 5 c.676G>C
that predict amino acid changes p.Cys16Trp and p.Ala226Pro, respectively,
which encode homozygous RHCE*03 (RHCE*cE).
Fourteen R2r (DcE/dce) samples (004_49- 004_62) and 6 r”r (dcE/dce)
samples (004_88- 004_93) showed homozygous SNPs in exon 1 c.48C>G
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predicting amino acid change p.Cys16Trp and heterozygous SNP c. 676G>C
in exon 5 that predict amino acid change p.Ala226Pro. These samples were
genotyped as heterozygous RHCE*03; RHCE*01 (RHCE*cE; RHCE*ce).
From 11 samples assigned Rh genotype by serology as R0r (Dce/dce), 9
samples (004_63, 004_64, 004_65, 004_66, 004_67, 004_68, 004_71, 004_72,
004_73) showed heterozygous SNP c.48C>G in exon 1 predicting amino
change p.Cys16Trp which indicates that the R0 allele presents c.48C in
exon 1 similar to the reference sequence. These samples were genotyped
as heterozygous RHCE*01; RHCE*01.01 (RHCE*ce; RHCE*ce.01). The other
two R0r samples (004_69 and 004_70) presented multiple exonic changes.
Sample (004_69) showed 2 heterozygous SNPs in exon 1 c.48C>G and
c.106G>A that predict amino acid changes p.Cys16Trp and p.Ala36Thr,
respectively. This sample was genotyped as heterozygous RHCE*02.09
(RHCE*Ce.09) encoded by c.106G>A and RHCE*01 (RHCE*ce) encoded by
c.48C>G change in exon 1. Sample (004_70) showed 6 heterozygous exonic
changes in exons 1, 5, and 6. These SNPs include c.48C>G (p.Cys16Trp) in
exon 1, c.712A>G (p.Met238Val), c.733C>G (p.Leu245Val), 787A>G (p.Arg
263Gly), and c.800T>C (p.Met267Lys) in exon 5, and c.916A>G (p.Ile306Val)
in exon 6. Exon 1 SNPs encode for RHCE*01 (RHCE*ce), while other changes
encode for RHCE*01.04.01 (RHCE*ceAR).
One R2Rz (DcE/DCE) sample (004_74) showed 6 heterozygous and 1 ho-
mozygous exonic changes. Heterozygous SNPs include exon 1 c.48C>G
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(Cys16Trp), exon 2 c.150C>T (p.silent), c.178C>A (p.Leu60Ile), c.201A>G
(p.silent), c.203A>G (p.Asn68Ser), c.307C>T (p.Pro103Ser), and the ho-
mozygous SNPs in exon 5 c.676G>C that predict amino acid change p.Ala226Pro
which is the key change for RhE expression. This sample genotyped as
heterozygous RHCE*02; RHCE*04 (RHCE*cE; RHCE*CE).
Two blood donor samples (004_86 and 004_87) from Black/Caribbean donors
were serologically assigned Rh genotype as r’r (dCe/dce). Both samples
tested as negative for the RHD gene by zygosity testing using ddPCR with
a ratio = 0 for both assays RHD5 and RHD7 against the reference gene
AGO1. However, both samples amplified amplicon 1 of the RHD gene,
indicating the presence of deletion or a hybrid RHD-CE-RHD gene. RHCE
sequencing analysis showed heterozygous SNPs c.48C>G (p.Cys16Trp) in
exon 1, c.733C>G (p.Leu245Val) in exon 5, and c.1006G>T (p.Gly336Cys)
in exon 7. The SNP in exon 1 encode RHCE*01 (RHCE*ce) allele and the
SNPs in exon 5 and 7 encode the variant allele RHCE*ceVS.03 (RHCE*01.02.03),
a common variant in individuals of Caribbean descent.
Six samples (004_75- 004_80) assigned Rh haplotype by serology as rr
(dce/dce), showed 1 homozygous SNP in exon 1 c.48C>G predicting amino
acid change p.Cys16Trp which encode for homozygous RHCE*01 (RHCE*ce)
allele.
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Table 4.2: RHCE gene NGS results (Ion PGM™).
Lab no. Rh serology* Ethnicity* RHD zygosity RHD Allele RHCE SNPs SNPs zygosity Exon Amino acid RHCE Allele
004_01 R1R1 Caucasian Homozygous RHD*01 150C>T Homozygous 2 silent RHCE*Ce; RHCE*Ce
178C>A Homozygous 2 Leu60Ile
201A>G Homozygous 2 silent
203A>G Homozygous 2 Asn68Ser
307C>T Homozygous 2 Pro103Ser
004_02 R1R1 Caucasian Homozygous RHD*01 = = = = RHCE*Ce; RHCE*Ce
004_03 R1R1 Other Homozygous RHD*01 = = = = RHCE*Ce; RHCE*Ce
004_04 R1R1 Caucasian Homozygous RHD*01 = = = = RHCE*Ce; RHCE*Ce
004_05 R1R1 Caucasian Homozygous RHD*01 = = = = RHCE*Ce; RHCE*Ce
004_06 R1R1 Caucasian Homozygous RHD*01 = = = = RHCE*Ce; RHCE*Ce
004_07 R1R1 Caucasian Discrepancy RHD*01W.01 = = = = RHCE*Ce; RHCE*Ce
004_08 R1r Caucasian Hemizygous RHD*01 48C>G Heterozygous 1 Cys16Trp RHCE*Ce; RHCE*ce
150C>T Heterozygous 2 silent
178C>A Heterozygous 2 Leu60Ile
201A>G Heterozygous 2 silent
203A>G Heterozygous 2 Asn68Ser
307C>T Heterozygous 2 Pro103Ser
004_09 R1r Caucasian Hemizygous RHD*01 = = = = RHCE*Ce; RHCE*ce
004_10 R1r Chinese Hemizygous RHD*01 = = = = RHCE*Ce; RHCE*ce
004_11 R1r Caucasian Hemizygous RHD*01 = = = = RHCE*Ce; RHCE*ce
004_12 R1r Caucasian Hemizygous RHD*01 = = = = RHCE*Ce; RHCE*ce
004_13 R1r Caucasian Hemizygous RHD*01 = = = = RHCE*Ce; RHCE*ce
004_14 R1r Caucasian Homozygous RHD*01 = = = = RHCE*Ce; RHCE*ce
004_15 R1r Caucasian Hemizygous RHD*01W.01 = = = = RHCE*Ce; RHCE*ce
004_16 R1r Caucasian Hemizygous RHD*01W.01 = = = = RHCE*Ce; RHCE*ce
004_17 R1r Caucasian Hemizygous RHD*01W.01 = = = = RHCE*Ce; RHCE*ce
004_18 R1r Caucasian Hemizygous RHD*01W.01 = = = = RHCE*Ce; RHCE*ce
004_19 R1r Caucasian Hemizygous RHD*01W.01 = = = = RHCE*Ce; RHCE*ce
004_20 R1r Caucasian Hemizygous RHD*01W.01 = = = = RHCE*Ce; RHCE*ce
004_21 R1r Caucasian Hemizygous RHD*01W.01 = = = = RHCE*Ce; RHCE*ce
004_22 R1r Caucasian Hemizygous RHD*01W.01 = = = = RHCE*Ce; RHCE*ce
004_23 R1r Caucasian Hemizygous RHD*01W.01 = = = = RHCE*Ce; RHCE*ce
004_25 R1r Caucasian Hemizygous RHD*01W.01 = = = = RHCE*Ce; RHCE*ce
continued . . .
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004_26 R1r Caucasian Hemizygous RHD*01W.01 = = = = RHCE*Ce; RHCE*ce
004_27 R1r Caucasian Hemizygous RHD*01W.01 = = = = RHCE*Ce; RHCE*ce
004_28 R1r Caucasian Hemizygous RHD*01W.03 = = = = RHCE*Ce; RHCE*ce
004_29 R1R2 Caucasian Homozygous RHD*01 48C>G Heterozygous 1 Cys16Trp RHCE*Ce; RHCE*cE
150C>T Heterozygous 2 silent
178C>A Heterozygous 2 Leu60Ile
201A>G Heterozygous 2 silent
203A>G Heterozygous 2 Asn68Ser
307C>T Heterozygous 2 Pro103Ser
676G>C Heterozygous 5 Ala226Pro
004_30 R1R2 Caucasian Homozygous RHD*01 = = = = RHCE*Ce; RHCE*cE
004_31 R1R2 Caucasian Homozygous RHD*01 = = = = RHCE*Ce; RHCE*cE
004_33 R1R2 Caucasian Homozygous RHD*01 = = = = RHCE*Ce; RHCE*cE
004_34 R1R2 Caucasian Homozygous RHD*01 = = = = RHCE*Ce; RHCE*cE
004_35 R1R2 Caucasian Hemizygous RHD*01W.02 = = = = RHCE*Ce; RHCE*cE
004_37 R1R2 Caucasian Hemizygous RHD*01 = = = = RHCE*Ce; RHCE*cE
004_39 R1R2 Caucasian Hemizygous RHD*01 = = = = RHCE*Ce; RHCE*cE
004_40 R1R2 Caucasian Hemizygous RHD*01 = = = = RHCE*Ce; RHCE*cE
004_41 R2R2 Caucasian Homozygous RHD*01W.02 48C>G Homozygous 1 Cys16Trp RHCE*cE; RHCE*cE
676G>C Homozygous 5 Ala226Pro
004_42 R2R2 Not disclosed Hemizygous RHD*01W.02 = = = = RHCE*cE; RHCE*cE
004_43 R2R2 Caucasian Homozygous RHD*01 = = = = RHCE*cE; RHCE*cE
004_45 R2R2 Caucasian Homozygous RHD*01 = = = = RHCE*cE; RHCE*cE
004_46 R2R2 Caucasian Homozygous RHD*01 = = = = RHCE*cE; RHCE*cE
004_47 R2R2 Caucasian Homozygous RHD*01 = = = = RHCE*cE; RHCE*cE
004_49 R2r Caucasian Hemizygous RHD*01 48C>G Homozygous 1 Cys16Trp RHCE*cE; RHCE*ce
676G>C Heterozygous 5 Ala226Pro
004_50 R2r Caucasian Hemizygous RHD*01 = = = = RHCE*cE; RHCE*ce
004_51 R2r Caucasian Hemizygous RHD*01 = = = = RHCE*cE; RHCE*ce
004_52 R2r Caucasian Hemizygous RHD*01 = = = = RHCE*cE; RHCE*ce
004_53 R2r Caucasian Hemizygous RHD*01 = = = = RHCE*cE; RHCE*ce
004_54 R2r Caucasian Hemizygous RHD*01W.02 = = = = RHCE*cE; RHCE*ce
004_55 R2r Caucasian Hemizygous RHD*01W.02 = = = = RHCE*cE; RHCE*ce
004_56 R2r Caucasian Hemizygous RHD*01W.02 = = = = RHCE*cE; RHCE*ce
004_57 R2r Caucasian Hemizygous RHD*01W.02 = = = = RHCE*cE; RHCE*ce
continued . . .
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004_58 R2r Caucasian Hemizygous RHD*01W.02 = = = = RHCE*cE; RHCE*ce
004_59 R2r Caucasian Hemizygous RHD*01W.02 = = = = RHCE*cE; RHCE*ce
004_60 R2r Caucasian Hemizygous RHD*01W.02 = = = = RHCE*cE; RHCE*ce
004_61 R2r Caucasian Hemizygous RHD*01W.02 = = = = RHCE*cE; RHCE*ce
004_62 R2r Caucasian Hemizygous RHD*01W.02 = = = = RHCE*cE; RHCE*ce
004_63 R0r Caucasian Hemizygous RHD*01 48C>G Heterozygous 1 Cys16Trp RHCE*01.01; RHCE*01
004_64 R0r Caucasian Hemizygous RHD*01 = = = = RHCE*01.01; RHCE*01
004_65 R0r Caucasian Hemizygous RHD*01 = = = = RHCE*01.01; RHCE*01
004_66 R0r Caucasian Hemizygous RHD*01 = = = = RHCE*01.01; RHCE*01
004_67 R0r Caucasian Hemizygous RHD*01 = = = = RHCE*01.01; RHCE*01
004_68 R0r Caucasian Hemizygous RHD*01 = = = = RHCE*01.01; RHCE*01
004_69 R0r Caucasian Hemizygous RHD*09.03.01 48C>G Heterozygous 1 Cys16Trp RHCE*Ce.09; RHCE*ce
106G>A Heterozygous 1 Ala36Thr
004_70 R0r Caucasian Hemizygous RHD*09.03.01 48C>G Heterozygous 1 Cys16Trp RHCE*ceAR; RHCE*ce
712A>G Heterozygous 5 Met238Val
733C>G Heterozygous 5 Leu245Val
787A>G Heterozygous 5 Arg263Gly
800T>C Heterozygous 5 Met267Lys
916A>G Heterozygous 6 Ile306Val
004_71 R0r Caucasian Hemizygous RHD*01 48C>G Heterozygous 1 Cys16Trp RHCE*01.01; RHCE*01
004_72 R0r Caucasian Hemizygous RHD*01 = = = = RHCE*01.01; RHCE*01
004_73 R0r Caucasian Hemizygous RHD*17.02 = = = = RHCE*01.01; RHCE*01
004_74 R2Rz Caucasian Homozygous RHD*01 48C>G Heterozygous 1 Cys16Trp RHCE*cE; RHCE*CE
150C>T Heterozygous 2 silent
178C>A Heterozygous 2 Leu60Ile
201A>G Heterozygous 2 silent
203A>G Heterozygous 2 Asn68Ser
307C>T Heterozygous 2 Pro103Ser
676G>C Homozygous 5 Ala226Pro
004_75 rr Caucasian Negative NA 48C>G Homozygous 1 Cys16Trp RHCE*ce; RHCE*ce
continued . . .
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004_76 rr Caucasian Negative NA = = = = RHCE*ce; RHCE*ce
004_77 rr Caucasian Negative NA = = = = RHCE*ce; RHCE*ce
004_78 rr Caucasian Negative NA = = = = RHCE*ce; RHCE*ce
004_79 rr Caucasian Negative NA = = = = RHCE*ce; RHCE*ce
004_80 rr Caucasian Negative NA = = = = RHCE*ce; RHCE*ce
004_81 r’r Caucasian Negative NA 48C>G Heterozygous 1 Cys16Trp RHCE*Ce; RHCE*ce
150C>T Heterozygous 2 silent
178C>A Heterozygous 2 Leu60Ile
201A>G Heterozygous 2 silent
203A>G Heterozygous 2 Asn68Ser
307C>T Heterozygous 2 Pro103Ser
004_82 r’r Caucasian Negative NA = = = = RHCE*Ce; RHCE*ce
004_83 r’r Caucasian Negative NA = = = = RHCE*Ce; RHCE*ce
004_84 r’r Caucasian Negative NA = = = = RHCE*Ce; RHCE*ce
004_85 r’r Caucasian Negative NA = = = = RHCE*Ce; RHCE*ce
004_86 r’r Black/Caribbean Negative NA 48C>G Heterozygous 1 Cys16Trp RHCE*ceVS.03; RHCE*ce
733C>G Heterozygous 5 Leu245Val
1006G>T Heterozygous 7 Gly336Cys
004_87 r’r Black/Caribbean Negative NA = = = = RHCE*ceVS.03; RHCE*ce
004_88 r”r Caucasian Hemizygous Novel variant 1 48C>G Homozygous 1 Cys16Trp RHCE*cE; RHCE*ce
676G>C Heterozygous 5 Ala226Pro
004_89 r”r Caucasian Negative NA = = = = RHCE*cE; RHCE*ce
004_90 r”r Caucasian Negative NA = = = = RHCE*cE; RHCE*ce
004_91 r”r Caucasian Negative NA = = = = RHCE*cE; RHCE*ce
004_92 r”r Caucasian Negative NA = = = = RHCE*cE; RHCE*ce
004_93 r”r Caucasian Negative NA = = = = RHCE*cE; RHCE*ce
004_95 No data No data Hemizygous RHD*01W.01 48C>G Heterozygous 1 Cys16Trp RHCE*Ce; RHCE*ce
150C>T Heterozygous 2 silent
178C>A Heterozygous 2 Leu60Ile
201A>G Heterozygous 2 silent
203A>G Heterozygous 2 Asn68Ser
307C>T Heterozygous 2 Pro103Ser
004_96 R1r No data Hemizygous RHD*03.01 NA NA NA NA Undetermined
004_98 No data No data Hemizygous RHD*25 48C>G Homozygous 2 Cys16Trp RHCE*cE; RHCE*ce
676G>C Heterozygous 5 Ala226Pro
continued . . .
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Lab no. Rh serology* Ethnicity* RHD zygosity RHD Allele RHCE SNPs SNPs zygosity Exon a.a change RHCE Allele
004_99 No data No data Hemizygous RHD*04.04 NA NA NA NA Undetermined
004_102 R1r No data Hemizygous Undetermined NA NA NA NA Undetermined
004_104 R2r No data Hemizygous Undetermined 48C>G Homozygous 1 Cys16Trp RHCE*cE; RHCE*ce
676G>C Heterozygous 5 Ala226Pro
004_106 No data No data Hemizygous Undetermined 48C>G Homozygous 2 Cys16Trp RHCE*cE; RHCE*ce
676G>C Heterozygous 5 Ala226Pro
004_109 R1r No data Hemizygous RHD*07.01 48C>G Heterozygous 1 Cys16Trp RHCE*Ce; RHCE*ce
150C>T Heterozygous 2 silent
178C>A Heterozygous 2 Leu60Ile
201A>G Heterozygous 2 silent
203A>G Heterozygous 2 Asn68Ser
307C>T Heterozygous 2 Pro103Ser
004_110 R1r No data Hemizygous RHD*07.01 = = = = RHCE*Ce; RHCE*ce
004_111 R1r No data Hemizygous RHD*17.01 NA NA NA NA Undetermined
004_113 No data No data Hemizygous RHD*01 NA NA NA NA Undetermined
004_114 No data No data Homozygous RHD*01 122A>G Heterozygous 1 Gln41Arg RHCE*CeCW; RHCE*Ce
150C>T Homozygous 2 silent
178C>A Homozygous 2 Leu60Ile
201A>G Homozygous 2 silent
203A>G Homozygous 2 Asn68Ser
307C>T Homozygous 2 Pro103Ser
004_116 No data No data Homozygous RHD*01 150C>T Homozygous 2 silent RHCE*Ce; RHCE*Ce
178C>A Homozygous 2 Leu60Ile
201A>G Homozygous 2 silent
203A>G Homozygous 2 Asn68Ser
307C>T Homozygous 2 Pro103Ser
*As supplied by the NHSBT, Bristol, United Kingdom
NA: Not applicable.
= Similar to previous.
Blue indicates samples Rh serology r’r (dCe/dce) does not agree with RHCE genotyping results RHCE*ceVS.03; RHCE*ce which indicates the presence of a




From the ISBT workshop 1996, 13 samples were genotyped for the RHCE
gene. The RHCE allele was not determined in 5 samples (004_96, 004_99,
004_102, 004_111, 004_113) which is due to either poor amplification of the
target gene by LR-PCR leading to low or lack of coverage or library reads
loss as a result of high polyclonal amplification in the library enrichment
step.
Three samples (004_95, 004_109, 004_110) showed 6 heterozygous exonic
SNPs that encode heterozygous RHCE*02; RHCE*01 (RHCE*Ce; RHCE*ce).
These changes include: c.48C>G (p.Cys16Trp) in exon 1 which encode for
RHCE*01 (RHCE*ce), c.150C>T (p.silent), c.178C>A (p.Leu60Ile), c.201A>G
(p.silent), c.203A>G (p.Asn68Ser), c.307C>T (p.Pro103Ser) in exon 2 which
encode RHCE*02 (RHCE*Ce) allele.
One sample (004_116) was genotyped as homozygous RHCE*02 (RHCE*Ce)
showing homozygous exonic changes associated with RhC which include
c.150C>T (p.silent), c.178C>A (p.Leu60Ile), c.201A>G (p.silent), c.203A>G
(p.Asn68Ser), c.307C>T (p.Pro103Ser) in exon 2.
Two samples (004_98, 004_106) were genotyped as heterozygous RHCE*03;
RHCE*01 (RHCE*cE; RHCE*ce). Homozygous SNPs in exon 1 c.48C>G
predicting amino acid change p.Cys16Trp and heterozygous SNP c. 676G>C
in exon 5 that predict amino acid change p.Ala226Pro, were detected in
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Table 4.3: Molecular basis of the different RHCE alleles detected by NGS.
Allele name* Phenotype* Nucleotide Exon (Intron) Amino acid
RHCE*01 or RHCE*ce c+e+f+ or RH:4,5,6 48C>G 1 Cys16Trp
RHCE*01.01 or RHCE*ce.01 c+e+ 48C 1 Cys16







RHCE*03 or c+E+cE+ or 48C>G 1 Cys16Trp
RHCE*cE RH:3,4,27 676G>C** 5 Ala226Pro
RHCE*04 or C+E+CE+ 48C 1 Cys16






RHCE*02.08.01 Partial C Cw+ MAR- 48C>G 1 Cys16Trp




RHCE*01.20.03 Partial c, partial e, V-VS+hrB– 48C 1 Cys16
or RHCE*ceVS.03 or RH:-10,20,-31 733C>G 5 Leu245Val
1006G>T 7 Gly336Cys
RHCE*01.04.01 V+wVS- Hr- hrs 48C 1 Cys16





RHCE*02.09 or RHCE*Ce.09 Partial C+ CX+ MAR- or RH:9-51 106G>A 1 Ala36Thr





One sample (004_106) showed homozygous SNPs c.48C>G (p.Cys16Trp)
in exon 1 and c.676G>C (p.Ala226Pro) in exon 5 that encode for homozy-
gous RHCE*03 (RHCE*cE).
One sample (004_114) showed heterozygous SNP c.122A>G in exon 1 that
predicts amino acid change p.Gln41Arg and homozygous SNPs c.150C>T,
c.178C>A, c.201A>G, c.203A>G, c.307C>T that predict amino acid changes
p.silent, p.Leu60Ile, p.silent, p.Asn68Ser, p.Pro103Ser, respectively. Exonic
changes encode heterozygous RHCE*02.08.01; RHCE*02 (RHCE*CeCW; RHCE*Ce).
Although ISBT samples were not supplied with Rh serological phenotyp-
ing results, through analysing RHD and RHCE NGS data, we were able
to establish Rh haplotype for 8 ISBT samples (004_95, 004_98, 004_106,
004_104, 004_109, 004_110, 004_114, 004_116). Table 4.4 lists the most pos-
sible Rh haplotype for these samples based on RHD and RHCE NGS re-
sults.
Table 4.4: Most probable Rh haplotype for IBST samples genotyped for RHD and RHCE
using NGS.
Lab no. Rh serology RHD zygosity RHD allele RHD intronic SNPs RHCE allele Rh haplotype
004_95 No data Hemizygous RHD*01W.01 R1, R0, Rz RHCE*Ce; RHCE*ce R1r (DCe/dce)
004_98 No data Hemizygous RHD*25 R2 RHCE*cE; RHCE*ce R2r (DcE/dce)
004_104 R2r Hemizygous Undetermined R2 RHCE*cE; RHCE*ce R2r (DcE/dce)
004_106 No data Hemizygous Undetermined R2 RHCE*cE; RHCE*ce R2r (DcE/dce)
004_109 R1r Hemizygous RHD*07.01 R1, R0, Rz RHCE*Ce; RHCE*ce R1r (DCe/dce)
004_110 R1r Hemizygous RHD*07.01 R1, R0, Rz RHCE*Ce; RHCE*ce R1r (DCe/dce)
004_114 No data Homozygous RHD*01 R1, R0, Rz RHCE*CeCW; RHCE*Ce R1R1 (DCe/DCe)




Multiple intronic SNPs were detected in all samples sequenced. Eighty-
nine intronic SNPs (Table 4.5), mostly located in intron 2, were present as
homozygous SNPs in R1R1 (RHCE*Ce; RHCE*Ce) samples, and as het-
erozygous SNPs in R1R2 (RHCE*Ce;RHCE*cE) samples, R1r (RHCE*Ce;
RHCE*ce) samples, and the R2Rz (RHCE*Ce; RHCE*CE) sample. From the
pattern of these SNPs we concluded that these SNPs are specific to C allele
including RHCE*Ce and RHCE*CE alleles.
Twenty-two intronic SNPs (Table 4.6) located in intron 1 and upstream
of the RHCE gene were present as homozygous SNPs in R2R2 (RHCE*cE;
RHCE*cE), R2r (RHCE*cE; RHCE*ce), r”r (RHCE*cE; RHCE*ce), and rr (RHCE*ce;
RHCE*ce) samples, and as heterozygous SNPs in R1R2 (RHCE*Ce; RHCE*cE)
samples, R1r (RHCE*Ce;RHCE*ce) samples, R0r (RHCE*ce.01; RHCE*ce)
samples, and the R2Rz (RHCE*cE;RHCE*CE) sample, which indicates that
these intronic SNPs are located in R2, r” (RHCE*cE) and r (RHCE*ce) alle-
les. These two alleles encode c indicating that these SNPs are c specific. All
intronic SNPs detected in different Rh haplotypes were compared to the
RHCE hg38 reference sequence (Table 4.7). No intronic changes specific to
RhE were detected, but allele reference sequence was established and sub-
mitted to GenBank based on the SNV present in exon 5 that encode Rhe to
RhE change.
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Table 4.5: Intronic SNPs present in samples with R1 and Rz haplotypes (RhC specific).
Position SNP* Intron rs no. α
25,409,808 A>T 1 rs28594470
25,409,676 G>A 1 rs71652382
25,409,655 G>C 1 rs71652381
25,409,650 A>G 1 rs71652380
25,409,635 T>C 1 rs2982326
25,409,530 T>C 1 rs375284259
25,409,482 A>G 1 rs71652379
25,409,354 T>C 1 rs581970
25,409,288 A>G 1 rs597377
25,409,207 T>C 1 rs581424
25,409,194 T>C 1 rs596939
25,409,073 G>A 1 rs596447
25,408,889 T>C 1 rs184592905
25,408,548 C>T 2 rs675936
25,408,514 A>del- 2 rs201437378
25,408,476 A>G 2 rs593705
25,408,386 C>T 2 rs147140560
25,408,274 C>T 2 rs189396125
25,408,183 A>C 2 rs1309971753
25,408,164 A>G 2 rs149867242
25,408,149 T>C 2 rs1329812325
25,408,147 T>C 2 rs1230452984
25,408,106 A>G 2 rs186132701
25,408,065 G>A 2 rs1345393229
25,408,063 C>G 2 rs1285130086
25,408,059 A>G 2 rs1402951394
25,408,027 C>T 2 rs181050023
25,407,962 T>A 2 rs1407745287
25,407,958 T>C 2 rs1398397158
25,407,949 C>A 2 rs1300077586
25,407,902 C>G 2 rs200103035
25,407,897 G>T 2 rs201812726
25,407,837 C>A 2 rs138441784
25,407,789 C>T 2 rs1296676005
25,407,786 G>C 2 rs1441844028
25,407,761 C>T 2 -
25,407,722 T>C 2 rs1418501291
25,407,694 T>C 2 -
25,407,688 G>C 2 -
25,407,634 A>G 2 rs924675715
25,407,631 G>C 2 rs966013933
25,407,630 T>A 2 rs912179584
25,407,626 G>C 2 rs1315056073
25,407,447 T>C 2 rs686738
25,407,349 A>G 2 rs138147046
Position SNP Intron rs no. α
25,407,340 A>T 2 rs185015905
25,407,310 C>G 2 rs150384644
25,407,278 A>G 2 -
25,407,275 G>A 2 -
25,407,267 T>C 2 rs1396520207
25,407,262 T>C 2 rs1166255958
25,407,253 C>A 2 -
25,407,249 C>T 2 -
25,407,202 C>T 2 rs1210277488
25,407,177 C>T 2 -
25,407,175 A>G 2 -
25,407,148 C>T 2 -
25,407,142 C>T 2 -
25,407,129 C>G 2 -
25,407,128 G>A 2 -
25,407,124 C>T 2 rs1461147141
25,407,115 G>A 2 rs374139742
25,407,008 G>A 2 rs141399586
25,406,976 A>G 2 rs147829334
25,406,914 C>T 2 rs190290858
25,406,909 G>A 2 rs1214049339
25,406,909 G>A 2 rs1214049339
25,406,878 A>G 2 rs1252070032
25,406,877 C>G 2 -
25,406,876 C>T 2 -
25,406,875 C>T 2 -
25,406,872 A>G 2 rs28759034
25,406,867 T>C 2 -
25,406,868 G>C 2 -
25,406,847 C>A 2 -
25,406,810 C>A 2 -
25,406,803 G>T 2 -
25,406,787 A>G 2 rs1476265413
25,406,719 A>G 2 rs185049399
25,406,718 A>C 2 rs142561320
25,406,697 C>T 2 -
25,406,689 G>C 2 rs1263698499
25,406,674 A>G 2 -
25,406,665 G>A 2 rs1281889085
25,406,649 A>G 2 rs1313773019
25,406,561 T>del- 2 -
25,406,557 T>C 2 rs192918853
25,406,534 A>G 2 rs187818188
25,406,526 C>T 2 rs148410263
* Intronic SNPs (hg38) were present as homozygous SNPs in R1R1 samples, and heterozygous SNPs in R1R2,




Table 4.6: Intronic SNPs present in samples with R2, r”, and r haplotypes (Rhc specific).
Position SNP* Intron rs no. α
25,421,866 T>C upstream rs4649082
25,421,744 G>A upstream rs2375313
25,421,164 C>T upstream rs2281179
25,421,155 G>A upstream rs2072933
25,421,082 C>T upstream rs2072932
25,420,072 T>C 1 rs2904813
25,420,908 G>T 1 rs2072931
25,419,823 G>A 1 rs2904815
25,419,154 C>T 1 rs2982360
25,418,713 G>T 1 rs2982358
25,418,570 T>C 1 rs2092326
25,417,977 C>T 1 rs1883427
25,417,674 C>T 1 rs636206
25,416,624 C>T 1 rs2982348
25,416,125 G>A 1 rs76440808
25,416,115 C>T 1 rs77258408
25,416,094 A>T 1 rs112136614
25,415,138 C>A 1 rs28633797
25,414,356 A>C 1 rs28530483
25,413,699 C>T 1 rs2982341
25,413,312 T>C 1 rs600580
25,412,573 G>A 1 rs12048617
*Intronic SNPs were present as homozygous SNPs in R2R2, R2r, r”r, and rr samples, and as heterozygous
SNPs in R1R2, R2Rz, R1r, and R0r samples. α From the database of SNPs (Sherry et al., 2001).
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Table 4.7: Position of intronic variations determined by NGS and their corresponding
nucleotide in the four main RHCE alleles RHCE*Ce, RHCE*CE and RHCE*cE, RHCE*ce in
comparison to the hg38 reference sequence.
Position rs no. α Intron hg38 RHCE*Ce, RHCE*CE RHCE*cE, RHCE*ce
25,421,866 rs4649082 upstream T T C
25,421,744 rs2375313 upstream G G A
25,421,164 rs2281179 upstream C C T
25,421,155 rs2072933 upstream G G A
25,421,082 rs2072932 upstream C C T
25,420,072 rs2904813 1 C C T
25,420,908 rs2072931 1 G G T
25,419,823 rs2904815 1 G G A
25,419,154 rs2982360 1 C C T
25,418,713 rs2982358 1 G G T
25,418,570 rs2092326 1 T T C
25,417,977 rs1883427 1 C C T
25,417,674 rs636206 1 C C T
25,416,624 rs2982348 1 C C T
25,416,125 rs76440808 1 G G A
25,416,115 rs77258408 1 C C T
25,416,094 rs112136614 1 A A T
25,415,138 rs28633797 1 C C A
25,414,356 rs28530483 1 A A C
25,413,699 rs2982341 1 C C T
25,413,312 rs600580 1 T T C
25,412,573 rs12048617 1 G G A
25,409,808 rs28594470 1 A T A
25,409,676 rs71652382 1 G A G
25,409,655 rs71652381 1 G C G
25,409,650 rs71652380 1 A G A
25,409,635 rs2982326 1 T C T
25,409,530 rs375284259 1 T C T
25,409,482 rs71652379 1 A G A
25,409,354 rs581970 1 T C T
25,409,288 rs597377 1 A G A
25,409,207 rs581424 1 T C T
25,409,194 rs596939 1 T C T
25,409,073 rs596447 1 G A G
25,408,889 rs184592905 1 T C T
25,408,548 rs675936 2 C T C
25,408,514 rs201437378 2 A del- A
25,408,476 rs593705 2 A G A
25,408,386 rs147140560 2 C T C
25,408,274 rs189396125 2 C T C
25,408,183 rs1309971753 2 A C A
25,408,164 rs149867242 2 A G A
25,408,149 rs1329812325 2 T C T
25,408,147 rs1230452984 2 T C T
25,408,106 rs186132701 2 A G A
25,408,065 rs1345393229 2 G A G
25,408,063 rs1285130086 2 C G C
25,408,059 rs1402951394 2 A G A
25,408,027 rs181050023 2 C T C
25,407,962 rs1407745287 2 T A T
25,407,958 rs1398397158 2 T C T
continued . . .
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Position rs no. α Intron hg38 RHCE*Ce, RHCE*CE RHCE*cE, RHCE*ce
25,407,949 rs1300077586 2 C A C
25,407,902 rs200103035 2 C G C
25,407,897 rs201812726 2 G T G
25,407,837 rs138441784 2 C A C
25,407,789 rs1296676005 2 C T C
25,407,786 rs1441844028 2 G C G
25,407,761 - 2 C T C
25,407,722 rs1418501291 2 T C T
25,407,694 - 2 T C T
25,407,688 - 2 G C G
25,407,634 rs924675715 2 A G A
25,407,631 rs966013933 2 G C G
25,407,630 rs912179584 2 T A T
25,407,626 rs1315056073 2 G C G
25,407,447 rs686738 2 T C T
25,407,349 rs138147046 2 A G A
25,407,340 rs185015905 2 A T A
25,407,310 rs150384644 2 C G C
25,407,278 - 2 A G A
25,407,275 - 2 G A G
25,407,267 rs1396520207 2 T C T
25,407,262 rs1166255958 2 T C T
25,407,253 - 2 C A C
25,407,249 - 2 C T C
25,407,202 rs1210277488 2 C T C
25,407,177 - 2 C T C
25,407,175 - 2 A G A
25,407,148 - 2 C T C
25,407,142 - 2 C T C
25,407,129 - 2 C G C
25,407,128 - 2 G A G
25,407,124 rs1461147141 2 C T C
25,407,115 rs374139742 2 G A G
25,407,008 rs141399586 2 G A G
25,406,976 rs147829334 2 A G A
25,406,914 rs190290858 2 C T C
25,406,909 rs1214049339 2 G A G
25,406,909 rs1214049339 2 G A G
25,406,878 rs1252070032 2 A G A
25,406,877 - 2 C G C
25,406,876 - 2 C T C
25,406,875 - 2 C T C
25,406,872 rs28759034 2 A G A
25,406,867 - 2 T C T
25,406,868 - 2 G C G
25,406,847 - 2 C A C
25,406,810 - 2 C A C
25,406,803 - 2 G T G
25,406,787 rs1476265413 2 A G A
25,406,719 rs185049399 2 A G A
25,406,718 rs142561320 2 A C A
25,406,697 - 2 C T C
25,406,689 rs1263698499 2 G C G
25,406,674 - 2 A G A
25,406,665 rs1281889085 2 G A G
25,406,649 rs1313773019 2 A G A
continued . . .
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Position rs no. α Intron hg38 RHCE*Ce, RHCE*CE RHCE*cE, RHCE*ce
25,406,561 - 2 T del- T
25,406,557 rs192918853 2 T C T
25,406,534 rs187818188 2 A G A
25,406,526 rs148410263 2 C T C
α From the database of SNPs (Sherry et al., 2001).
- Not found in the database of SNPs.
4.3.4 Microsatellite Variation in Intron 2
Polymorphism in the RHCE intron 2, (AC) and (GCAC) described in Kemp
et al. (1999) in samples with Rhc variation, were investigated in samples,
with Rhc expression, sequenced in this study. Only samples with homozy-
gous RHCE*c genes were analysed for these variations, which included 6
rr (dce/dce) samples (004_75- 004_80), 11 R0r (Dce/dce) samples (004_63-
004_73), and 6 R2R2 (DcE/DcE) samples (004_41- 004_47). Heterozygous
RHCE genes were not included due to the inability to distinguish cis/trans
position. The RHCE gene in the hg38 reference sequence have 13 AC re-
peats and 4 GCAC repeats, which were also present in R0r samples. Other
Rh haplotypes including rr samples showed (AC)11 –1 3 and (GCAC)6,
(AC)9 and (GCAC)6 were seen in R2R2 samples, and (AC)11 and (GCAC)6
were seen in r”r samples, results summarised in Table 4.8.
Although there was breakage of coverage in intron 2 for a few samples,
which made variant calling for that region challenging, we were able to
confirm the presence of the 109 bp insertion in samples with the RHCE*Ce
allele and the absence of this 109 bp sequence from samples with RHCE*cE
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Table 4.8: Frequency of microsatellite GCAC and AC repeats in RHCE intron 2 in different
Rh haplotypes.
Rh haplotype GCAC repeat AC repeat
R0 (Dce) 4 13
r (dce) 6 11-13
R2 (DcE) 6 9
r” (dcE) 6 11
allele (Kemp et al., 1999; Zhou et al., 2008). In samples with the RHCE*cE
allele, a gap of 109 bp was noticed in intron 2 as shown in Figure 4.6, while






Figure 4.6: Insertion detected in intron 2 in samples with RHCE*Ce allele (top) and missing from samples with RHCE*cE allele




4.4.1 RHCE Reference Allele Sequences
The RHCE NGS data was analysed and exonic and intronic changes de-
tected from samples with different Rh haplotypes were compared. The
aim was to create RHCE alleles reference sequences. The RHCE gene was
sequenced from (n=87) blood donor samples and (n=13) ISBT 1996 work-
shop samples. Blood donor samples included different serologically pre-
dicted Rh genotypes including 7 R1R1, 20 R1r, 9 R1R2, 6 R2R2, 14 R2r, 11
R0r, 1 R2Rz, 6 rr, 7 r’r, and 6 r"r samples. Sequence data was aligned and
analysed against the hg38 reference sequence (NC_000001.11) (Tatusova
et al., 2016). This reference sequence is RHCE*ce.01 (RHCE*01.01) and
shows a SNP in exon 1 c.48G>C (p.Trp16Cys). Therefore, samples with
r, r", and R2 haplotypes showed the SNP c.48C>G (p.Cys16Trp) in exon 1.
Based on the exonic and intronic changes in different RHCE alleles, three
reference sequences were established and submitted to Genbank and reg-
istered with accession numbers MN091965 for RHCE*Ce allele, MN091966
for the RHCE*cE allele, and MN624142 for the RHCE*ce allele.
4.4.1.1 RHCE Variant Alleles
The RHCE sequencing analysis revealed different exonic mutations that
were assessed to determine the RHCE allele for each sample (Table 4.2).
The RHCE alleles were undetermined in four samples (004_97, 004_102,
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004_111, 004_112) due to coverage breakage in coding regions. This might
be due to high percentage of polyclonal amplification during library en-
richment that led to the loss of over 40% of the library reads (Figure 4.1).
The RHCE alleles detected in all samples sequenced include RHCE*ce (RHCE*01),
RHCE*ce.01 (RHCE*01.01), RHCE*Ce (RHCE*02), RHCE*cE (RHCE*03), RHCE*CE
(RHCE*04), RHCE*ceVS.03 (RHCE*01.20.03), RHCE*CeCW (RHCE*02.08.01),
RHCE*Ce.09 (RHCE*02.09), and RHCE*ceAR (RHCE*01.04.01) (Table 4.3).
Two samples (004_86 and 004_87) from Black/Caribbean donors were as-
signed their Rh genotype by serology as r’r (dCe/dce) and tested neg-
ative for the RHD zygosity testing using ddPCR (Table 3.1). The two
samples presented three heterozygous exonic changes in the RHCE gene
that encode heterozygous RHCE*ce; RHCE*ceVS.03 alleles. The variant
RHCE*ceVS.03 allele is a common allele in RhD negative individuals of
Afro/ Caribbean descent (Noizat-Pirenne et al., 2002; Moulds et al., 2014).
This haplotype is known as r′s haplotype (Moulds et al., 2014). The r′s
haplotype have mutated Rh genes including a hybrid RHD-RHCE-RHD
allele on the RHD gene, and ces on the RHCE gene. The combination of
the two mutated genes encode for negative D (Moulds et al., 2014), par-
tial c (Pham et al., 2009), weak partial e known as es (Rodrigues et al.,
2004), VS (RH20), V (RH10) (Daniels et al., 1998), hrB (RH31) (Beal et al.,
1995), and HrB (RH34) antigens. Both r′s haplotype type 1 and 2 encode
for a weak partial C (Lomas et al., 1994). Both samples (004_86 and 004_87)
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were phenotyped by serology as RhC positive. Patients, with r′s haplotype
who are incorrectly phenotyped, are at risk of developing Rh alloantibod-
ies to missing or altered epitopes, for instance, anti-C in a seemingly Rh
C-positive person (Noizat-Pirenne et al., 2002; Moulds et al., 2014).
Sample (004_113) showed heterozygous SNP c.122A>G (p.Gln41Arg) in
exon 1 homozygous SNPs c.48C>G (p.Cys16Trp), c.178C>A (p.Leu60Ile),
c.203A>G (p.Asn68Ser), c.307C>T (p.Pro103Ser) that encode RHCE*CeCW.
Rh antigen Cw (Rh8) is one of the many low frequency antigens in the Rh
system with about 2% frequency in Whites. This variant has been associ-
ated with DCe allele but has been rarely observed in D and/or C negative
individuals (Mouro et al., 1995). In sample (004_113), Cw allele was ob-
served in DCe haplotype as heterozygous allele, however, the Cw allele
can be present as homozygous alleles RHCE*CeCW:RHCE*CeCW. In such
cases, MAR (RH51), a high incident Rh antigen, shows negative expres-
sion on the RBCs (O’Shea et al., 2001; Orzińska et al., 2016). Individuals
with such a haplotype are able to produce anti-MAR-like antibodies af-
ter a sensitisation event such as transfusion or pregnancy. This antibody
is able to agglutinate RBCs with most Rh phenotypes excluding D- - and
Rhnull phenotypes as both are MAR negative. Finding compatible blood
products for patients with anti-MAR-like antibodies is very difficult due
to the limitation of screening antisera availability and the probability of
finding MAR negative blood products (Orzińska et al., 2016). Therefore,
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it is especially important to identify Cw alleles to prevent sensitisation in
the first place which could be through sequencing or PCR as performed
by Orzińska et al. (2016).
Sample (004_70) showed heterozygous SNPs in exon 5 c.712A>G (p.Met238Val),
c.733C>G (p.Leu245Val), c.787A>G (p.Arg263Gly), c.800T>A (p.Met267Lys)
and a SNP at exon 6 c.916A>G (p.Ile306Val) which all encode the rare vari-
ant allele RHCE*ceAR, first described by Hemker et al. (1999) and com-
monly found in Africans. This sample was phenotyped by serology as R0r
(Dce/dce) and was genotyped using NGS as RHCE*ceAR;RHCE*ce. The
variant RHCE*ceAR allele is known to express partial e but different stud-
ies have described anti-c in individuals with homozygous RHCE*ceAR al-
leles indicating that the rare allele also encodes for a partial c (Peyrard
et al., 2009; Hipsky et al., 2010). Serological testing might fail to identify
partial c/e in individuals with homozygous variants which might lead
subsequently to allo-antibody production in these patients, which stresses
the importance of molecular genotyping to prevent immunisation.
4.4.2 RHCE Allele Specific Intronic SNPs
Analysing intronic SNPs detected (Table 4.7), showed different patterns of
intronic SNPs that are specific to the RHCE allele. Samples with Rh haplo-
type R0 (Dce) showed similar sequence to the hg38 reference sequence
and no intronic SNPs were detected. Eighty-nine intronic SNPs (Table
4.5) were detected in introns 1 and 2 in samples with RhC including R1
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(DCe) and Rz (DCE). These SNPs are close to the hotspot RhC mutations in
exon 2 c.150C (silent), c.178C>A (p.Leu60Ile), c.201A>G (silent), c.203A>G
(p.Asn68Ser), c.307C>T (p.Pro103Ser) which may explain the intronic SNP
distribution in intron 2. We concluded that these intronic SNPs are spe-
cific to the RHCE alleles with RhC expression, which include RHCE*Ce
and RHCE*CE.
A further 22 intronic SNPs (Table 4.6) were detected in samples with Rh
serologically predicted haplotype R2 (DcE), r" (dcE) and r (dce). Sam-
ples with serologically predicted haplotype R2 (DcE) and r" (dcE) samples
showed RhE change in exon 5 c.676G>C (p.Ala226Pro) and Rhc change
in exon 1 c.48C>G (p.Cys16Trp). Samples with serologically predicted Rh
haplotype r (dce) showed exon 1 Rhc change c.48C>G (p.Cys16Trp). We
concluded that these SNPs are specific to RHCE*ce and RHCE*cE.
No other intronic changes were detected that are RhE specific. This might
be due to the development of the RhE allele from a single mutation after
the development of the RHCE*C allele from RHCE*ce and RHD genes re-
combination (Kemp et al., 1999; Zhou et al., 2008). Kemp et al. (1999) also
described intronic changes in RHCE intron 2 that link to the Rh variants
development. Most intronic SNPs detected in this study were in introns 1
and 2 which might be linked to the Rhce change to RhCe which is encoded
by c.307C>T in exon 2.
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4.4.3 Rh Haplotype Determination Using Intronic Varia-
tions
Intronic SNPs in specific Rh haplotypes represent a novel approach in de-
termining Rh haplotypes. These polymorphisms could be targeted through
PCR to guide in Rh allele determination. For example, Rh phenotype
D+C+c+E-e+ could be assigned by serology as R2r (DCe/dce) or R2R0
(DCe/Dce). Serology issues, as in this example, are resolved using the
frequency of Rh alleles in the population (Daniels, 2013b), which mostly
underestimate the rare genotypes or overestimate the most common alle-
les as we found in some samples that were assigned by serology as R1R2
but found to be hemizygous for the RHD gene (Sillence et al., 2017), (sec-
tion 3.3.1).
Different Rh alleles could be present in similar frequencies in a specific
population. For example, in Black Africans the homozygous (Dce/Dce)
and heterozygous (Dce/dce) haplotypes occur at a similar rate (Kemp
et al., 1999). Therefore, assigning these haplotypes using serology alone
could lead to incorrectly assigned haplotype. ddPCR has been proven
to be an accurate tool in determining RHD zygosity (Sillence et al., 2017)
which enable the differentiation between such haplotypes (Dce/dce and
Dce/Dce).
Targeting intronic repeat regions, by PCR, like (GCAC) and (AC) in intron
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2 in samples with c+ antigen (Kemp et al., 1999) and the 109 bp insertion in
intron 2 in samples with C+ antigen could resolve such issues and enable
better RHCE genotyping. Zhou et al. (2008) performed RHCE genotyping,
through targeting 109 bp intron 2 insertion in the RHCE gene and c.48C>G
polymorphism in exon 1, for 320 samples by PCR-SSP. Genotyping by tar-
geting more than one polymorphism in the gene, including intronic ones,
provides accurate results and eliminates the possibility of false positives
or false negatives (Zhou et al., 2008).
In this study we utilised allele specific intronic SNPs in conjunction with
serology and RHD zygosity results to reassign the Rh genotype for sam-
ples that were incorrectly assigned their Rh haplotypes by serology, see
section 3.4.7.
For 10 ISBT samples, Rh haplotype was determined (Table 4.4) by utilis-
ing RHD and RHCE genotyping results, RHD zygosity testing results, and
intronic SNP patterns present in the RHD and the RHCE genes. Targeting
intronic SNPs has proved here to be effective in support of the determina-
tion of the Rh haplotype for these samples.
4.4.4 Primer Specificity and Breakage of Coverage
RHCE specific primers were used to amplify the gene for sequencing. Al-
though primers were assessed to ensure their specificity to the target gene
using Primer-BLAST on the NCBI website (Altschul et al., 1997), regions
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around exons 2 and 8 were very challenging to amplify. Multiple primer
pairs were designed for these two regions and were tested and optimised
using various annealing temperatures and primer concentrations. Most
primers designed amplified samples with the R2 haplotype but not sam-
ples with R1 haplotype, which shows how different the sequence allele
in that region for both haplotypes may be. A similar issue of PCR allele
discrimination was noticed in ABO blood group gene genotyping using
NGS (Altayar, 2016). To overcome this issue, smaller size amplicons were
designed to target these regions. Nevertheless, breakage of coverage in
intron 8 and intron 2 in some samples was still noticed.
4.5 Conclusion
In this work, we were able to sequence the RHCE gene using NGS from
samples (n=100) with different Rh haplotypes. The RHCE alleles were
identified in 95 samples. Due to low coverage in specific areas of the RHCE
gene, RHCE alleles were not identified in 5 samples. Nevertheless, we
were able to identify the RHCE alleles in most samples with adequate cov-
erage, over all coding exons and most introns, to call variants.
Through complete NGS of the RHCE gene, we were able to study in-
tronic mutations in the RHCE gene and their relation to a specific Rh al-
lele. 89 intronic SNPs (Table 4.5) were found in samples assigned their
genotype by serology as R1 and Rz, which lead to the conclusion that
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these intronic changes are RhC specific. Twenty-two intronic SNPs (Ta-
ble 4.6) were found in samples assigned their genotype by serology as R2,
R0, r , and r”, which lead to the conclusion that these SNPs are Rhc spe-
cific. These SNPs were not affected by the presence or absence of the RHD
gene. Fully sequencing the RHCE using NGS has led to the establishment
of three RHCE allele specific reference sequences, in which one is for the
RhCe allele, one for the Rhce allele, and one for the RhcE allele.
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5. General Discussion and Future
Work
5.1 General Discussion
5.1.1 Advantages of NGS in BGG
One of the main aims of pre-transfusion testing is to minimise risk asso-
ciated with transfusion, whether that is coming from blood transmitted
infections or immunological reaction due to blood group antigens incom-
patibility. The first advancement of genomic testing was put into use to
screen blood donors for human immunodeficiency virus (HIV) and hep-
atitis C virus through nucleic acid testing (NAT) (Hyland et al., 2019). Ge-
nomics testing was also introduced for HLA typing, generating a strong
impetus to use genomic testing for BGG (Möller et al., 2016).
Routine serological testing for blood group antigen phenotyping and com-
patibility testing has been used in transfusion facilities for decades (Hy-
land et al., 2019). Serological testing provides the ability to screen for major
blood groups such as ABO and Rh expeditiously. However, identification
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of blood group antigens polymorphisms remains an issue that is beyond
serological testing ability.
The most important blood groups, ABO and Rh, are the most challenging
regarding genomic genotyping and they can inexpensively and efficiently
be phenotyped by serological testing (Storry et al., 2019). However, Rh is
the most polymorphic blood group system with 55 antigens which could
be difficult to identify and easily mis-phenotyped by serology alone, there-
fore, BGG has an important role to fulfil and ensure correct genotyping
when serology fails to deliver accurate results. In this work, NGS was
utilised on Ion PGM™ platform to fully sequence the RHD, RHAG, and
RHCE genes from samples with different Rh phenotypes.
The results of the use of NGS in BGG to overcome limitations in other
genotyping platforms have been promising (Fichou et al., 2016; Chou et al.,
2017; Dezan et al., 2017; Tounsi et al., 2018). Exome sequencing utilizing
NGS or conventional sequencing (Sanger) could have been used to iden-
tify variants; however, exome sequencing cannot identify intronic varia-
tions such as intronic insertion associated with RHD partial alleles (Chou
et al., 2017). NGS allows the use of LR-PCR approach, enabling the ampli-
fication of the RHD gene (<60 kb) in only 6 overlapping amplicons about
10 kb in size. On the other hand, Sanger sequencing can sequence DNA
fragments up to 1 kb (Zhang et al., 2011). Therefore, complete sequencing
of the RHD gene using NGS was the preferred method, which provided
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a complete sequence of the gene in most samples with high coverage that
allowed accurate variants calling. Using NGS over Sanger sequencing also
enables the sequencing of different blood group genes simultaneously al-
lowing NGS to be used for BGG in reference laboratories to identify blood
group variants (Montemayor-Garcia and Westhoff, 2018). Fichoua et al.
(2019) utilised LR-PCR amplicons and NGS to establish allele reference se-
quences for the ACKR1 gene encoding the Duffy antigens.
We were able to design target specific primers and optimise LR-PCR con-
ditions to amplify genes in multiple overlapping amplicons for NGS. This
led to identifying novel RHD alleles, establishment of two RHD allele ref-
erence sequences, one for the R1, R0, Rz haplotypes and one for the R2
(DcE) haplotype, and establishment of three RHCE allele reference se-
quences for the RHCE*Ce allele, the RHCE*cE allele, and the RHCE*ce al-
lele.
Complete sequencing of the RHD, RHAG, and RHCE genes using NGS
generated adequate depth of coverage that was efficient in detecting ex-
onic and intronic changes, enabling the identification of the RHD, RHAG,
and RHCE alleles in most samples. For a few samples where complete se-
quence of the target gene was not achieved due to amplification failure in
one or more of the LR-PCR amplicons, the RHD or RHCE allele was not




Identification of novel variants of blood group genes would not be pos-
sible using current BGG platforms such as HEA BeadChip™ (BioArray
Solutions Ltd) (Hashmi et al., 2005, 2007; Kappler-Gratias et al., 2011),
BLOODChip® (Progenika) (Avent et al., 2007), Genome Lab SNP Stream
(Beckman Coulter) (Denomme and Van Oene, 2005), ID CORE XT (López
et al., 2018), or HIFI Blood 96™ (Boccoz et al., 2016) as they are designed
to target specific SNV that encode specific variant alleles (Liu et al., 2014;
Finning et al., 2016; Orzińska et al., 2018), hence, novel variants remain
unidentified. The Finnish samples are a good example of that, where
novel RHD allele variants were not determined using SSP-PCR-PCR test-
ing (Tammi, 2019). Sequencing 35 Finnish samples revealed the presence
of 8 novel RHD variant alleles that could be specific to the Finnish popula-
tion. Two other RHD novel variants were found in blood donor samples.
These two novel alleles are possibly unique to the United Kingdom popu-
lation.
Identification of novel variants and their genetic background is crucial in
expanding our knowledge of blood group gene polymorphisms. This
knowledge will aid in developing new BGG assays that rely on high-
throughput sequencing. It will also help in updating the current BGG
assays, that depend on targeting blood group gene SNPs, to include more
blood group gene SNPs. The use of NGS in BGG will supplement serolog-
ical testing and BGG molecular assays.
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The main question asked frequently is when will serology be replaced by
molecular genotyping. The simplest answer to that question is this might
not happen in any near future, although many will disagree (Avent et al.,
2015; Boccoz et al., 2018). Serological phenotyping is efficient, cost effec-
tive, and accurate for the most important blood groups like ABO and Rh
that are tested routinely in transfusion facilities. However, serology test-
ing alone is just not enough. Some cases are beyond serological testing
capabilities such examples include but not limited to ABO discrepancy,
cases of multiple antibodies, and inconclusive Rh phenotyping. Serologi-
cal testing will always be needed to assess blood group antigen status on
the RBCs.
Current scenario in blood banks is that samples are serologically pheno-
typed for most clinically significant blood group antigens (such as ABO
and Rh) and when a variant allele is suspected, the sample could be geno-
typed using the available BGG assay. If results remain inconclusive, then
WGS or WES would be the best option for blood group gene allele de-
termination utilising NGS. Serological screening for blood group antigen
phenotyping remains an invaluable test in transfusion facilities.
NGS is a high throughput technique that generates a vast amount of data
which allows exploration of genetic variations and detection of novel al-
leles. It is appropriate to consider NGS as a confirmation or identification
test when serological testing or other genotyping platforms fail to provide
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compatible results (Fürst et al., 2020), as in the case of the Finnish samples
where serology and SSP-PCR results were incompatible due to the pres-
ence of novel RHD variants which were identified after RHD NGS.
BGG has been beneficial for patients with chronic illness who are trans-
fusion dependent to lower the risk of immunisation (Bakanay et al., 2013;
Dezan et al., 2017). BGG will enable the establishment of blood donor
databases of fully genotyped donors that would make finding compatible
donors easier, especially in the case of a rare blood group antigen or in the
presence of antibodies to a high frequency antigen (Perreault et al., 2009;
St-Louis et al., 2010). To justify the genotyping cost for donors, it is impor-
tant to genotype frequent donors (Jungbauer, 2011b).
In this work we utilised NGS to sequence the Rh genes, RHD and RHCE,
and established unique allele specific reference sequences by studying in-
tronic changes and their relation to a specific Rh haplotype. In the RHD
gene, it is clear that there is a significant difference between the R2 (DcE)
haplotype and other haplotypes R1 (DCe), R0 (Dce), Rz (DCE) in intronic
changes that lead to establishing two RHD allele specific reference se-
quences. The reference sequences were registered with Genbank with ac-
cession numbers MG944308 for the R1, R0, Rz haplotypes and MG944309
for the R2 haplotype.
In the RHCE gene, intronic SNP analysis led to identifying intronic changes
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unique to a specific RHCE allele. These intronic changes allowed the es-
tablishment of 3 RHCE allele specific reference sequences, in which one
was for the RHCE*Ce allele, one for the RHCE*cE allele, and one for the
RHCE*ce allele that were submitted to Genbank and registered with acces-
sion numbers MN091965, MN091966, and MN624142, respectively.
Intronic SNP patterns identified in both the RHD and RHCE genes might
be evidence of their evolutionary rise from a single haplotype (R0) (Carritt
et al., 1997; Kemp et al., 1999), (section 1.4). RHD and RHCE intronic SNPs
can be targeted by PCR to distinguish between different Rh haplotypes
that cannot be differentiated from each other using serology. For example,
the RHD allele cannot be distinguished between R1r′′ (DCe/dcE) and R2r′
(DcE/dCe). Targeting R2 specific intronic SNPs by PCR can differentiate
between the R2 allele and other RHD alleles.
5.1.2 SMS in BGG
SMS, also known as TGS, is a sequencing approach that will change ge-
nomics and researchers ability to sequence and analyse genomes of any
kind. In this work, SMS was utilised through MinION™ sequencing for
RHD genotyping. MinION™ is a USB portable device that generates 400
megabases of data in a 48-h run and uses reads that can exceed 100,000 bp
in length (Karamitros and Magiorkinis, 2015).
Thirteen samples were sequenced and results were compared to the ones
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obtained by Ion PGM™. In this work, RHD genotyping using MinION™
proved to be successful and alleles determined agreed with the ones iden-
tified using NGS. The advantages of using MinION™ over NGS are the
faster library preparation and sequencing time and the sequencing of longer
reads that would allow of better assembly (Loman et al., 2015). Although
LR-PCR amplicons were used to amplify the RHD gene for sequencing
for both platforms, direct enrichment of any target gene will be possible
though biotinylated PCR-generated baits that allow capturing the targeted
gene for sequencing (Karamitros and Magiorkinis, 2015).
Currently, there are numerous published papers in scientific journals about
the utilisation of MinION™ and data handling and analysis. However,
most of these papers focus on micro-organisms genome assembly and
analysis (Quick et al., 2016; Faria et al., 2017). The human genome is larger
and far complex therefore more work is needed to explore the potential
power of this approach in human genome sequencing and analysis to im-
prove sequencing accuracy and develop user-friendly interfaces for data
analysis (Magi et al., 2016).
5.1.3 Study Limitations
One of the limitations of high throughput sequencing is the challenge in-
troduced by the vast amount of data generated and issues associated with
that such as management of data analysis, data storage, maintenance of
252
GENERAL DISCUSSION
confidentiality, and data ownership (McBean et al., 2014; Tilley and Grim-
sley, 2014). To overcome some of these challenges, optimisation of bioin-
formatic tools for data analysis, storage and handling are crucial for future
development of BGG using high-throughput sequencing. The amount of
data generated from high throughput BGG cannot be logged-in, handled
and analysed manually as it will require a long time, a vast amount of ef-
fort and is prone to human error; therefore, computerised large-scale geno-
typing databases are necessary for the future of BGG (Denomme, 2013).
Perreault et al. (2009) designed a blood donor database programme that
enabled sequencing of 10 555 blood donors for 22 blood group antigens.
The programme allowed the generation of barcodes, the storing of geno-
typing results, finding compatible donors and checking for the availability
of components. Clear guidelines need to be established to address legal
and ethical challenges in high-throughput sequencing including data pro-
tection, privacy, and ownership (Godard et al., 2003; Tilley and Grimsley,
2014; Naveed et al., 2015).
Cost is a major factor in determining the feasibility of applying BGG using
NGS. Although cost of sequencing has decreased substantially in recent
years, it remains high (McBean et al., 2014) when compared to other BGG
assays. Different studies have aimed to estimate the cost of blood transfu-
sion /unit and then breakdown the cost into different areas (Forbes et al.,
1991; Shander et al., 2007; Leahy and Mukhtar, 2012; Mazonson et al., 2014;
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Stubbs, 2014). Mazonson et al. (2014) calculated the average direct cost of
serological testing for antibody-positive patients in four medical centres
in the United States, which was $114 per work up and $195 per patient.
Serological phenotyping mean cost was about $20 per antigen. Many of
the serological testing techniques used to assess blood group antibodies
are costly and time consuming, for example, a cell panel costs from $33
to $55 depending on the number of cells in the panel (Mazonson et al.,
2014). Therefore, the use of BGG for patients with chronic illnesses will
benefit the most from such an advancement to limit, if not prevent, allo-
sensitisation.
Quirino et al. (2019) compared the cost and effectiveness of BGG differ-
ent microarray platforms including, SSP-PCR, restriction fragment length
polymorphism-polymerase chain reaction (RFLP-PCR) and compared re-
sults to serological testing (centrifugation gel method) for RHCE, Kidd,
Kell, and Duffy blood group systems. They tested 16 samples and showed
that serological testing for target blood group antigens cost $32.45 per sam-
ple and results were achieved in about 25 minutes, SSP-PCR cost $18.07
per sample and results were available in 3 hours and 20 minutes, and
RFLP-PCR cost $38.22 per sample and testing took 19 hours and 30 min-
utes. Therefore, SSP-PCR is the most economically effective and serologi-
cal testing is the most time efficient technique.
NGS library preparation and sequencing on Ion PGM™ in this work was
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calculated for 20 samples from PCR amplification to the actual sequenc-
ing run to be £4160, which is £208 per sample for one gene in addition to
the cost of DNA extraction, which is £2.50 per sample using the QIAamp
DNA Blood Mini kit (Qiagen Ltd, United Kingdom). When compared,
NGS cost per sample, to serological phenotyping cost, $20 per antigen, the
huge difference in cost of $188 shows the limitation of NGS affordability.
NGS sequencing is also limited by the considerably long preparation time
including PCR, library preparation, enrichment, sequencing, and data anal-
ysis. DNA library preparation for NGS is a time-consuming process that
requires a lot of manual handling (Tilley and Grimsley, 2014). In this work,
manual library preparation from PCR amplification to the point of data
analysis, for 20 samples, required about 10 working days. Processing time
for NGS is now decreasing due to the introduction of semi automated li-
brary preparation machines which are crucial to enable NGS-based BGG
(Avent et al., 2015; McBean et al., 2014; Tilley and Grimsley, 2014). For
example, SPRIworks Fragment Library Systems (Beckman Coulter, UK)
carry out library preparation (size selection and purification) for three
NGS platforms including for the Illumina Genome Analyzers, Roche GS
FLX DNA Sequencer and Life Technologies SOLiD Sequencers. However,
this system processes only 10 samples at a set-up and takes 3-4 hours. Ion
Chef™ Instrument (Thermo Fisher Scientific) was introduced to simplify
the Ion PGM™ library handling and chip loading and to eliminate incon-
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sistency associated with manual handling.
Nevertheless, the whole process of preparation and handling, from DNA
extraction to data analysis, is considerably long and cannot compete with
other BGG platforms (Tilley and Grimsley, 2014) such as microarrays based
tests. However, NGS can be used for selected samples where commer-
cially available BGG assays fail to deliver accurate results. BGG should be
updated regularly by adding new blood group gene variants to allow the
detection of a wider range of variant alleles.
Another issue faced using NGS for BGG is the homology between some of
the blood group genes, such as the RHD and RHCE genes of the Rh blood
group system and the gyp genes of the MNS blood group system (Tilley
and Grimsley, 2014). Homology levels affect primer specificity as we have
had in this study and aligning data could be difficult and complicated. We
had difficulties amplifying from hybrid RHD genes, see section 3.4.11.
The RHD and RHCE genes were fully sequenced on the Ion PGM™ through
LR-PCR amplification in six and eight overlapping amplicons, respectively.
Although LR-PCR is an efficient technique in amplifying target genes for
sequencing, the LR-PCR approach is limited. Hybrid RHD-RHCE alleles
or partial alleles may not amplify if a primer position is compromised by
deletion or mutations. For example, some of the RHD and RHCE primers
failed to amplify from samples suspected to have hybrid genes such as
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RHD*DVI.01 samples. This could be resolved using hybrid pairs of primers;
for example, an RHD specific forward primer and an RHCE specific re-
verse primer or vice versa.
Another issue we faced with the LR-PCR approach was primers discrim-
inating between alleles of the RHCE gene, specifically in the region of in-
tron 8. Amplification of these two regions of the RHCE gene was very
challenging as most of the primers designed only amplified samples with
R2 alleles and failed to amplify other alleles like R1. Nevertheless of our
attempt to design smaller fragments for both regions, low and breakage of
coverage still persisted in a region of intron 8 (25,378,316- 25,381,617).
5.2 Future Work
Regarding RHD genotyping, including different RHD variant alleles would
enable the assessment of the encoding sequences and the analysis of their
intronic SNPs. Optimising a PCR multiplex protocol for the RHD gene,
would cut time and labour from library preparation, which would allow
testing more samples at ounce. Current RHD primers may fail to amplify
hybrid RHD-RHCE-RHD alleles or partial D alleles may not amplify if a
primer position is compromised by deletion or mutations, as observed
in some samples. Therefore, designing primers that target hybrid alleles
would be useful to sequence these variant alleles by using a hybrid primer




For RHCE genotyping, future work includes optimising primers for in-
tron 8 to acquire an adequate coverage over that region and eventually
optimise a PCR multiplex reaction. Eventually, optimising a PCR multi-
plex reaction for both Rh genes together would enable fast and efficient
amplification and thus faster sequencing of both genes.
MinION™ sequencing of the RHD gene and allele determination for all
samples sequenced was accomplished successfully. Establishment of a
user friendlily software for data assembly and analysis would enable the
use of MinION™ more widely in BGG. With future advancement in Min-
ION™, it would enable SMS BGG using a PCR free sequencing approach.
For RHD zygosity testing, designing a new target in the RHD gene is nec-
essary that is not commonly affected in RHD-RHCE hybrid alleles. In this
study, RHD exons 5 and 7 were targeted for zygosity testing using ddPCR.
A few samples presented a deletion in exon 5, mostly affected by a conver-
sion event in the RHD gene. Therefore, including more targets for testing
is necessary to increase confidence in zygosity results. RHD exons 2 and 9
are suitable candidates for testing as they are less affected by deletion and
conversion.
In this work, blood group genes including RHD, RHCE, and RHAG were
sequenced using NGS (Ion PGM™) to study variation in the population
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which led to the establishment of two Rh allele specific reference sequences
for the RHD gene and three for the RHCE gene through intronic variation
analysis of both genes. Complete sequencing of the RHD gene also re-
sulted in the identification of 10 novel variants of the RHD gene that cause
weakened and negative expression of the RhD protein. The RHD gene was
also sequenced using SMS (MinION™) which was successful in determin-
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Abstracts
Silja M Tammi*, Wajnat A. Tounsi*, Susanna Sainio, Michele Kiernan,
Neil D. Avent, Tracey E. Madgett, Katri Haimila. Next-generation se-
quencing of 35 RHD variants in 16,253 serologically D negative preg-
nant women in Finnish population. Blood Advances, 2020; 4(20):4994-
5001.
Fetal RHD screening for targeted routine antenatal anti-D prophylaxis has
been implemented in many countries, including Finland, since the 2010s.
Comprehensive knowledge of the RHD polymorphism in the population
is essential for the performance and safety of the anti-D prophylaxis pro-
gram. During the first 3 years of the national screening program in Fin-
land, over 16,000 samples from RhD2 women were screened for fetal RHD;
among them, 79 samples (0.5%) containing a maternal variant allele were
detected. Of the detected maternal variants, 35 cases remained inconclu-
sive using the traditional genotyping methods and required further anal-
ysis by next-generation sequencing (NGS) of the whole RHD gene to un-
cover the variant allele. In addition to the 13 RHD variants that have
been previously reported in different populations, 8 novel variants were
also detected, indicating that there is more variation of RHD in the RhD-
Finnish population than has been previously known. Three of the novel
alleles were identified in multiple samples; thus, they are likely specific
to the original Finnish population. National screening has thus provided
Abstracts
new information about the diversity of RHD variants in the Finnish popu-
lation. The results show that NGS is a powerful method for genotyping the
highly polymorphic RHD gene compared with traditional methods that
rely on the detection of specific nucleotides by polymerase chain reaction
amplification.
Abstracts
Wajnat A. Tounsi, Tracey E. Madgett and Neil D. Avent. Complete RHD
next generation sequencing: establishment of reference RHD alleles.
Blood Advances, 2018; 2:2713-2723.
The Rh blood group system (ISBT004) is the second most important blood
group after ABO and is the most polymorphic one, with 55 antigens en-
coded by 2 genes, RHD and RHCE. This research uses next-generation se-
quencing (NGS) to sequence the complete RHD gene by amplifying the
whole gene using overlapping long-range polymerase chain reaction (LR-
PCR) amplicons. The aim was to study different RHD alleles present in the
population to establish reference RHD allele sequences by using the analy-
sis of intronic single-nucleotide polymorphisms (SNPs) and their correla-
tion to a specific Rh haplotype. Genomic DNA samples (n=69) from blood
donors of different serologically predicted genotypes including R1R1 (DCe/DCe),
R2R2 (DcE/DcE), R1R2 (DCe/DcE), R1Rz (DcE/DCE), R1r (DCe/dce),
R2r (DcE/dce), and R0r (Dce/dce) were sequenced and data were then
mapped to the human genome reference sequence hg38. We focused on
the analysis of hemizygous samples, as these by definition will only have
a single copy of RHD. For the 69 samples sequenced, different exonic SNPs
were detected that correlate with known variants. Multiple intronic SNPs
were found in all samples: 21 intronic SNPs were present in all samples in-
dicating their specificity to the RHD*DAU0 (RHD*10.00) haplotype which
the hg38 reference sequence encodes. Twenty-three intronic SNPs were
found to be R2 haplotype specific, and 15 were linked to R1, R0, and Rz
Abstracts
haplotypes. In conclusion, intronic SNPs may represent a novel diagnostic
approach to investigate known and novel variants of the RHD and RHCE
genes, while being a useful approach to establish reference RHD allele se-
quences.
Abstracts
Kelly A. Sillence, Amr J. Halawani, Wajnat A. Tounsi, Kirsty A. Clarke,
Michele Kiernan, Tracey E. Madgett, Neil D. Avent. Rapid RHD zygos-
ity determination using digital PCR. Clinical Chemistry 63(7), 1388-1397.
BACKGROUND: Paternal zygosity testing is used for determining homo-
or hemizygosity of RHD in pregnancies that are at a risk of haemolytic
disease of the fetus and newborn. At present, this is achieved by using
real-time PCR or the Rhesus box PCR, which can be difficult to interpret
and unreliable, particularly for black African populations.
METHODS: DNA samples extracted from 53 blood donors were analysed
using 2 multiplex reactions for RHD specific targets against a reference
(AGO1) to determine gene dosage by digital PCR. Results were compared
with serological data, and the correct genotype for 2 discordant results
was determined by long-range PCR (LR-PCR), next-generation sequenc-
ing, and conventional Sanger sequencing.
RESULTS: The results showed clear and reliable determination of RHD
zygosity using digital PCR and revealed that 4 samples did not match the
serologically predicted genotype. Sanger sequencing and long-range PCR
followed by next-generation sequencing revealed that the correct geno-
types for samples 729M and 351D, which were serologically typed as R1R2
(DCe/DcE), were R2r (DcE/dCe) for 729M and R1r′′ (DCe/dcE), R0ry
(Dce/dCE), or Rzr (DCE/dce) for 351D, in concordance with the digital
PCR data.
Abstracts
CONCLUSIONS: Digital PCR provides a highly accurate method to rapidly
define blood group zygosity and has clinical application in the analysis of
Rh phenotyped or genotyped samples. The vast majority of current blood
group genotyping platforms are not designed to define zygosity, and thus,
this technique may be used to define paternal RH zygosity in pregnancies
that are at a risk of haemolytic disease of the fetus and newborn and can
distinguish between homo- and hemizygous RHD-positive individuals.
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The Rh blood group system (ISBT004), second most important blood group
after ABO, is encoded by two genes, RHD and RHCE. Recombination,
deletion, and point mutations in these two genes generate Rh allelic di-
versity. Blood group genotyping (BGG) could decrease Rh mistyping and
minimise adverse reactions following blood transfusion. In this work, we
explore the possibility of applying single molecule sequencing (SMS) in
BGG. MinION™, introduced by Oxford Nanopore Technologies in 2016,
depends on driving DNA through nanopores embedded in a membrane
using a voltage, which changes as different nucleotides pass through. Stud-
ies have shown the great potential of the MinION™ real time sequencing,
for example, during outbreaks of Ebola and Zika viruses. MinION™ se-
quencer has also been utilised in ABO genotyping and was successful in
differentiating between six ABO genotypes (AA, AO, BB, BO, AB, OO).
We aimed to genotype the RHD gene using MinION™ and compare re-
sults for the same samples to the NGS data obtained from the Ion Personal
Genome Machine™ (Ion PGM™). Our aim was to test the suitability and
efficiency of the MinION™ sequencer in BGG.
The RHD human reference sequence in the hg38 assembly encodes a vari-
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ant RHD allele RHD*DAU0 encoded by c.1136C>T (p.Thr379Met) in exon
9. Therefore, all 13 samples showed a homozygous SNP in exon 9 c.1136T>C
(Met379Thr), i.e. none were RHD*DAU0. Exonic changes were detected
in 12 of the 13 samples encoding variant RHD alleles, which included 4
known variants in 5 samples and 6 novel variants in 7 samples. Known
variants included RHD*11, RHD*15 (in two samples), RHD*01W.02, and
RHD*09.04. Novel variants included c.829G>A (p.Gly277Arg) in exon 6,
c.784delC (p.Gln262fs) in exon 5, two exon 3 mutations c.421delG (p.Val141fs)
and c.422T>A (p.Val141), two mutations in exon 9 c.1154G>C (p.Gly385Ala)
and c.1163T>G (p.Leu388Arg), c.519C>G (p.Tyr173*) in exon 4, and c.1016G>C
(p.Gly339Ala) in exon 7. Reference sequences for the novel RHD alle-
les were established and submitted to GenBank. All exonic and intronic
changes detected were compatible with the ones detected by Ion PGM™.
The RHD human reference sequence in the hg38 assembly encodes a vari-
ant RHD allele RHD*DAU0 encoded by c.1136C>T (p.Thr379Met) in exon
9. Therefore, all 13 samples showed a homozygous SNP in exon 9 c.1136T>C
(Met379Thr). One sample showed a wild type RHD allele. Exonic changes
were detected in 12 samples encoding variant RHD alleles, which included
4 known variants in 5 samples and 6 novel variants in 7 samples. Known
variants included RHD*11, RHD*15 (in two samples), RHD*01W.02, and
RHD*09.04. Novel variants included c.829G>A (p.Gly277Arg) in exon 6,
c.784delC (p.Gln262fs) in exon 5, two exon 3 mutations c.421delG (p.Val141fs)
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and c.422T>A (p.Val141), two mutations in exon 9 c.1154G>C (p.Gly385Ala)
and c.1163T>G (p.Leu388Arg), c.519C>G (p.Tyr173*) in exon 4, and c.1016G>C
(p.Gly339Ala) in exon 7. Reference sequences for the novel RHD alle-
les were established and submitted to GenBank. All exonic and intronic
changes detected were compatible with the ones detected by Ion PGM™.
In this research, the RHD gene was sequenced in 13 samples using Min-
ION™ single molecule sequencing and the RHD allele was determined in
all cases. MinION™ is a powerful tool and was successful here in BGG.
With the advantage of allele phasing in single molecule sequencing, it is
hoped that the more complicated genetic structures, such as exist for the
hybrid RHD/RHCE genes, can be more easily assessed in the future. How-
ever, challenges remain with developing a straightforward user-friendly
data analysis pipeline for translating this work into the clinic.
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The Rh blood group system (ISBT004) is the second most important blood
group after ABO. Two closely related genes, RHD and RHCE, encode 55
different antigens. Blood group genotyping could decrease Rh mistyping
and eventually minimise the adverse reactions following blood transfu-
sion, especially for blood transfusion dependent patients.
We aimed to use LR-PCR to amplify the Rh genes to get a full sequence
including promoter, introns and all exons. We focused on establishing ref-
erence alleles for the RHD and RHCE genes by studying intronic SNPs in
both genes and their relationship to specific Rh haplotypes.
Genomic DNA samples (n=92) from blood donors and the ISBT 1996 work-
shop of different phenotypes were sequenced using the Ion Personal Genome
Machine™ (Ion PGM™). The RHD gene was sequenced from all samples
and the RHCE gene was sequenced from blood donor samples. Data was
then mapped to the hg38 reference sequence and analysed using the CLC
Workbench 9.5.
Multiple exonic SNPs were detected that encode 12 RHD variant alleles.
Due to *DAU0 (RHD*10.00) being the hg38 reference sequence for the
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RHD gene, 21 homozygous SNPs were detected in all samples which are
thought to be specific to the reference allele. Compared to the reference
sequence, multiple intronic SNPs were detected that are suspected to be
a haplotype specific. Twenty-three SNPs were homozygous SNPs in all
samples with the R2 haplotype and 15 SNPs were homozygous in all sam-
ples with R1 haplotype. Intronic SNP analysis of the RHCE gene revealed
over 100 intronic SNPs and confirmed the presence of the 109 bp inser-
tion in intron 2 in samples with R1 haplotype. More than 50 intronic SNPs
were detected in all R2 and r samples.
In this research, 92 samples were sequenced for the RHD gene and the
RHCE gene to study different alleles present in the population to establish
reference allele sequences by utilising the analysis of intronic SNPs and
their correlation to a specific Rh haplotype. Intronic SNPs are suspected to
be related to a specific haplotype, which may represent novel diagnostic
approaches to investigate known and novel variants of both genes.
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The Rh blood group system (ISBT004) is the second most important blood
group after ABO. Two closely related genes, RHD and RHCE, encode 55
different antigens. Recombination, deletion, and point mutations in these
two genes generate Rh allelic diversity, with the eight most common Rh
haplotypes being: R1 (DCe), R2 (DcE), R0 (Dce), Rz (DCE), r (dce), ry
(dCE), r’ (dCe), and r” (dcE). The RhD antigen is the most clinically sig-
nificant antigen due to its high immunogenicity and being the main cause
of haemolytic disease of the fetus and newborn.
Serological testing is fast, cost friendly, and efficient; however, limited by
many factors like the availability of antisera and reactivity of the antibod-
ies. Blood group genotyping (BGG) could be widely used in transfusion
practice where serology tests may fail to clarify issues or resolve discrep-
ancies.
Different DNA microarray-based tests were introduced that enable geno-
typing of variant blood groups by targeting specific single nucleotide poly-
morphisms (SNPs). Although these assays are very accurate, they are de-
signed to target certain nucleotides while novel variants remain unknown.
Complete DNA sequencing could be the most relevant technique to thor-
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oughly study blood group variations.
In this research we aimed to use long-range PCR (LR-PCR) to amplify the
complete Rh genes and then next generation sequencing (NGS) to get a
full sequence including promoter, introns and all exons, that would en-
able us to study RHD and RHCE gene variations and detect novel alleles.
Genomic DNA samples (n=92) from blood donors of different phenotypes
were sequenced using the Ion Personal Genome Machine™ (Ion PGM™)
for RHD and RHCE. Data analysis revealed intronic SNPs that link to a
specific Rh haplotype and have led to the establishment of reference alle-
les. NGS may represent a novel diagnostic approach to investigate known
and novel variants of both genes.
The Rh blood group system (ISBT004) is the second most important blood
group after ABO that is encoded by the RHD and the RHCE genes. We
aimed to establish a sequencing method using next generation sequenc-
ing to get a full sequence of the Rh genes including promoter, introns and
all exons, that would enable us to study RHD and RHCE gene variations
and detect novel alleles.
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The Rh blood group system (ISBT004) is the second most important blood
group after ABO. Two closely related genes, RHD and RHCE, encode 55
different antigens. Recombination, deletion, and point mutations in these
two genes generate Rh allelic diversity and generate the eight most com-
mon Rh haplotypes which include: R1 (DCe), R2 (DcE), R0 (Dce), Rz
(DCE), r (dce), ry (dCE), r’ (dCe), and r” (dcE). Blood group genotyping
could decrease Rh mistyping and eventually minimise the adverse reac-
tions following blood transfusion, especially for blood transfusion depen-
dent patients. Previous studies have used exome sequencing to identify
Rh variation but the high homology between the RHD and RHCE genes
could make it challenging to analyse data, especially exons 8 and 10, where
there are no amino acid differences between the two genes.
We aimed to use LR-PCR to amplify the Rh genes to get a full sequence
including promoter, introns and all exons. We focused on establishing ref-
erence alleles for the RHD and RHCE genes by studying intronic SNPs in
both genes and their relationship to specific Rh haplotypes.
Genomic DNA samples (n=92) from blood donors and the ISBT 1996 work-
shop of different phenotypes were sequenced using the Ion Personal Genome
Machine™ (Ion PGM™). The RHD gene was sequenced from all samples
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and the RHCE gene was sequenced from blood donor samples. Data was
then mapped to the hg38 reference sequence and analysed using the CLC
Workbench 9.5.
Multiple exonic SNPs were detected that encode 12 RHD alleles which in-
clude RHD*01W.1, RHD*01W.02, RHD*01W.3, RHD*03.01, RHD*25, RHD*04.04,
RHD*06.01, RHD*03.01, RHD*07.01, RHD*17.01, and RHD*17.02. One novel
allele was identified, in which one RHD hemizygous sample showed SNP
L110P that encodes RHD*07.01 and RHD-RHCE(4)-RHD that encodes RHD*17.02,
which means that this RHD allele is a hybrid between two variant RHD al-
leles. Due to RHD*DAU0 (RHD*10.00) being the hg38 reference sequence
for the RHD gene, 21 homozygous SNPs were detected in all samples
which are thought to be specific to the reference allele. Compared to the
reference sequence, multiple intronic SNPs were detected that are sus-
pected to be a haplotype specific. Twenty-three SNPs were homozygous
SNPs in all samples with the R2 haplotype and 15 SNPs were homozygous
in all samples with R1 haplotype.
Intronic SNP analysis of the RHCE gene revealed over 100 intronic SNPs
in intron 2 and confirmed the presence of the 109 bp insertion in intron 2 in
samples with the R1 haplotype. More than 50 intronic SNPs were detected
in all R2 and r samples.
In this research, 92 samples were sequenced for the RHD gene and the
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RHCE gene to study different alleles present in the population to establish
reference allele sequences by utilising the analysis of intronic SNPs and
their correlation to a specific Rh haplotype. Intronic SNPs are suspected to
be related to a specific haplotype, which may represent novel diagnostic
approaches to investigate known and novel variants of both genes.
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The Rh blood group system (ISBT004) is the second most important blood
group after ABO. Two closely related genes, RHD and RHCE, encode 55
different antigens. Recombination, deletion, and point mutations in these
two genes generate Rh allelic diversity. Complete DNA sequencing could
be the most relevant technique to thoroughly study blood group varia-
tions. Complete blood group genotyping could decrease Rh mistyping
and eventually minimise the adverse reactions following blood transfu-
sion.
We aimed to use LR-PCR to amplify the Rh genes to get a full sequence
including promoter, introns and all exons. We focused on establishing ref-
erence alleles for the RHD and RHCE genes by studying intronic SNPs in
both genes and their relationship to specific Rh haplotypes.
Genomic DNA samples (n=69) from blood donors and (n=23) from ISBT
1996 workshop of different phenotypes were sequenced for the RHD gene
and 31 samples of blood donors were sequenced for the RHCE gene using
the Ion Personal Genome Machine™ (Ion PGM™).
Multiple exonic SNPs were detected that encode 12 RHD alleles which in-
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clude RHD*01W.1, RHD*01W.02, RHD*01W.3, RHD*03.01, RHD*25, RHD*04.04,
RHD*06.01, RHD*03.01, RHD*07.01, RHD*17.01, and RHD*17.02. One novel
allele was identified, in which one RHD hemizygous sample showed a
hybrid between two variant RHD alleles which include RHD*07.01 and
RHD*17.02. Multiple intronic SNPs were identified in the RHD and RHCE
genes, which are suspected to be haplotype specific.
In this research, 92 samples were sequenced for the RHD gene and 31 for
the RHCE gene to study different alleles present in the population to es-
tablish reference allele sequences by utilising the analysis of intronic SNPs
and their correlation to a specific Rh haplotype. Intronic SNPs are sus-
pected to be related to a specific haplotype, which may represent novel
diagnostic approaches to investigate known and novel variants of both
genes.
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The Rh blood group system (004) is the second most important blood
group after ABO. Two closely related genes, RHD and RHCE, encode over
50 different antigens in the Rh system. Recombination, deletion, and point
mutations in these two genes generate Rh allelic diversity which makes the
Rh blood group the most polymorphic blood group. In the past decade,
different DNA microarray-based tests were introduced that enable geno-
typing of variant blood group specific single nucleotide polymorphisms
(SNPs). However, these assays have limitations because they target cer-
tain nucleotides or DNA regions through PCR, while novel ones remain
unknown. Complete sequencing could be the most relevant technique to
thoroughly study blood group variations. Complete blood group geno-
typing could decrease Rh mistyping and eventually minimise the adverse
reactions following blood transfusion especially for blood transfusion de-
pendent patients.
This research aims to use Next Generation Sequencing (NGS) to sequence
the RHD gene to detect RHD variants present in the population, which
will help expand the knowledge about the underlying molecular mecha-
nism of these variants. This research also focuses on investigating intronic
SNPs that could be linked to a specific haplotype that might be used in the
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future to predict Rh haplotype.
Genomic DNA samples from blood donors of different phenotypes includ-
ing 6 R1R1, 6 R2R2, 7 R1R2, 6 R1r, 6 R2r, and 6 R0r were sequenced us-
ing the Ion Personal Genome Machine™ (Ion PGM™). All samples were
tested for RHD zygosity using digital PCR. The RHD gene was ampli-
fied in 6 overlapping amplicons using RHD-specific primers. The 200-base
pair read sequencing libraries were prepared and then sequenced on the
Ion PGM™ using a 316 chip. Data was then mapped to the hg38 human
genome reference sequence and analysed using the CLC Workbench 9.5.
In one R2R2 sample, one exon 9 SNP 25321889 G>C was detected result-
ing in the amino acid change Gly385Ala which is linked to weak D type
2. Multiple intronic SNPs were detected in all samples in which 15 ho-
mozygous SNPs were present in all 37 samples, which could indicate an
error in the human reference sequence. Another 19 SNPs were present in
all R2R2 and R2r samples as homozygous SNPs and in R1R2 samples as
heterozygous SNPs. Fourteen intronic SNPs were present in all R1R1, R1r
and R0r as homozygous SNPs and heterozygous SNPs in all R1R2 sam-
ples. Sixteen heterozygous intronic SNPs were only present in the R2R2
weak D type 2 sample. Intronic SNPs are suspected to be linked to a spe-
cific haplotype, which could be used in the future to establish an assay to
genotype Rh antigens without the need to fully sequence the Rh genes.
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In this research, 37 samples were sequenced on the Ion PGM™ to study
RHD mutations and assist the RHD variations present in the population.
Intronic SNPs were also analysed to determine their relation to specific
haplotypes. Multiple SNPs are suspected to be related to a specific hap-
lotype; however, more samples and different Rh phenotypes need to be
sequenced to confirm this.
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The Rh blood group system (004) is the second most important blood
group after ABO. Two closely related genes, RHD and RHCE, encode over
50 different antigens in the Rh system. Recombination, deletion, and point
mutations in these two genes generate Rh allelic diversity which makes the
Rh blood group the most polymorphic blood group. This research aims to
use Next Generation Sequencing (NGS) to sequence the RHD gene to de-
tect RHD variants present in the population, which will help expand the
knowledge about the underlying molecular mechanism of these variants.
Genomic DNA samples from blood donors of different phenotypes includ-
ing 6 R1R1, 6 R2R2, 7 R1R2, 6 R1r, 6 R2r, and 6 R0r were sequenced using
the Ion Personal Genome Machine™ (Ion PGM™). Data was then mapped
to the hg38 human genome reference sequence and analysed using the
CLC Workbench 9.5.
For 37 samples sequenced, one exon 9 SNP 25321889 G>C was detected
in one R2R2 sample resulting in the amino acid change Gly385Ala which
is linked to weak D type 2. Multiple intronic SNPs were detected in all
samples, with some of them suspected to be linked to a specific haplo-
type. These intronic SNPs could be used in the future to establish an assay
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to genotype Rh antigens without the need to fully sequence the Rh genes.
To confirm the relation of these intronic SNPs to a specific Rh haplotype,
more samples and variant Rh phenotypes need to be sequenced.
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The Rh blood group system is the most important protein blood group
system and the most polymorphic one. Rh system includes five leading
antigens: RhD, RhC, Rhc, RhE, and Rhe. Only two highly homologous
genes, RHD (encodes the RhD protein) and RHCE (encodes the RhC/c
and RhE/e proteins), give rise to 49 different variants.
Previous next generation sequencing (NGS) work on the RHD gene in our
laboratory has identified seven different RHD intronic single nucleotide
polymorphisms (SNPs) (Halawani, 2015), suspected to be linked to the R2
(DcE) haplotype. Four of the seven SNPs have been tested to confirm if
they are linked to the R2 haplotype. SNPs tested are: 25,614,400 C>G,
25,621,980 C>T, 25,627,066 C>G and 25,648,349 T>C. Genomic DNA sam-
ples from blood donors of different phenotypes were tested (6 R2R2, 4
R1R1, 1 R2r, and 1 R1r).
RHD-specific primers amplified the regions around the SNPs and the PCR
amplicons were subjected to Sanger sequencing. Results were aligned
with the hg38 human genome reference sequence. For all four SNPs anal-
ysed, the R2R2 and R2r samples showed the mutations but not the R1R1
and R1r samples. These SNPs could be used in the future to predict Rh
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antigen status without the need for full RHD and RHCE genes sequencing.
Future aims are to use NGS to study Rh genetic basis. Improvements will
be made to the long-range PCR and the NGS protocols to obtain a better
coverage depth of sequences to identify the frequency of mutations and
any novel SNPs.
